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BCG is the only vaccine against tuberculosis and has been used for over 90 
years. BCG efficacy is variable, especially in countries with high TB prevalence, 
where over a million deaths due to tuberculosis, are still reported annually. New 
TB vaccines are under development to either replace or boost the BCG 
vaccine. However, our understanding of the immune response required for 
protection against TB disease, remains inadequate. Identification of a 
protective immune response is only possible in a clinical trial of an efficacious 
vaccine, allowing comparison of vaccine-induced immune responses in 
protected and unprotected individuals. In the absence of such a vaccine, as 
is the case with TB, we can only explore biomarkers of risk of disease.  
The most commonly measured outcomes of anti-mycobacterial immunity in 
clinical trials, specific Th1 cells, are typically thought to be protective in TB. 
However, to date, human mycobacteria-specific Th1 responses have not 
correlated with risk of TB disease. New approaches are urgently required to 
identify other factors at play in conferring protection against TB. 
In this thesis, we explored BCG-specific cytotoxic T cells as candidate 
correlates of risk of TB disease in BCG-vaccinated infants. We hypothesized 
that reduced production of cytotoxic molecules by T cells in response to BCG 
are associated with risk of developing TB disease. We designed a 
case/control study nested within a large trial of newborn BCG-vaccination. 
Blood was collected at 10 weeks and infants, were followed up for two years. 
We compared outcomes in infants ultimately diagnosed with TB (at risk of TB 
disease) and two groups of healthy infants (not at risk of TB disease), the 
first group had household contact with TB cases, the second group were 
randomly selected from the community, which is endemic for TB. Amongst 
these groups, we designated a training and a test cohort to allow validation 
of candidate correlates of risk of TB. 
We observed increased frequencies of BCG-specific T cells expressing 
cytotoxic molecules at 10 weeks of age in infants at risk of TB disease 
compared with infants not at risk in the training cohort. However, these 
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findings could not be validated in the test cohort. We also measured 
proliferative potential of BCG-specifc T cells and Th1 cytokine production by 
proliferating cells in these groups. We found no differences in BCG-induced 
capacity of T cells to proliferate, and to express Th1 cytokines between the 
infant groups. 
We investigated cytotoxic T cell secretion of cytotoxic molecules and the 
capacity of these cells to kill BCG-infected monocytes. We optimised a flow 
cytometry-based cellular assay that measured monocyte killing by BCG-
specific cytotoxic T cells. Lastly, we optimised a flow cytometric bead array 
assay that quantifies soluble molecules in culture supernatants.  
In summary, our data suggest that increased frequencies of BCG-specific 
cytotoxic T cells, with capability to kill mycobacteria-infected cells, may be 
associated with risk of TB disease. However, this was not validated in a 
second, test cohort.  Further studies may explain the paradoxical nature of 
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Figure 1.1.  Global presentation of TB incidence rates as estimated in 2012 . (From 
WHO Global Tuberculosis Report 2013 [1]). 
	  
Chapter 1: General Introduction 
1.1. Epidemiology of TB disease 
Mycobacterium tuberculosis (M.tb), the causative pathogen of tuberculosis, 
still remains responsible for 1.3 million deaths per year [1]. A third of the 
worlds population is estimated to be infected with M.tb of which 
approximately 10% will develop active tuberculosis (TB) disease [2]. South 
Africa ranks among the three countries with the highest burden of 
tuberculosis in the world. TB incidence rate in South Africa was estimated at 
925 per 100 000 in 2012 with 2% of reported new cases in children 15 years 
and younger [1]. This is coupled to a TB mortality rate of 51 per 100 000. 
Clearly, combating TB disease remains unsuccessful despite a global 
vaccination coverage of 89% of newborns in TB endemic countries with 
Bacille Calmette-Guerin (BCG), the only licensed TB vaccine [3].  
 
 
1.2. TB Pathogenesis 
TB is primarily a chronic disease of the lung. Infection is established through 
inhalation of M.tb-containing aerosols expelled by TB diseased individuals 
through coughing. There are three possible outcomes after inhalation of 
M.tb (Figure 1.2). An indeterminate group of individuals appear to clear the 
infection as these individuals remain unsensitized to M.tb-specific antigens, 
even after known exposure to TB patients. About 90% of individuals do 
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Figure 1.2. Three infection outcomes of Mycobacterium tuberculosis. (i) A small 
proportion of individuals are able to clear M.tb before infection is established. (ii) Some 
individuals, such as HIV+ patients, can develop acute TB disease upon infection. (iii)  The 
majority of individuals are able to contain M.tb infection, however 10% of these may 
develop disease due to a weakend immune system, becoming infectious if untreated. 
(From Kaufmann et al, Nature Medicine Reviews, 2005 [6]).	  
establish infection but do not develop TB disease, a phenomenon known as 
latent TB infection (LTBI). In these individuals, the pathogen is maintained 
within granulomas, highly organized structures comprising an array of 
immune cells concentrated around a central region of infected macrophages 
[4]. In addition, about 10% of infected individuals progress to disease due to 
loss of control of M.tb in the lesion so that the pathogen can replicate and 
escape the granuloma. The pathogen may spread to other sites of the lung 
and the individual becomes diseased, displaying symptoms such as 
coughing, weight-loss and night sweats [5]. Such individuals become 
infectious and spread the pathogen. In more severe cases, the infection can 
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1.3. The host immune response to M.tb 
1.3.1. Recognition and  Uptake of M.tb by APCs 
The M.tb cell wall consists of an array of components including 
polysaccharides, lipids and proteins. This provides a selection of pathogen 
associated molecular patterns (PAMPs) for recognition and uptake of M.tb 
by various pattern recognition receptors (PRR). PRRs, such as toll-like 
receptors (TLRs), are expressed either on the surface of phagocytic cells, 
granulocytes, macrophages (Mϕ) and dendritic cells (DCs) or intracellularly. 
TLRs are a group of thirteen mammalian PRRs able to recognize microbial 
molecules. Of these, only TLR-1 to TLR-10 have been identified in humans, 
with TLR-11, -12 and -13 being restricted to mice [7].  TLR-2 recognises and 
binds the glycolipid lipoarabinomannan (LAM), which is a major component 
of the cell wall of M.tb [8]. TLR-2 can also form functional heterodimeric 
pairs with TLR-1 or TLR-6 inducing macrophage activation upon recognition 
of mycobacterial lipopeptide [9] [10]. Mycobacterial lipopolysaccharides and 
β-glucans are recognised by TLR-4 and the c-type lectin receptor, Dectin-1, 
respectively [11], [12]. Dendritic cells are also equipped with an additional c-
type lectin receptor, DC-SIGN, for detection of β-glucan, ManLAM and 
lipomannans. Through the recognition of ManLAM, DC-SIGN also mediates 
internalisation of M.tb  [13]. In addition, intracellular recognition is mediated 
by the endocytic TLR-9 and the cytoplasmic NOD-like receptor, NOD-2, 
which detects bacterial CpG DNA and peptidoglycans, respectively [14].  
Phagocytosis of M.tb is mainly mediated by three receptors expressed on 
the surface of the phagocytic cell. Complement receptors (CR1 and CR3) 
mediate engulfment of M.tb opsonised with complement [15]. Uptake of non-
opsonised M.tb is mediated through another c-type lectin receptor, mannose 
receptor [16], and scavenger receptors which binds mannose and 
lipopolysaccharides, respectively. Interestingly, the fate of M.tb appears to 
be dependent on the PRR-PAMP interactions and binding of these PRRs 
appears to elicit different immune responses to M.tb [17]. For example, 
engagement of the mannose receptor, induces an anti-inflammatory 
response  and blocks phagolysosome fusion  promoting intracellular survival 
of M.tb [17] [18] [20].  
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1.3.2. Innate mechanisms of killing M.tb 
In the lung, M.tb is taken up by resident alveolar Mϕ through phagocytosis 
where it resides within phagosomes. Typically, phagosomes undergo 
maturation through acidification in order to fuse with lysosomes. Within the 
phagolysosome M.tb comes under the attack of degradative enzymes that 
are active at low pH. In addition to lysosomal/proteolytic enzymes, infected 
Mϕ also produce free radicals that are detrimental to cell survival. Infected 
Mϕ increase oxygen consumption, undergoing oxidative stress leading to 
the subsequent production of microbicidal reactive oxygen intermediates 
(ROI). Activation of murine Mϕ by IFN-γ and TNF-α also trigger the 
production of reactive nitrogen intermediates (RNI) which have been shown 
to kill mycobacteria [21].  
Much of the success of M.tb to survive intracellularly is ascribed to its ability 
to arrest phagolysosome formation and phagosome escape [22]. However, 
Mϕ are able to circumvent M.tb-induced phagosome arrest through 
autophagy, usually a homeostatic process through which cells recycle 
essential nutrients during starvation. Autophagy involves the formation of 
double-membrane vesicles around a specific organelle in the cell, which is 
then targeted for degradation through lysosomal activity. Induction of 
autophagy through IFN-γ has been shown to increase acidification and 
promote maturation of mycobacteria-containing phagosomes [23]. A vitamin 
D-dependant antimicrobial pathway has also been identified in Mϕ and 
neutrophils. Through this pathway, vitamin D increases the production of the 
microbicidal peptide, cathelicidin, which in turn induces autophagy [24]. 
Cathelicidin has been shown to have a direct killing effect on BCG and M.tb, 
possibly through the disruption of the mycobacterial cell wall [25], [26].  
1.3.3. Engagement of the host adaptive immune system 
In addition to the innate mechanisms described above, Mϕ and DCs also 
engage cells of the adaptive immune system, comprising B lymphocytes (B 
cells) and T lymphocytes (T cells) [27]. B cells primarily generate antibodies 
while T cells produce cytokines and cytotoxins to combat infection. Initial 
engagement of these cells during infection, ultimately leads to 
immunological memory, the hallmark of the adaptive immune system. 
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Establishing pathogen-specific immunological memory is the aim of 
vaccination and essential to effectiveness of vaccines, including BCG, to 
prevent disease development.  Initiation of an adaptive immune response, 
however, requires antigen recognition and presentation by antigen 
presenting cells (APC). 
1.3.4. Antigen processing and presentation 
B cells can function as both an APC and as an effector cell to establish 
immunological memory. Cell-surface expression of B-cell receptors or 
immunoglobulins allow B cells to recognize and engulf specific antigens. 
These include proteins, lipids, polysaccharides, nucleic acids and some 
chemicals termed haptens associated with extracellular pathogens. B cells 
are able to process these antigens, which are loaded onto MHC class II 
molecules for presentation to CD4 T cells.  A specific group of Th cells, T 
follicular helper cells (Tfh), induce maturation of B cells to become plasma 
cells which produce antigen-specific antibody.   
Unlike B cells, T cells require APCs for antigen presentation of intracellular 
pathogen. APCs utilize two pathways of antigen processing and ultimate 
presentation to T cells. An exogenous pathway is used to present antigens 
from phagocytosed pathogens, which are retained within a phagolysosome 
for degradation. MHC class II containing vesicles, derived from the Golgi 
apparatus, fuse with the phagolysosome to allow binding of pathogenic 
peptides by MHC class II molecules. The peptide-bound MHC molecules 
are transported to the cell surface for presentation of antigen to CD4 T cells.  
The MHC class II exogenous pathway is predominantly used to present 
antigens of mycobacteria retained within the phagolysosome. An 
endogenous pathway entails degradation of intracellular proteins, including 
antigens from pathogens in the cytoplasm. Typically, viral proteins are 
degraded into peptides via this pathway through a cytoplasmic protein 
complex known as the proteasome. The peptide is transported to the 
endoplasmic reticulum where it is loaded onto major histocompatibility 
complex (MHC) class I molecules and the complex is then moved to the cell 
surface through the Golgi apparatus. At this point, peptides bound to MHC 
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class I molecules (MHCI) are presented to a T lymphocyte subset called 
CD8 T cells.  
Mycobacteria can induce the endogenous MHCI antigen presentation 
pathway through cross-priming [28][29]. This involves induction of  
programmed cell death leading to the formation of apoptotic vesicles which 
are taken up by bystander DC. The phagocytosed pathogen product is 
translocated from the phagosome, possibly through the action of saposin, to 
the cytosol for loading onto MHCI. However, M.tb has been shown to block 
apoptosis of host Mϕ through induction of anti-apoptotic proteins [30]. These 
evasion tactics are examples of a large number of mechanisms by which 
M.tb has managed to manipulate the host immune system to promote its 
survival [31]. CD4 and CD8 T cells are regarded as conventional T cells 
characterized by surface-expression of the αβ T cell receptors. In addition, 
APCs are also able to present microbial lipids to a group of unconventional 
T cells through engagement of the MHCI-related molecule, CD1. Lipids are 
loaded onto CD1 molecules for presentation to CD1-restricted T cells, 
including natural killer (NK T cells) and gammadelta T cells (γδ T cells). In 
essence, antigen processing and presentation enables APCs to activate T 
cells of the adaptive immune system if they fail to resolve the infection. 
1.3.5. Establishing immunological memory 
T cell priming primarily takes place in the lymph node. Pathogens taken up 
by immature DCs that patrol mucosal sites and tissues become activated 
and migrate to the regional lymph nodes. Within the lymph node, DCs 
undergo a process of maturation characterized by a loss of phagocytic 
function as well as increased surface expression of MHC molecules and co-
stimulatory molecules [27]. This enables DCs to prime naïve T cells to 
differentiate into a specific helper CD4 T (Th) cell subsets or CD8 T cells. 
Activation and subsequent proliferation of naïve T cells requires 
MHC:antigen:TCR (CD4 or CD8) engagement as well as a co-stimulatory 
signal. This is followed by T cell differentiation which requires a specific 
cytokine milieu, provided mostly by innate cell inflammation. Peptides bound 
to MHC molecules class I and II are presented to CD8 and CD4 T cells, 
respectively. These effector cells will then mount a pathogen-specific 
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Figure 1.3. The five CD4 Th cell subsets of the adaptive immune system. (From 
O’Shea et al, Science, 2010 [32]). 
	  
immune response. Once the pathogen has been eradicated, a huge 
proportion of the effector cells die with a small surviving proportion 
becoming long-lived antigen-specific memory cells. Upon recognition of 
MHC-bound antigen, memory cells have the capacity to mount a rapid and 
stronger immune response. Thus, through primary infection or vaccination 
immunological memory is established which confers life-long protective 
immunity.  
 
1.4. Cell-mediated adaptive immune mechanisms against M.tb 




Naïve CD4 T cells can develop into either Th1, Th2, Tregs, Th17 or Tfh 
helper cells (Figure 1.3). Activation of Th cell subset and the type of Th cell 
differentiation depends on the strength of TCR-MHC II binding (signal 1) and 
cytokine milieu (signal 3) [33]. The co-stimulatory molecules engaged during 
binding (signal 2) are also crucial in Th cell activation and differentiation and 
absence of this signal leads to T cell anergy. Each Th cell subset is 
characterized by the expression of a unique set of transcription factors 
coupled with the production of specific cytokines (Figure 3). Mycobaterial 
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infection classically induces the development of Th1 responses through 
MHC class II antigen presentation and the expression of the Th1 type 
cytokines IL-12 and IFN-γ. This commits naïve CD4 T cells to a Th1 immune 
response. The  importance of this CD4 T cell in M.tb infection and diseases 
is discussed in more detail in sections 1.4.3 and 1.4.4.  
(i) Th2 cells 
IL-4 production is the hallmark of the Th2 response as IFN-γ is to the Th1 
response. Th2 cells are important in the immune response to parasites, 
such as helminths, by promoting B-cell activation through the production of 
IL-4, IL-5, IL-9 and IL-13 [27]. However, initiation of a Th2 response 
counteracts a Th1 immune response. IL-4 iduces expression of STAT6, the 
transcription factor required to initiate a Th2 T cell differentiation in B cells 
and other human cells [34], [35]. In murine macrophages, IL-4 has also 
been shown to downregulate the antimicrobicidal iNOS [36], Dwivedi et al 
also described the induction of Th2 differention with subsequent T cell 
production of IL-4, when infecting murine DC with virulent M.tb [37]. 
Interestingly, this was not observed for DC infected with BCG or an RD1 
knock-out M.tb strain which rather induced a Th1 response as measured by 
IFN-γ production. Nonetheless, various groups have observed an 
association between increased Th2 activity and TB disease [38]. This is of 
course of great concern in the development of post-exposure TB vaccines. 
(ii) Th17  cells 
Th17 cells constitute the third major subset of effector CD4 T cells and 
require both TGF-β and IL-6, among other cytokines including IL-1β and 
TNF-α, for T cell differentiation. Further expansion and effector function of 
Th17 requires IL-23. Th17 cells are characterized by the expression of the 
transcription factor, RORγt, and cytokines IL-17 and IL-22, and granulocyte 
macrophage colon-stimulating factor (GM-CSF) [39]. Their ability to produce 
IL-17 makes Th17 cells important to control the early stages of infection 
through the induction of acute inflammation. At the site of infection, 
surrounding cells bind IL-17 which leads to the production of chemokines for 
the robust recruitment of neutrophils. In a murine TB vaccination study, IL17 
induced production of chemokines specific for the recruitment of antigen-
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specific Th1 cells to the lung, after aerosal M.tb challenge [40]. In addition to 
the requirement of IL-23 for Th17 persistence, this study also described a 
role for IL-23 in restricting mycobacterial growth. Thus, Th17 cells may be 
important in early M.tb infection.  Furthermore, Wozniak et al described a 
BCG-specific Th17 cells that, under the modulation of IFN-γ, have a 
protective role in M.tb infection [41].  
(iii) Treg cells 
Regulatory T cells (Treg) mediate suppression and prevention of 
alloreactive immune responses and pathogen-induced immunopathology. 
Two subsets of regulatory T cells have been identified based on origin and 
mode of action [42]. A naturally occurring subset, nTregs, originates from 
thymocytes in the thymus and an induced or adaptive subset, iTreg, which 
differentiate from naïve CD4 T cells in the periphery in the presence of TGF-
β alone. Tregs characteristically express the transcription factor FoxP3. 
However, nTregs induce a suppressive action through surface-bound CTLA-
4 and the IL2-receptor, CD25 while iTregs secrete the immunosuppressive 
cytokines IL-10 and TGF-β.	   In some infections, the immunosuppressive 
function of Tregs is exploited to avoid pathogen clearance and to establish 
chronic infection [43]. In the context of M.tb infection, murine studies have 
shown that Tregs hinder efficient clearance of the pathogen by inhibiting Th 
proliferation [44]. Furthermore, Shafiani et al described the existence of a 
M.tb-specific Treg population which delayed priming and subsequent 
migration of effector T cells into the lung of infected mice [45]; a mechanism 
through which M.tb could establish infection.  
(iv) Tfh cells 
T follicular helper (Tfh) cells are localised to follicles of secondary lymphoid 
organs where they are responsible for recognition of B cells expressing 
antigen-bound MHC. Interaction with Tfh cells activate B cells to divide and 
differentiate into antibody-producing plasma cells [27]. Development of Tfh 
cells requires the presence of IL-6. These cells are characterized by the 
expression of the transcription factor Bcl-6 and expression of CXCR5 and 
ICOS; cell-surface molecules required for binding of follicular dendritic cells 
and B cells, respectively. Tfh cells can also induce antibody class switching 
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to IgG2a or IgG1, through the expression of IFN-γ and IL-4, respectively 
[46]. Localisation of Tfh in ectopic lymphoid structures in lung tissue is 
associated with optimal control of M.tb in a non-human primate model of 
latent TB [47].  
1.4.2. Role of CD8 T cells in M.tb infection 
CD8 T cells originate from the same double negative thymocytes as CD4 T 
cells which mature in the thymus and become T cells with cell-surface 
expression of either CD4 or CD8. CD8 T cell function is associated with 
cytolytic killing of target cells infected with cytosolic pathogens such as 
viruses. Cytolytic molecules are produced and maintained within cytotoxic 
granules within CD8 T cells and are released upon cell-cell contact with an 
infected cell. Extracellular pathogens and phagosomal mycobacteria can be 
detected by CD8 cells through the process of cross-presentation [29]. CD8 
T cells  also produce IFN-γ for activation of MHCI antigen-presenting 
macrophages.   
The role of CD8 T cells in TB has received less attention than CD4 cells 
because M.tb primarily resides in the phagosome of infected cells. However, 
CD8 T cells may have a critical role in vaccination against TB. Using BCG-
vaccinated non-human primates, Chen et al showed increased 
mycobacterial load associated with dissemination of M.tb infection when 
CD8 T cells were depleted prior to BCG vaccination [48].  Interestingly, in 
addition to CD4 T cell responses, our group has also observed increased 
CD8 T cell function after vaccination with BCG and novel candidate TB 
vaccines [49], [50], [51], [52]. 
A group of T cells bearing unconventional TCRs are also important in 
immunity against M.tb [53] [54] [55]. These include γδ T cells and natural 
killer T cells (NK T cells) which recognize lipids presented on CD1-
molecules. Similar to CD4 and CD8 T cells, γδ and NK T cells also display 
cytolytic activity  in addition to the production of Th1 and Th2 cytokine [56]. 
1.4.3. Cytokine effector function of CD4 Th1 and CD8 T cell subsets 
The importance of CD4 and CD8 T cells lies in their capacity to recognize 
antigen presented by APCs and to mount a specific reaction in order to 
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irradicate the pathogen. This specific response involves a cascade of events 
regulated, in the case of M.tb, by Th1 cytokines such as IFN-γ, IL-2 and 
TNF-α. IFN-γ-production by CD4 T cells plays an important role in the 
activation of anti-microbial action by APCs [57]. IFN-γ-knockout mice are 
highly susceptible to M.tb-infection due to defective macrophage activation 
and reduced iNOS expression. The importance of this cytokine in humans is 
emphasized in individuals with defective IFN-γ or IFN-γ receptor expression; 
these individuals are predisposed to severe mycobacterial infections [58].  In 
addition to these innate antimicrobial effects, IFN-γ also enhances antigen 
processing and presentation. IL-2 is required for T-cell expansion and 
differentiation [59], a crucial component for establishing immunological 
memory against the specific pathogen. TNF-α has also been shown to have 
a pivotal role in granuloma formation and chemokine attraction to the site of 
infection [60], [61]. The importance of TNF-α is further emphasized by 
studies reporting an increased risk of TB disease in patients with rheumatoid 
arthritis who are on anti-TNF therapy [62]. M.tb infection can induce the 
production of Th2 cytokines such as IL-4 which has been associated with 
poor outcome in TB disease [63], [64]. Furthermore, blocking of this cytokine 
leads to reduced mycobacterial burden after challenge in mice [65]. 
Immunity against tuberculosis clearly relies on both CD4 Th1 and CD8 T cell 
function as illustrated by numerous studies conducted in animal models. 
CD4 T cells induce macrophage activation through the production of IFN-γ, 
IL-2 and TNF [66] . IFN-γ specifically from CD4 T cells enhances CD8 T cell 
effector and cytotoxic function in response to M.tb infection and also inhibits 
M.tb growth in mice [67]. Murine CD4 T cells appear to control M.tb infection 
through direct recognition of MHCII; M.tb growth in the absence of MHCII 
expression is comparable to growth in the absence of CD4 T cells [68]. 
Mogues et al, elegantly confirmed the importance of CD4 and CD8 T cells in 
a series of gene-knockout mouse models of  M.tb infection [69]: CD4 
knockout and MHCII knockout mice showed dramatically reduced survival 
time associated with increased mycobacterial growth in the lung, liver and 
spleen after H37Rv infection compared to CD8 and MHCI knockout mice. 
CD8 and MHCI knockout mice had reduced survival and increased 
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mycobacterial growth compared to wildtype, although not to the extent of the 
CD4 and MHCII knockout mice. Reduced expression of NOS2 and IFN-γ 
was also observed in CD4 and MHCII knockout mice compared to wildtype, 
CD8 and MHCI knockout mice. Similarly, In a study of MHCI-knockout mice, 
Flynn et al illustrated that CD4 cells alone were not sufficient to control M.tb 
growth after challenge [70]. 
1.4.4. Cytotoxic effector function of CD4 and CD8 T cell subsets 
Classically, cytotoxic function has been associated with CD8 T cells, natural 
killer (NK) cells and NK T cells. Cytotoxic potential is detectable in both 
effector as well as memory CD8 T cells in viral infection studies of mice [71]. 
Cytotoxic activity of CD4 T cells has also been implicated in various viral 
infections and cancers [72]. More interesting is the demonstration of the 
ability of a cytotoxic CD4 T cell subset, expressing cytotoxic molecules, to 
kill M.tb [73]. Thus, in addition to Th cytokine production, CD4 together with 
CD8 T cells can mount a cytolytic response against intracellular pathogens, 
involving the cytotoxic molecules granulysin, perforin and granzyme B, 
among others [74]. Appay et al. described cytotoxic CD4 T cells, derived 
from HIV infected patients, as highly differentiated antigen-experienced cells 
that had lost expression of CD28, CD27, CD45RO and CCR7, possibly due 
to chronic activation [74]. Interestingly, these cells also expressed the Th1 
cytokines, TNF-α and IFN-γ, but not IL-2. However, the involvement of 
cytotoxic CD4 T cells may be pathogen-specific as cytolytic potential of 
these cells have not been detected in murine LCMV-infection [71]. 
Cytotoxic CD8 T cells have been shown to lyse M.tb-infected Mϕ and also 
reduce mycobacterial growth [75]. The recombinant form of granulysin, a 
saposin-like protease, has been shown to directly kill various bacteria, 
including M.tb,  as well as fungi and parasites [76]. Decreased perforin 
production which translates into reduced lysis of mycobacterial antigen-
pulsed Mϕ, has been observed in peripheral blood mononuclear cells 
(PBMCs) from TB patients, compared to healthy controls [77], [78]. BCG 
also induces expression of granzyme B and perforin by antigen-specific 
CD8 T cells in healthy 10-week-old infants vaccinated at birth [49].  
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1.4.5. Mechanism of cytotoxic killing 
In addition to the induction of innate mechanisms involving pathogen killing 
through activation of APCs, infected cells can also be detected and killed by 
cytotoxic T cells (CTLs). CTLs have the ability to induce apoptosis of target 
cells through either cytotoxic degranulation (the release of cytotoxic 
granules) or the Fas-FasL pathway. Fas-FasL death pathway appears to be 
involved in homeostatic control of T cells and defects in this pathway are 
associated with lymphoproliferative disorders in mice and humans [79]. 
Cytotoxic degranulation is associated with killing of pathogen-infected cells 
by CTLs. CTLs produce cytotoxic molecules which are contained within 
lysosomal structures, termed cytotoxic granules. When these effector CTLs 
come into contact with an infected cell, the granules migrate toward the 
interface between the effector and the target cell, called the immunological 
synapse, and the preformed cytotoxic molecules are released. Three types 
of cytotoxic molecules have been identified i.e. perforin, granzymes and 
granulysin.  
1.4.6. Cytotoxic molecules 
Perforin is part of the membrane attack complex protein family (MACPF) 
and,  in a calcium-dependent manner, binds lipids and polymerizes to form 
pores in the cell membrane [80]. Perforin and granzymes synergistically 
initiate apoptosis of target cells; perforin forms pores in the cell membrane 
of the target cell which allows entry of granzymes into the cell [81].  
Granzymes are a family of serine proteases consisting of thirteen isoforms 
which have been identified, to date, in mice [82]. Humans express only five 
isoforms, granzyme A, B, H, K and M, of which granzyme A and B have 
been extensively studied. Granzyme B induces apoptosis through cleavage 
of BID, a pro-apoptotic protein, which leads to the release of mitochondrial 
cytochrome c and subsequent DNA fragmentation  [83].  
Granulysin is a lytic protein with saposin-like protease activity which binds 
membrane lipids and activates lipid-degrading enzymes of target cells 
leading to cell death through apoptosis [84]. In order to prevent autolysis of 
CTLs, granulysin is expressed as a 15kDa inactive precursor which, under 
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conditions of acidification, is reduced to a 9kDa cytolytic protein. Granulysin 
has been shown to have direct antimicrobicidal acivity against an array of 
bacteria, fungi and parasites, as well as M.tb [76]. Ernst et al successfully 
illustrated the ability of granulysin to permeabilize the cell membrane of M.tb 
[85]. Granulysin formed pores in the cell wall causing the detachment of the 
inner and outer membranes and leading to the ultimate release of the 
cytosol.  
 
1.5. The BCG-induced immune response  
Following WHO guidelines, BCG is administered as a percutaneous or 
intradermal injection into the deltoid muscle. At the site of inoculation, BCG 
is likely to follow a similar fate as described for M.tb. Briefly, at the site of 
delivery,  BCG induces an inflammatory response leading to the recruitment 
and maturation of monocytes and immature DCs. Mϕ internalize BCG and 
initiate innate responses to kill the pathogen. BCG is also taken up by 
Langerhans cells (immature DCs in the skin) and migrate to regional lymph 
nodes. BCG induces DC maturation characterized by increased surface 
expression of MHC molecules and co-stimulatory molecules [86].  Mature 
DCs also lose their phagocytic function. Naïve CD8 T cells are primed to 
become cytotoxic T cells whereas naïve CD4 T cells can develop in an array 
of helper T cells depending on the cytokine milieu present during priming 
[27]. BCG-pulsed DCs induce the production of Th1 cytokines by naïve CD4 
and CD8 T cells mediated by IL-12 [87]. Within the DC, BCG is taken up into 
phagosomes that allow antigen presentation through MHC class II 
molecules to CD4 T cells [88]. BCG can also induce apoptosis of infected 
cells leading to the release of apoptotic vesicles that contain mycobacterial 
antigens. These are then taken up by bystander DCs and processed 
through the endosomal pathway for cross-priming of CD8 T cells through 
MHC class I antigen presentation  [29]. BCG has also been shown to prime 
CD8 T cells through a MHC-independent pathway through CD1 molecules 
[88]. More over, Kawashima et al also showed preferential recognition of live 
and dead BCG by CD8 and CD4 T cells, respectively. Clearly the role of 
CD8 T cells is underestimated. 
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In addition to a Th1 response, BCG vaccination induces effector responses 
of other Th subsets. Burl et al reported increased expression of Treg, Th17 
as well as Th2 specific cytokines in 41/2 month old newborn vaccinees  
compared to unvaccinated controls [89]. We have also observed detectable 
Treg and Th2 function in 10-week old newborn vaccines, measured by IL-10 
and IL4 expression, respectively. However expression of these cytokines 
was at notably low levels compared to Th1 cytokines [90].  
Newborn BCG vaccination can induce expression of cytotoxic molecules by 
both CD4 and CD8  T cells  as measured in infant blood [49] [91]. In work 
done in our laboratory, Soares et al showed a peak cytotoxic CD4 response 
induced by BCG at 6 weeks after vaccination, measured by intracellular  
expression of perforin, granulysin and granzyme B [91]. Cytotoxic molecules 
remained detectable at 10 weeks post-vaccination in both CD4 and CD8 T 
cells [49], [91], [92]. 
 
1.6. Vaccine-induced immunity 
Immunity against disease is dependent on host ability to mount an immune 
response, which clears the pathogen by eliminating the infection, and ideally 
prevents disease recurrence. In the absence of such natural immunity 
against a specific pathogen, a protective immune response can be induced 
by vaccination. Characteristics of the immune response elicited through 
vaccination depend on route of administration, i.e. oral or injected, and the 
type and formulation of vaccine. Generally, vaccines are killed or live, 
attenuated forms of the pathogen (e.g. smallpox, yellow fever, measles, 
mumps, rubella and chicken pox) or subunit vaccines comprising pathogen 
product such as proteins, polysaccharides or DNA, often formulated in 
adjuvant (e.g. hepatitis B, HiB, pneumococcal vaccines). Live attenuated 
vaccines are typically the most successful vaccines and can confer lifelong 
protection by eliciting a humoral immune respone and establishing B cell 
memory. For example, vaccination against smallpox induces vaccinia virus-
specific B cells and IgG antibody titers which persisted up to 60 years after 
vaccination [93]. Similarly, neutralising antibodies could be detected up to 
40 years after yellow fever vaccination in a group of US WWII veterans [94].	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In addition to induction of B cell memory, various viral vaccines also induce 
long-lived T cell memory [95].   
BCG is a live attenuated strain of the bovine TB pathogen, Mycobacterium 
bovis. BCG has been in use as the only vaccine against TB disease since 
1921, more than 90 years. BCG vaccination appears to protect against M.tb 
infection as shown by various groups using BCG-scaring as proxy [96], [97]. 
Despite its variable efficacy of 0-80% in protection against TB disease [98], 
[99], BCG protects against severe forms of childhood TB such as milliary 
and TB meningitis [100]. Thus, the immune response which confers 
protection against TB in some, but not in others, needs to be elucidated. 
This will aid in the development of safer and better vaccines to either boost 
the BCG primed response or to replace BCG. 
Several studies conducted in our group and by others have described the 
characteristics of BCG-induced immune responses in infants [49], [90], [91], 
[101], [102]. BCG is given at birth in many TB endemic countries and 
appears to have an adjuvant effect, enhancing protective immunity induced 
by subsequent EPI vaccinations. This observation was illustrated 
immunologically by Ota et al, who showed enhanced proliferation and 
cytokine production (IFN-γ, IL-5 and IL-13) in response to vaccine antigens 
in BCG-vaccinated infants who also received HBV, DPT and OPV	  compared 
to BCG-unvaccinated infants [103]. Investigation of infant mortality also 
supports a non-specific beneficial role for newborn BCG vaccination in 
addition to protecting against TB [104]–[107]. Moulton et al, reported 
reduced mortality in the first six months of life in infants who were BCG 
vaccinated, compared with unvaccinated infants [107].  
Considerable effort and progress is being put into global development of 
new TB vaccines, even in the absence of correlates of protection, or risk of 
TB disease. Th1 cytokines are thought to be important in maintenance of 
latency and resistance to disease progression [61] [108]. However, a study 
of disseminated TB pediatric patients determined no difference in the levels 
of IFN-γ and TNF-α between kids who received BCG compared to those 
who did not [109]. Similarly, our group reported no differences in BCG-
specific Th1 responses in infants who developed TB compared to those who 
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remained healthy. Using intracellular cytokine staining of whole blood 
collected 10 weeks after BCG vaccination, similar levels of expression of 
IFN-γ, TNF-α and IL-2 was detected between infants who ultimately 
developed TB disease, and those who remained healthy [50]. Further 
analysis of these proteins on a soluble level in the same cohort also 
revealed no differences (data not published). Clearly other factors are at 
play. 
 
1.7. Methods of measuring immune responses 
T cell responses are thought to be essential for protective immunity against 
TB. As such, new TB vaccines are designed to induce a T cell-mediated 
immune against M.tb infection. The development of a flow cytometry-based 
whole blood assay (WBA) to detect antigen-specific CD4 and CD8 T cells 
allows assessment of vaccine-induced responses [110]. This assay is ideal 
for infant studies in which blood volumes are limited. Flow cytometry assays 
based on small volumes of whole blood allow measurement of many 
different parameters, at phenotypic (cell-surface) and functional levels 
(intracellular cytokine stain; ICS). A more direct measure of antigen- or 
vaccine-specific T cells makes use of tetramers i.e. fluorescently labeled 
MHC molecules conjugated to antigenic peptides from the relevant 
pathogen [111] [112]. However, this approach is limited by the requirement 
for prior knowledge of the restricting HLA element, which makes tetramer 
work expensive and only feasible in a subset of subjects who possess the 
relevant HLA alleles. 
Lymphoproliferation assays allows for the expansion and detection of 
antigen-specific T cells which are present in low levels in blood samples. 
Whole blood or isolated PBMC are incubated with antigen for up to 6 or 7 
days and antigen specific cells are detected as cells undergoing division. 
These proliferating cells are then flow cytometrically detected based on 
BrdU incorporation, dye dilution of Oregon Green (or CFSE), or high Ki67 
expression [113]. This offers the added benefit of facilitating measurement 
of other markers by addition of other fluorescently labeled antibodies to 
define function and phenotype of antigen-specific proliferating cells.  
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In addition to intracellular detection, cytokine levels can also be quantified 
as secreted soluble molecules in serum, plasma or culture supernatants.  
Thus, the use of a single blood volume can be expanded measure multiple 
T cell outcomes. The enzyme-linked immunosorbent assay (ELISA), can 
detect soluble molecules by using protein-specific capture and detection 
antibodies, which binds different epitopes on the particular protein. This 
assay is restrictive in the volume of sample required and the number of 
proteins that can be detected in one sample. Multiplex assays, such as the 
commercially available flow cytometry-based bead assay, the Luminex bead 
array, allows simultaneous detection of up to 42 different markers. In brief, 
micron-sized beads are fluorescently stained and conjugated with capture 
antibodies specific to a protein which is quantified by the binding of a 
fluorescent secondary antibody [114]. This technology, refered to as a 42-
plex bead array, has received favourable use in infant study due to minute 
sample volume required [115] [116] [102]. Although a hundred different 
fluorescent beads are available, at this point only 42 distinct cytokines and 
chemokines can be measured in a single assay.   
Vaccine-induced cytotoxic potential, conventionally associated with CD8 T 
cells, can also be assessed by flow cytometry [49]. Cytotoxic potential is 
described as the ability of cytotoxic cells to produce cytotoxic molecules and 
their subsequent release through degranulation. PBMC are incubated with 
antigen for three days after which fluorescent-labeled antibodies specific for 
cytotoxic molecules like granzymes, granulysin and perforin can be detected 
intracellularly. Degranulation is determined by detection of CD107, which 
becomes exposed on the cell surface after granule release. Cytotoxic 
function, however, is measured as the ability of antigen-specific cytotoxic T 
cells to kill target cells presenting antigen via cell surface MHC. 
Traditionally, this was measured as chromium (51Cr) release, in which 
cytoplasms of target cells are labeled with 51Cr and co-cultured with 
cytotoxic effector cells [117]. The amount of  51Cr released is directly 
associated with degree of target cell killing. Other killing assays, in which 
cells are labelled with non-hazardous fluorochromes or dyes that allow 
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detection of the reduction in flourescent cells by flow cytometry, are now in 
use [118] [119].  
In essence, flow cytometry technology provides a powerful tool for extensive 
exploration of vaccine- or infection-induced immune response. This 
technology has contributed immensely to our current understanding of 
immune cells and their functions and interactions.  
 
1.8. Immune correlates of risk of TB disease 
BCG-induced immunity against TB disease is suboptimal. This, together 
with the complications of intercurrent HIV-infection, has urged the re-
evaluation and development of TB vaccines. However, rational vaccine 
design is hampered by the lack of correlates of protection against TB 
disease.  The success of many EPI vaccines can be ascribed to their 
induction of defined antibody responses that correlate with protection 
against the disease [120]. As TB disease is thought to be associated with 
cell-mediated immune responses, the role of antibody responses has 
traditionally received limited attention [121]. 
In contrast, Th1 cytokines, particularly IFN-γ, have been widely explored as 
possible biomarkers of protection. However, despite strong evidence that 
such Th1 cytokines are necessary for immunity against TB, to date, 
identifying a correlate of risk of TB has been unsuccessful. New approaches 
are required to identify a measurable marker which indicate resistance to or 
risk of TB disease. 
 
1.9. Current Study 
In this study, we aimed to investigate BCG-specific cytotoxic T cell function 
following routine BCG vaccination at birth, as a biomarker of risk of TB 
disease. First, we determined whether BCG-specific cytotoxic potential 
translates into cytotoxic killing of BCG-infected target cells and describe the 
optimisation of a flow cytometry based assay to investigate BCG-induced 
target-specific killing. Furthermore, we compared BCG-induced production 
of cytotoxic molecules by CD4 and CD8 T cells at 10 weeks of age, in 
infants at risk or not at risk of TB disease. Finally, we optimised a bead array 
	   22	  
assay to measure release of cytotoxic molecules by flow cytometry. In 
essence, we uncovered an immune profile that may correlate with risk of 
developing TB disease. 
 
1.9.1. Objective 1 (Chapter 2) 
To determine if BCG-induced T cell production of cytotoxic molecules is 
associated with killing of monocytes infected with mycobacteria. 
Specific aims: (i) To determine optimal BCG inoculating dose and 
monocyte infection time to measure T cell-mediated killing of infected cells. 
(ii) To determine the effect of IL-2 mediated T cell expansion on cytotoxic 
molecule production and killing capacity of mycobacteria-specific T cells.  
1.9.2. Objective 2 (Chapter 3) 
To investigate cytotoxic capacity, cytokine production and 
lymphoproliferation as candidate biomarkers of risk of tuberculosis, following 
BCG vaccination at birth. 
Specific aims: (i) To compare BCG-induced T cell expression of cytotoxic 
molecules and cytotoxic function of CD4 and CD8 T cells at 10 weeks of 
age in infants at risk or not at risk of TB disease. (ii) To compare BCG-
induced proliferation and cytokine expression of CD4 and CD8 T cells at 10 
weeks of age in infants at risk and infants not at risk of TB disease. 
1.9.3. Objective 3 (Chapter 4) 
To establish methodology for optimising custom bead array assays for 
detection of soluble molecules by flow cytometry 
Specific aims: (i) To establish methodology for optimisation of a custom 
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Chapter 2: Optimisation of a flow cytometry assay of    
mycobacteria-specific killing  
2.1. Background 
This chapter aims to describe the optimisation of a flow cytometry based 
assay to measure killing of BCG-infected monocytes by mycobacteria-
specific T cells. Development of this assay may be useful in our 
understanding of the role of cytotoxic T cells in TB disease development in 
our cohort of BCG-vaccinated infants. 
Traditionally, cytotoxic killing was assessed in a chromium (51Cr) release 
assay involving preincubation of target cells with radioactive sodium 
chromate (Na251CrO4) [117]. 51Cr is taken up into the cytosol of the cells and 
upon killing of the targets by effector cells, is released into the culture 
supernatant. Released 51Cr can then be measured with a gamma counter. 
However, the use of radioactive isotypes off course holds many health 
hazards and thus advances have been made in the development of non-
hazardous alternatives to radioactive assays.  
Carboxyfluorescein diacetate succinimidyl ester (CFSE) is one such 
alternative and has been widely used in both in vivo and in vitro assay 
systems [118].  CFSE-based assays enables the assessment of various T 
cell responses and processes such as cell migration, tolerance, proliferation 
and cell death by flow cytometric analysis. Briefly, cells of interest are 
stained with the fluorescent dye which is taken up in the cell cytosol. 
Processes such as proliferation can then be quantified as a dye dilution as 
the fluorescent dye is halfed between daughter cells.  
A second alternative is the use of the chloromethyl derivative, CellTrackerTM 
Orange CMTMR (CTO) to assess cytolytic killing as desribed in the VITAL 
assay [122]. Assessment of killing of target cells by effectors using this 
approach has shown good correlation with the chromium release assay 
[119]. This compound is able to stain cells fluorescent orange by reacting 
with intracellular thiols in the cytoplasm. 
We have available in our laboratory, an adapted version of the VITAL assay 
to assess killing of PPD-pulsed monocytes by antigen-specific T cells. As 
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described below, this assay makes use of the two fluorescent dyes: CTO 
and the CFSE-derivative Oregon Green® (OG). Infected and uninfected, 
control monocytes are stained with OG and CTO, respectively. Equal 
amounts of infected and control monocytes are cultured with effector T cells 
and killing is then determined as a ratio of the amount of OG+ infected cells 
to CTO+ control cells as quantified by flow cytometry. 
We wanted to determine whether BCG-induced T cell production of 
cytotoxic molecules was associated with killing of monocytes infected with 
mycobacterial antigens. Studies suggest that mycobacteria can kill APC 
directly [17], [123]. We thus assessed the viability of monocytes after 
incubation with live BCG at the dose used in the 3-day cytotoxic marker 
assay i.e. MOI 0.1. We also compared viability of monocytes after infection 
with live and heat-killed BCG at this dose. Infection efficiency of the dose as 
well as optimal time required to infect monocytes with minimal killing of 
monocytes was determined. The addition of IL-2 to expand mycobacteria-
specific T cell populations was also assessed for possible direct effects on 




2.2.1. Blood collection 
Informed consent was obtained from healthy adult volunteers by using a 
protocol approved by the University of Cape Town Research Ethics 
Committee. Heparinised whole blood was collected from each participant for 
the expansion of mycobacteria-specific T cells and the isolation of 
autologous monocytes.  
2.2.2. Expansion of mycobacteria-specific effector cells 
On day 1 of the assay, PBMC were isolated from fresh whole blood by 
density gradient centrifugation. PBMC were incubated at 2 x 106 PBMC in 
1mL culture medium (12.5% v/v AB serum in RPMI) at 37°C in 5% CO2 in 
medium alone, 2µg/mL purified protein derivative (PPD Tuberculin RT50; 
Staten Serum Institute) or BCG MOI 0.1 (BCG Vaccine SSI, Danish 1331, 
Staten Serum Institute). On day 3, 100µL cells from each condition were 
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collected before 50 units of IL-2 (eBioscience) were added and incubated 
further. Another 100µL cells were collected on day 6 and cultures were 
replenished with 500µL fresh culture medium and incubated overnight. On 
day 7, cells were harvested with repeated wash steps with cold RPMI 
followed by centrifugation, resuspension in fresh culture medium and resting 
overnight at 37°C in 5% CO2.  
2.2.3. Preparation of mycobacteria-pulsed target cells 
On day 7, autologous monocytes were isolated from freshly prepared PBMC 
using anti-CD14 microbeads (MACS Miltenyi Biotec) following the 
manufacturer’s recommendations. Isolated monocytes were resuspended 
and divided among three conditions: one part of the cells were left unpulsed 
(control target cells), one part was pulsed with 20µg/mL PPD and the 
remaining cells were pulsed with BCG at MOI 0.1. Cells were incubated at 
37°C in 5% CO2 overnight in culture medium. Next, pulsed monocytes were 
washed and stained with 0.5µg/mL OG or 50µM CTO. For co-culture of 
target cells with effector T cells, antigen-pulsed monocytes were stained 
with OG and control target cells were stained with CTO. 
2.2.4. Co-culture of target and effector T cells 
Cell counts were determined and effector and target cells were co-cultured 
at the following ratios, with target cells consisting of equal numbers of 
control and antigen-pulsed cells: 50:1, 30:1, 10:1, 5:1, 1:1 and 0.5:1 in 
FACS tubes. Cells were incubated overnight at 37°C in 5% CO2, harvested, 
stained with 1µg/mL LIVE⁄DEAD® Fixable Violet Dead Cell Stain (Invitrogen) 
and acquired fresh on a LSRII flow cytometer to assess killing of target cells 
by mycobacteria-specific effector cells (Figure 2.1 and Figure 2.5). Anti-CD3 
PacBlue, anti-perforin FITC and anti-IL4 PE were used to set compensation 
for the violet viability dye (ViViD), OG and CTO, respectively. Data was 
analyzed using Flowjo 8.8.4 (Treestar). 
2.2.5. Flow-cytometric analysis of cytotoxic molecule production 
Cultured PBMC collected on day 3 and day 6 were washed and stained with 
1µg/ml ViViD. Cells were fixed with FACS lysing solution (BD Biosciences) 
and cryopreserved. Later, cryopreserved, fixed cells were thawed, washed  
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and permeabilized with Perm/Wash solution (BD Bioscences), and stained 
with the following antibodies for 1 hour at 4°C: anti- CD3 Qdot605 (clone 
UCHT1), anti-CD8 Cy5.5PerCP (Sk1), anti-granzyme B Alexa 700 (GB11), 
anti-perforin FITC (δG9), anti-Ki67 (B56; all from BD Biosciences) and anti-
granulysin PE (eBioDH3, eBioscience). Cells were then washed and 
acquired on a LSRII flow cytometer, using FACS Diva 6.1 software. Anti-
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mouse kappa beads (BD Biosciences), stained with the respective 
fluorescent-labeled antibody, were used to configure compensation settings. 
Anti-CD3 PacBlue (UCHT1) was used to set compensation for the violet 
viability stain. Data was analyzed using Flowjo 8.8.4. 
 
2.3. Results 
2.3.1. Monocyte viability after BCG co-culture 
To determine how many monocytes remained viable at BCG MOI 0.1 at 
different incubation periods, we pulsed monocytes with BCG for 2, 4 and 18 
hours.  
Monocytes were selected based on their side scatter/forward scatter 
distribution and viable cells were identified as CTO+Vividlow (Figure 2.2. A). 
Viability of monocytes were comparable between 2 hours and 4 hours with 
medians of 99.8% at each timepoint. A decrease in viable monocytes at 18 
hours was observed compared with 2 and 4 hours of culture (Figure 2.2. B). 
At 18 hours 99.1% monocytes were viable, however, no statistical 
significance could be detected between the timepoints. An accumulation of 
dead cells as Vividhigh cells was observed when comparing 2hrs and 18hrs 
incubation of monocytes with BCG (Figure 2.2. C). Data collected from three 
donors indicated that higher proportions of monocytes die at the later 
timepoints. 
We concluded that a sufficient number of monocytes do remain viable up to 
18 hours of incubation with BCG at an MOI 0.1.  
2.3.2. Monocyte viability after infection with live or heat-killed BCG  
We also explored the viability of the monocytes after infection with heat-
killed BCG. BCG was resuspended in 250µL RPMI and incubated at 60ºC 
for 30 minutes in a waterbath. Freshly isolated monocytes were incubated 
without BCG or in the presence of live or heat-killed BCG MOI 0.1 for 18 
hours. 
Data was collected from four adult donors (Figure 2.3. A). Low numbers of 
cells were detected for two donors (DN025 and DN053). Monocyte survival 
in the absence of BCG was variable with only two donors (DN009 and 
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Figure 2.2. Monocyte infection with BCG over time. Monocytes were freshly isolated 
from healthy adult donor whole blood, stained with CTO and co-cultured with BCG for 2, 4 
and 18 hours at 40 000 monocytes per condition. After co-culture with BCG for 2, 4 and 18 
hours, monocytes were stained with the violet viability dye and acquired on the flow-
cytometer. (A) Viable monocytes were detected as CTO+Vividlow. (B) Monocyte viability 
was measured in four adult donors. (C) The accumulation of Vividhigh cells over time during 






DN074) showing increased viability compared to incubation with live or heat-
killed BCG. In all donors, there was a lower number of viable monocytes 
when cells were cultured with heat-killed BCG compared to live BCG (Figure 
2.3. A and B). However, no significant difference was detected between the 
viability of monocytes cultured with live or heat-killed BCG. 
We concluded that culture of monocytes with heat-killed BCG does not 
improve the viability of the cells.  
2.3.3. Low monocyte death detected at BCG MOI 0.1 
BCG has the capacity to kill infected monocytes directly. In our established 
cytotoxic marker assay, BCG is used at MOI 0.1 which induced detectable 
levels of T cell proliferation, IFN-γ expression and CD8 degranulation [10]. 
To determine a link between production of cytotoxic marker by BCG-specific 
T cells and killing of BCG-infected monocytes, we assessed killing capacity 
at MOI 0.1 compared to higher doses (MOI 1 and 5), lower doses (MOI 0.01 
and 0.001) and no BCG. 
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Figure 2.3. Infection of monocytes with live and heat-killed BCG MOI 0.1. Monocytes 
were freshly isolated from healthy adult donor whole blood, stained with CTO and co-
cultured with BCG, live or heat-killed for 18 hours at 40 000 monocytes per condition.   After 
co-culture with BCG, monocytes were stained with the violet viability dye and acquired on 
the flow-cytometer. Data collected from four adult donors is shown. (A) Infected monocytes 
were detected as CTO+Vividlowand the number of viable monocytes was determined. (B) A 
viability index was calculated for each donor as the number of viable monocytes under 














High doses of BCG were associated with the lowest viability compared to 
cultures with no BCG added after 18hours incubation (Figure 2.4. A). Low 
doses BCG i.e. MOI 0.001, 0.01 and 0.1, showed levels of viability 
comparable to uninfected monocytes. In four adult donors tested, an 
average of 99.1% monocytes remained viable after 18hours incubation with 
MOI 0.01. Decreasing the dose further did not improve the viability of 
monocytes (Figure 2.4. B and C). 
We concluded that BCG MOI 0.1 is an optimal dose which does not lead to 
marked killing of monocytes.   
 
2.3.4. Effect of IL-2 on cytotoxic molecule production and killing by 
cytotoxic T cells 
On day 3 of our killing assay protocol, IL-2 was added to cultures to promote 
survival and to expand the number of specific effector T cells [119]. We 
wanted to assess whether the addition of IL-2 had an effect on production of 
cytotoxic molecules as well as the killing capacity of antigen-specific 
cytotoxic cells. PBMC were cultured with or without the addition of IL-2 on 
day 3, in the presence of either PPD or BCG or in medium alone. Cells were 
collected after 6 days of culture. Intracellular expression of granzyme B,  
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Figure 2.4. Monocyte viability after infection with BCG at different doses. 
Monocytes were freshly isolated from whole blood collected from healthy adult donors 
and stained with CTO. Cells were cultured without BCG (UNS) or with BCG MOI ranging 
from 5 to 0.001, for 18 hours at 40 000 monocytes per condition. After culture, 
monocytes were stained for viability and acquired on the flow-cytometer. (A) Viable 
monocytes were detected as CTO+Vividlow. Numbers indicate the viable monocyte count 
with the relative proportion of live monocytes in parenthesis . The viable monocyte count 


















granulysin, perforin and Ki67 by CD4 and CD8 T cells was determined on 
day 3 and day 6 using flow-cytometry. The ability of expanded cells to kill 
infected target cells was also determined by flow-cytometric analysis (Figure 
2.1. and 2.5.). 
Data collected from four adult donors, indicated increased production of 
Ki67, perforin and granzyme B on days 3 and 6 upon BCG-stimulation in the 
presence of IL-2 compared to expansion without IL-2 (Figure 2.6. A). 
Similarly, granulysin and granzyme B production of PPD-specific cells were 
increased in the presence of IL-2 (Figure 2.6. A). However, IL-2 appeared to 
decrease perforin production by BCG- and PPD-specific cells. None of 
these differences were significant. 
BCG-specific effectors expanded in the presence of IL-2 appeared to have 
higher killing capacity to those expanded without IL-2 (Figure 2.6. B). 
However, again this was not signficant. Similarly, the killing capacity of PPD- 
specific effectors expanded in the presence or absence of IL-2 were not  
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Figure 2.5.  Flow-diagram illustrating the flow-cytometric analysis to determine 
killing by cytotoxic T cells. Prior to effector:target co-culture, BCG-pulsed target and 
control (unpulsed) target cells were stained with OG and CTO, respectively. All cells were 
stained with ViViD  after co-culture to exclude dead cells (ViViDhigh). Effector cells  
(CTOlowOGlow) were also excluded. BCG-pulsed targets (OGhigh) and control targets 
(CTOhigh) were selected and killing capacity determined as a ratio of the number of control 
















different (Figure 2.6. C). Specific killing by effectors expanded with IL-2 
addition in the absence of antigen could not be detected (Figure 2.6. B and 
C). A significant difference could only be detected in the killing capacity of 
effectors expanded with BCG and IL-2 compared with no antigen and IL-2 
(p=0.032). Similarly, PPD-specific effectors expanded with or without IL-2 
addition showed significantly higher killing compared to effectors expanded 
in the absence of PPD with IL-2 addition (p=0.008). 
We concluded that the addition of IL-2 to expand the effector cell population, 
had no effect on the production of cytotoxic molecules and killing capacity of 
mycobacteria-specific CD4 and CD8 T cells.  
 
2.4. Discussion 
Our laboratory has developed a flow-cytometric assay to measure killing of 
PPD-pulsed monocytes by PPD-specific cytotoxic T cells. In this 
optimisation exercise we aimed to expand the use of this assay to measure 
killing of mycobacteria-infected monocytes by BCG-specific cytotoxic T 
cells. Ultimately, we wanted to investigate cytotoxic killing of BCG-infected 
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Figure 2.6.  The effect of IL-2 addition on cytotoxic T cell function. (A) Freshly 
isolated adult PBMC were cultured with BCG or PPD. Production of perforin, granulysin 
and granzyme B by Ki67+ CD4 (grey) and CD8 (white) T cells was assessed by flow-
cytometry on day 3 (clear bars) and on day 6 with (grey bars) and without (black bars) IL-
2. Data shown is the median with interquartile ranges calculated from four adult donors. 
Killing of BCG-infected (B) and PPD-pulsed (C) monocytes by the antigen-specific 
effectors expanded with (black squares) or without IL-2 (white squares) was also 









monocytes by antigen-specific effectors in infants. However, due to the 
bloodvolume required to obtain sufficient cell numbers for this assay, we 
opted to pursue our investigation in adults. Sufficient cell yields were 
obtainable using adult whole blood.  
Our established killing assay protocol requires pulsing of monocytes with 
PPD for 18 hours. However, infection of monocytes with live BCG for 18 
hours may lead to increased cell death. We compared viability of monocytes 
pulsed with live BCG for 2, 4 and 18 hours. Viability of the monocytes 
decreased over time, however, this decrease was not signifcant. In these 
experiments, a BCG MOI 0.1 was used. Which is consistent with our 
cytotoxic marker assay [49]. We found this dose to be optimal for infecting 
monocytes. In addition, infection with heat-killed BCG did not improve 
monocyte viability in the four donors assessed. This observation should, 
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however, be interpreted with causion due to the low sample size.  
Interestingly, both live and heat-killed BCG have also been shown to 
prevent apoptosis through the upregulation of anti-apoptotic proteins [124]. 
IL-2 has been shown to be a master regulator of proliferation of hemapoietic 
cells [125] and thus have long been used in cytotoxicity assays to expand 
antigen-specific effectors. IL-2 has also been shown to play a role in the 
development of cytotoxic T cells and NK cells. Following suit, our cytotoxic 
killing assay uses IL-2 to expand antigen-specific T cells [119]. Thus, we 
wanted to determine that our assay is specific and not driven by the 
recombinant IL-2 added to induce proliferation. Indeed, we did not find 
differences in the production of cytotoxic molecules by specific T cells 
cultured in the absence or presence of IL-2. Similarly, no difference could be 
detected between the killing capacity of these cells. Moreover, cells 
expanded in the presence of IL-2 in medium alone showed significantly 
lower killing capacity compared to mycobacteria-specific cytotoxic T cells. 
In essence, we have expanded the use of our flow-cytometry based 
cytotoxicity assay to determine killing of BCG infected target cells by 
mycobacteria-specific T cells. Firstly, we have identified an optimal dose of 
BCG to ensure that killing is driven by cytotoxic T cells and not by the 
bacteria itself. Secondly, we determined that IL-2 does not contribute to the 
cytotoxic potential and function of the T cells. 
 
2.5. Contributions 
Alana Keyser designed and conducted the experiments, analysed the data 
and wrote this chapter under supervision of Prof. W.A. Hanekom, Prof. T. 
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3.1. Abstract 
Our aim was to identify biomarkers of protection against TB disease in 
infants, following routine vaccination with Bacille Calmette-Guerin (BCG) at 
birth. 5,675 infants were enrolled at 10 weeks of age, when blood was 
collected and stored. During 2 years of follow-up, 29 infants developed 
culture-positive pulmonary TB: they were regarded as being at risk of TB 
disease. Two groups of healthy infants were regarded as not at risk of TB 
disease: 55 infants from households where adults had TB, and 55 infants 
randomly selected from the cohort. 
PBMC from the infants at risk and those not at risk of TB disease, stored at 
10 weeks of age, were retrieved and mycobacteria-specific responses 
compared.  We found no difference in proliferation of CD4 and CD8 T-cells 
following incubation of PBMC with BCG for 6 days, between the 4 groups. 
However, these infants’ CD4 and CD8 T-cells had greater capacity to produce 
granzyme B, perforin and granulysin, following incubation of PBMC with BCG 
for 3 days. 
To validate findings, we repeated assays in another group of 29 infants at risk of 
TB disease and 55 infants not at risk of TB disease, from the same cohort. The 
only finding that could be validated was a greater frequency of CD4 T-cells 
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producing granzyme B among infants at risk of TB disease; other findings from 
the discovery cohort did not validate. 
We conclude that a commonly used outcome of mycobacteria-specific 
immunity, the proliferative response and Th1 cytokine production, did not 
correlate with ultimate prevention of TB disease progression. Rather, our 
results suggest that capacity to produce cytotoxic molecules might be a 
correlate of risk of TB disease, and should be studied further.  
 
3.2. Introduction 
BCG has been in use as the only vaccine against TB disease for the past 90 
years. Despite high vaccination coverage in TB endemic countries, the 
disease still remains very common. Clearly, BCG-induced protection against 
TB disease is suboptimal. However, BCG does protect against severe forms 
of TB in children, and is therefore used extensively.  
A considerable number of new TB vaccines, aimed at either replacing BCG 
or boosting the BCG-induced immune response, are at various stages of 
clinical trials [126]. Development of these vaccines is hampered by the lack 
of defined biomarkers of protection against TB disease. Correlates of 
protection may be identified in the setting of a clinical trial of an effective 
vaccine, which included a placebo group. In the meantime, we are focusing 
on correlates of risk of TB disease, with the hypothesis that knowledge 
gained would inform about protection.   
Establishment of memory T cell pools through vaccination is thought to be 
essential in protection against disease. IL-2 is required for the expansion 
and maintainence of such memory T cell pools [127], [128]. IFN-γ produced 
by both CD8 and CD4 T cells is thought to have an essential role for M.tb 
control due to the multiple antimicrobial functions [57] [129] [130]. IFN-γ 
activates macrophages to produce the antimicrobial molecules, RNI and 
ROI to control the intracellular pathogen, and the cytokine induces 
upregulation of MHC class II molecules on the surface of infected 
macrophages [131]. In addition, IFN-γ induces autophagy, another 
mycobacteria [23]. TNF-α has been shown to be important in the induction 
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of chemokine expression for the recruitment of macrophages, granuloma 
formation and RNI production [60] [132]. The importance of TNF-α in the 
host response against tuberculosis is further emphasized by the association 
between TB disease progression and anti-TNF therapy of autoimmune 
patients [133]. 
Thus, together, these cytokines potentially presents a united front in the host 
response against TB disease progression. Moreover, proliferative capacity 
and concomitant production of these Th1 cytokines, IL-2, IFN-γ and TNF-α 
in response to M. bovis-challenge have been associated with protection in 
BCG-vaccinated mice [134].  
In addition to the Th1 response, host responses against TB infection also 
involve killing of infected APC and the pathogen by cytotoxic T cells. This 
cytolytic response involves production of cytotoxic molecules such as 
granzyme B, perforin and granulysin by CD4 and CD8 T cells [73]. These 
molecules have the ability to penetrate infected macrophages and dendritic 
cells and induce killing mechanisms either directly or through the induction 
of caspases [135] [136]. BCG vaccination has been shown to induce the 
expression of these molecules, and reduced expression of granulysin and 
perforin have been implicated in TB disease progression [49] [78] [137] 
[138]. 
Anti-inflammatory Th2 cytokines have been shown to associate with poor 
outcome in TB infection. Mice vaccinated with a M.tb-culture filtrate in the 
presence of the Th2-inducing adjuvant aluminum, showed increased 
expression of IL-4 and IL10 associating with increased mycobacterial growth 
[139]. Moreover, IL-4 has been shown to be expressed at high levels in TB 
cases compared to controls in various studies [38] [140]. A pre-existing or 
induced Th2 immune response may thus lead to predisposition to develop 
TB disease. 
In this study we aimed to identify biomarkers of risk of TB disease in BCG-
vaccinated infants who went on to develop TB within the first two years of 
life. We compared proliferative capacity and cytokines produced by 
proliferating cells as well as production of cytotoxic molecules by T cells in 
	   37	  
response to BCG between infants who went on to develop TB and those 
who remained healthy at 10 weeks after vaccination when infants were 
healthy. We hypothesized that reduced proliferative capacity and 
concomitant Th1 cytokine production as well as reduced production of 
cytotoxic molecules by T cells in response of BCG, will associate with risk of 
developing TB disease. In addition, we hypothesized that a measurable Th2 
immune response in terms of IL4 expression will associate with disease 
development.  
 
3.3. Materials and Methods 
3.3.1. Participant recruitment, enrollment, blood collection and follow-
up 
Study participants were recruited at the South African Tuberculosis Vaccine 
Initiative (SATVI) field site in the Worcester area, near Cape Town, South 
Africa.  Infants, 10 weeks of age, who received Japanese BCG within 24 
hours of birth, were recruited and enrolled into the study. Infants were 
excluded when BCG had not been administered within 24 hours after birth, 
when significant perinatal complications had been present, when any acute 
or chronic disease at the time of enrollment, including clinically apparent 
anaemia, when infants had been born to HIV+ mothers, or when the infant 
was from a household where any person had TB disease or a cough. 
Informed consent was obtained from the parent or legal guardian according 
to US Department of Health and Human Services and Good Clinical 
Practice guidelines. This included protocol approval by the University of 
Cape Town Research Ethics Committee. 
Heparinised blood was collected from each infant, at 10 weeks of age. 
Study participants were followed up for a period of two years to identify 
those who developed TB. Infants who had a household TB contact and 
those who had signs suggestive of TB disease were admitted to a dedicated 
ward. Evaluation for possible TB included a chest X-ray, 2 induced sputa 
and 2 gastric washings for M.tb smear or culture, a tuberculin skin test and a 
HIV test. Infants and children with a positive HIV antibody test were 
excluded from the study. A diagnostic algorithm was used to classify TB 
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cases as definite, probable and possible. Definite disease (n=29) was 
defined as culture positive TB, whereas probable disease (n=29) was 
defined as culture negative presenting with clinical and epidemiological 
features strongly suggestive of TB disease. Among children who did not 
have TB disease, household controls were defined as children exposed to a 
household TB contact (n=55), while community controls were defined as 
healthy infants with unknown TB exposure (n=55).  
At 10 weeks of age when blood was collected and cryopreserved for 
analysis, all infants were clinically healthy but may have presented different 
levels of risk of developing TB. TB cases identified during the two-year 
follow-up period, were considered to be, at the 10 week-bleed, at risk of TB 
disease. Similarly, control groups were considered as not at risk at 10 
weeks of age,  as they did not ultimately develop TB disease. 
3.3.2. Cytotoxic marker assay 
PBMC were isolated from blood collected at 10 weeks of age by density 
gradient centrifugation, and cryopreserved. Later, PBMC were thawed in 
culture medium (12.5% v/v AB serum in RPMI) containing 10µg/mL DNase 
(Sigma-Aldrich). After washes, cells were rested overnight at 37°C in 5% 
CO2. Duplicate wells containing 2x105 cells in 200µL culture medium were 
incubated with BCG, prepared as previously described [49], at an MOI of 
0.1, at 37°C in 5% CO2.  Staphylococcus enterotoxin B (SEB, 0.5µg/mL) 
served as positive control, while medium only served as negative control. 
On day 4, cells were harvested with EDTA (2mM) and stained with 1µg/ml 
Fixable Violet Dead Cell Stain (LIVE⁄DEAD®, Invitrogen). Cells were fixed 
with FACS lysing solution (BD Biosciences) and cryopreserved. Later, 
cryopreserved, fixed cells were thawed, washed and permeabilized with 
Perm/Wash solution (BD Bioscences), and stained with the following 
antibodies for 1h at 4°C: anti-CD4 Qdot605 (clone UCHT1), anti-CD8 
Cy5.5PerCP (Sk1), anti-granzyme B Alexa 700 (GB11), anti-perforin FITC 
(δG9; all from BD Biosciences) and anti-granulysin PE (eBioDH2, 
eBioscience). Cells were then washed and acquired on a LSRII flow 
cytometer (BD Biosciences), using FACS Diva 6.1 software. Anti-mouse 
kappa beads (BD Biosciences), stained with the respective fluorescent-
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labeled antibody, were used to configure compensation settings beforehand. 
Anti-CD4 PacBlue (UCHT1) was used to set compensation for the violet 
viability stain. A positive response was regarded as a frequency of 
granzyme B-expressing CD4 or CD8 T cells, following SEB incubation, that 
was greater than the median frequency plus 4 median absolute deviations 
(MAD) of the negative control, 
3.3.3. Lymphoproliferation assay  
PBMC were stained with 1µg/mL Oregon Green (Molecular Probes) and 
rested overnight at 37°C in 5% CO2. PBMC were incubated with BCG, MOI 
0.01, at 2x105 in 200µL culture medium for 6 days, at 37°C in 5% CO2. 
Controls included SEB (0.05µg/mL) or medium alone. To determine the 
cytokine producing capacity of specific (proliferating) cells, phorbol 12-
myristate 13-acetate (PMA, 50ng/mL, Sigma-Aldrich) and ionomycin 
(250ng/mL, Sigma-Aldrich) was added on day 6, in the presence of brefeldin 
A (10µg/mL, Sigma-Aldrich), for 5 hours. Cells were then harvested, stained 
with the viability stain, fixed and cryopreserved as described above. Later, 
cells were thawed and washed as described above, and stained with anti-
CD4 and anti-CD8 as above, and with anti-IFNγ Alexa 700 (B27), anti-IL2 
APC (MQ1-17H12), anti-TNFα PECy7 (MAb11), anti-IL4 PE (8D4-8, all from 
BD Biosciences). Compensation settings were configured as mentioned 
above. Anti-perforin FITC (δG9) was used to set compensation for Oregon 
Green. A ositive proliferative response was regarded as a frequency of 
proliferating CD4 T cells, following SEB stimulation, that was greater than 
the median frequency plus 4 MAD of the negative control. 
3.3.4. Data analysis and statistical considerations 
Flow cytometric data was analyzed using Flowjo 8.8.4 (Treestar). For the 
cytotoxic marker assay, results from infants who had a frequency of 
granzyme B-expressing CD4 or CD8 T cells, following SEB incubation, that 
was greater than the median frequency plus 4 median absolute deviations 
(MAD) of the negative control, were included. Similarly, only infants who had 
a frequency of proliferating CD4 T cells, following SEB stimulation, that was 
greater than the median frequency plus 4 MAD of the negative control, were 
included in the analysis of the lymphoproliferation assay. Furthermore, 
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infants with fewer than 25 proliferating cells in response to BCG were 
excluded from the analysis of the cytokine production by proliferating CD4 T 
cells. The proliferation index was calculated as the frequency of CD4 and 
CD8 T cells proliferating in response to BCG divided by the proliferating 
frequencies in unstimulated samples. Boolean gating was used to identify 
subsets of CD4 and CD8 T cells expressing combinations of cytotoxic 
markers. 
Assay results were compared between the following groups of infants: a 
training cohort consisting of infants who ultimately were classified to have 
definite TB disease, household controls and community controls; a test 
cohort, to validate observations made in the training cohort, consisting of 
infants who ultimately were classified to have probable TB, and community 
controls.  Differences between the three groups were assessed by the 
Kruskall-Wallis test. The Mann-Whitney U test was then used to compare 
individual groups. P-values were adjusted for multiple comparisons by using 
the Bonferonni correction. A p-value < 0.05 was considered as significant. 
3.3.5. Generation of expanded effector cells 
PBMC were isolated from fresh, adult whole blood by density gradient 
centrifugation. Cells were incubated with 2µg/mL purified protein derivative 
(PPD Tuberculin RT50; Staten Serum Institute) or medium alone as 
negative control, at 2 x 106 PBMC in 1mL culture medium at 37°C in 5% 
CO2. On day 4, cells were resuspended and 200µL of cells were used to 
assess cytotoxic capacity as described above. Fifty units of IL-2 was added 
to the remaining cells and incubated until day 6. Cultures were then 
replenished with fresh culture medium and incubated overnight. On day 7, 
cells were harvested with repeated wash steps with cold RPMI followed by 
centrifugation, resuspension in fresh culture medium and incubation 
overnight at 37°C in 5% CO2, for co-culture with target cells (below). 
3.3.6. Generation of PPD-pulsed target cells 
On day 7 of effector T cell expansion, PBMC were isolated from fresh, adult 
whole blood by density gradient centrifugation. Autologous monocytes were 
isolated using anti-CD14 microbeads (MACS Miltenyi Biotec) as per the 
manufacturer’s recommendations. Isolated monocytes were then 
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resuspended of which half of the cells were left unpulsed (control target 
cells) and half were pulsed with 20µg/mL PPD at 37°C in 5% CO2 overnight 
in culture medium. Next, pulsed monocytes were washed and stained with 
0.5µg/mL Oregon Green. Control target cells were stained with 50µM 
CellTracker Orange CMTMR (Molecular Probes).  
3.3.7. Co-culture of effector and target cells 
Cell counts were determined and effector and target cells were co-cultured 
at the following ratios with the target cells consisting of equal numbers of 
control and pulsed cells: 50:1, 20:1, 10:1, 5:1, 1:1 and 0.5:1. Cells were 
incubated overnight at 37°C in 5% CO2, harvested, stained with the violet 
viability dye and acquired fresh on a LSRII flow cytometer to asses killing by 
PPD-specific effector cells. Anti-CD4 PacBlue, anti-perforin FITC and anti-
IL4 PE were used to set compensation for the violet viability dye, Oregon 
Green and CellTracker Orange, respectively. 
 
3.4. Results 
3.4.1. Study participants 
A total of 5,724 infants routinely vaccinated with BCG at birth, were 
randomly enrolled from a parent cohort of 11,680 infants [141]. Figure 3.1. 
shows the selection of the 3 groups of infants included in the training cohort 
(black boxes), to identify markers that associate with risk of TB disease, and 
2 groups of infants included in the test cohort (dark grey boxes), to test 
observations found with the first round of analysis.  
3.4.2. Increased expression of cytotoxic molecules by CD4 and CD8  
T cells in infants at risk of TB disease, in the training cohort 
Cytotoxicity is a critical T cell function allowing the immune system to kill 
pathogens either directly or after they have been taken up by APC. 
Cytotoxic molecules are constitutively expressed and maintained within 
cytotoxic granules in the cytosol. These granules migrate to the cell surface 
where the contents is released into the immunological synapse to 
commence killing of the infected cell. We assessed the production of 
cytotoxic markers by CD4 and CD8 T cells in our 3 day cytotoxic marker 
assay, which allows for the measurement of newly synthesised molecules  
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Figure 3.2. Flow-cytometric analysis to assess cytotoxic capacity of CD4 and CD8 
T cells. A representative sample illustrating the gating strategy used to identify CD4 and 
CD8 T cells producing cytotoxic molecules in response to stimuli.  
accumulated in the granules. PBMC collected at 10 weeks, when all infants 
were healthy, were thawed, incubated with BCG and assessed for the 
production of granzyme B, perforin and granulysin. The frequency of CD4 
and CD8 T cells expressing cytotoxic markers was assessed by flow 
cytometry (Figure 3.2). Incubation of PBMC with BCG induced production of 
cytotoxic markers granzyme B, granulysin and perforin by both CD4 and 
CD8 T cells in all three groups of infants (Figure 3.3. A–D). Frequencies of 





Infants at risk who ultimately developed TB disease, had higher frequencies 
of CD4 T cells producing granulysin, compared with household controls 
(Figure 3.3. A). This group also had higher frequencies of CD4 T cells co-
expressing granulysin, granzyme B and perforin, and CD4 T cells co-
expressing granulysin and granzyme B (Figure 3.3. B). Among CD8 T cells, 
infants at risk of TB disease had higher frequencies of CD8 T cells 
expressing granzyme B, compared to those who are not at risk of TB 
disease (Figure 3.3. C). Infants at risk of TB disease also had a higher 
frequency of CD8 T cells co-expressing granulysin and granzyme B, 
compared to community controls (Figure 3.3. D). Assessment of cytotoxic  
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Figure 3.3. Cytotoxic capacity of BCG-specific CD4 and CD8 T cells. PBMCs were 
stimulated for three days with BCG, SEB or medium alone. (A) Frequency of total 
granzyme B, granulysin and perforin producing CD4 T cells in response to BCG, as 
determined by intracellular staining and flow cytometry. (B) Frequency of CD4 T cell 
subsets producing combinations of the cytotoxic molecules in response to BCG. (C) 
Frequency of total granzyme B, granulysin and perforin producing CD8 T cells in response 
to BCG. (D) Frequency of CD8 T cell subsets producing combinations of the cytotoxic 
molecules in response to BCG. (E) Frequency of total granzyme B, granulysin and 
perforin producing CD4 T cells in response to SEB. (F) Frequency of total granzyme B, 
granulysin and perforin producing CD8 T cells in response to SEB. Horizontal lines 
indicate the median values. The Kruskall-Wallis test was used to determine differences 
between the three groups. Significance of differences was determined using the Mann-































molecule expression in response to SEB showed high frequencies of CD4 
(Figure 3.3. E) and CD8 (Figure 3.3 F) T cells producing granzyme B, 
granulysin and perforin at comparable levels between the three groups.  
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We concluded that the capacity of T cells to express cytotoxic markers, 
following incubation with PBMC for 3 days with BCG, was greater in infants 
at risk compared to those not at risk of TB disease. 
3.4.3. CD4 and CD8 T cell proliferative response, and cytokine 
producing potential of specific cells, in the training set 
Another important T cell functional characteritic is the ability to proliferate 
upon encounter of antigen. This allows for the expansion of the antigen-
specific memory T cell population for effective activation of the APC to 
eliminate the pathogen. We assessed proliferation of PBMC following 
incubation with BCG with a dye dilution assay (Figure 3.4. A). Proliferation 
of both CD4 and CD8 T cells in response to BCG could be detected after 
stimulation in most infants (Figure 3.4. B). Interestingly, CD4 and CD8 T 
cells showed similar levels of proliferation in response to BCG. The capacity 
to proliferate was similar in the 4 groups of infants (Figure 3.4. B).  We 
conclude that there is no difference in the CD4 and CD8 T cell proliferation 
in reponse to BCG, between infants at risk and those not at risk of TB 
disease. 
The capacity of BCG-expanded cells to produce either Th1 or Th2 
cytokines, or combinations of Th1 cytokines, was also compared between 
protected and unprotected infants. Cytokine production was induced by 
incubating the OG-stained, cultured PBMC with PMA and Ionomycin for 5 
hours before cells were harvested.  OG-stained PBMCs were fixed and 
stained intracellularly with flourescent antibodies for detection of IFN-γ, IL-2, 
TNF-α and IL-4 production by proliferating cells. Cytokine production was 
detected by gating on OGlow CD4 and CD8 T cell populations (Figure 3.4. A 
and 3.5. A). A total of 49 infants were excluded due to poor proliferation of 
CD4 T cells in response to SEB (SEB-induced proliferation < 3MAD + 
median above the unstimulated condition) and a low number of CD4 
proliferating cells (< 25) in response to BCG.  
BCG-expanded PBMC produced higher levels of cytokine production 
compared with PBMC cultured in medium alone (Figure 3.5. A). Dividing  
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Figure 3.4. Proliferative potential of BCG-specific CD4 and CD8 T cells. PBMCs were 
stained with Oregon Green and stimulated for six days with BCG, SEB or medium alone. 
(A) Flow cytometric detection of Oregon green low CD4 and CD8 proliferating T cells. (B) 
BCG-induced proliferation of CD4 and CD8 T cells expressed as proliferation above 
background. Bars indicate medians. The Kruskall-Wallis test was used to determine 
differences between the three groups. Significance of differences was determined using 
the Mann-Whitney test for non-parametric data. P-values were adjusted for multiple 
comparisons by using the Bonferroni correction. No significant differences were found 







CD4. T cells showed comparable expression of IFN-γ, IL-2 and TNF-α in all 
three  groups (Figure 3.5. B) in response to BCG. IL-4 expression by CD4 T 
cells was detected at similar levels in all groups.  However, these levels 
were much lower compared to CD4 T cells producing the Th1-cytokines. No 
difference could be detected when comparing Th1 cytokine co-expression 
by proliferating CD4 T cells between the three groups (Figure 3.5. C). 
Cytokine production by CD8 proliferating T cells could not be analysed due 
to a low number of samples meeting our criteria of >25 proliferating cells. 
We concluded that there is no difference in the expression of Th1 and Th2 
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Figure 3.5. Cytokine production by BCG-induced proliferating CD4 T cells. Oregon 
Green-stained PBMC, cultured with BCG, SEB or medium alone for six days, were 
restimulated with PMA and ionomycin for 5 hours. PBMC were harvested, stained with 
Vivid and fixed.  Cytokine production by proliferating CD4 T cells were determined by 
intracellular cytokine staining. (A) Flow cytometric detection of cytokine produced by CD4 
T cells. Results shown are gated on the Oregon Greenlow CD4 T cell population. (B) 
Frequency of total IFN-γ, IL-2, TNF-α and IL-4 producing Oregon Green low CD4 T cells 
as determined by intracellular staining and flow cytometry. (C) Frequency of CD4 T cell 
subsets producing combinations of the cytokines. Bars indicate medians. The Kruskall-
Wallis test was used to determine differences between the three groups. Significance of 
differences was determined using the Mann-Whitney test for non-parametric data. P-
values were adjusted for multiple comparisons by using the Bonferroni correction. No 
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3.4.4.  Evaluation of increased BCG-induced CD4 and CD8 cytotoxic T 
cell function in a infant test cohort. 
BCG-induced responses in a second group of 29 infants at risk of TB 
disease (probable TB cases) and 55 community controls, not at risk of TB 
disease, were analysed to validate our findings of increased cytotoxic 
potential, proliferative capacity and IFN-γ production in TB unprotected 
infants. We repeated the assays described on cryopreserved PBMCs 
collected at 10 weeks of age from these infants. 
 CD4 T cells showed quantitatively no difference in cytotoxic marker 
expression in response to BCG between the groups (Figure 3.6. A). BCG 
did, however, induce a significantly higher frequency of CD4 T cells 
producing only granzyme B in infants at risk compared to the group not at 
risk of TB disease. (Figure 3.6. B) was detected BCG-stimulation induced 
similar levels of CD4 and CD8 T cell proliferation in both groups. Similar 
frequencies of CD8 T cells and subsets expressing granzyme B, granulysin 
and perforin was detected in the two groups (Figure 3.6. C and D). 
No difference in BCG-induced proliferation of CD4 and CD8 T cells could be 
detected between the infants at risk and the groups not at risk of TB 
disease. A total of 14 and 17 infants showed no CD4 or CD8 T cell 
proliferation, respectively, above the unstimulated sample in response to 
BCG. Qualitative analysis of cytokine production showed similar frequencies 
of proliferating CD4 T cell subsets between the two groups (Figure 3.6. E).  
We compared the cytotoxic responses of infants in the training and test 
cohorts (Figure 3.7). This showed increased production of cytotoxic markers 
by the community control group of the test cohort compared to the control 
groups of the training cohort. Community controls in the test cohort showed 
higher frequencies of CD4 T cells producing granulysin and perforin 
compared to controls of the training cohort (Figure 3.7. A). Similarly, controls 
of the test cohort showed increased frequencies of CD8 T cells producing 
granulysin and granzyme B (Figure 3.7. B).  Interestingly, no differences 
were detected in the CD4 and CD8 T cell cytotoxic responses among the 
groups of infants at risk of TB disease in the training and test cohorts.   
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Figure 3.6. Validation of findings in a test cohort. PBMCs from a second group of 29 
TB unprotected and 55 TB protected infants were used to validate results from the training 
group. All assays were repeated and the same gating strategies were used. Frequency of 
total granzyme B, granulysin and perforin producing CD4 (A) and CD8 T cells (C). 
Frequency of CD4 (B) and CD8 T cell subsets (D) producing combinations of the cytotoxic 
molecules. (E) BCG-induced proliferation of CD4 and CD8 T cells expressed as 
proliferation above background. (F) Frequency of CD4 T cell subsets producing 
combinations of the cytokines. Horizontal lines indicate the median values. Significant 
differences were determined using the Mann-Whitney test for non-parametric data. P<0.05 
























We concluded that infants at risk of TB disease have a higher frequency of 
CD4 T cells producing only granzyme B in response to BCG, compared to 
infants not at risk of TB disease; however, we could not validate other 
differences seen in the primary analysis. 
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Figure 3.7. Comparison of cytotoxic T cell responses. Frequencies of total 
granzyme B, granulysin and perforin producing CD4 (A) and CD8 T cells (B) are 
plotted for comparison of the test (circles) and validation (squares) cohorts. Horizontal 
lines indicate the median values. Significant differences were determined using the 

















3.4.5. Good correlation between production of cytotoxic molecules 
and killing capacity of mycobacteria-specific T cells. 
Co-culture of PPD-specific T cells with PPD-pulsed monocytes showed a 
reduction in the percentage of monocytes after 18 hours at various ratios of 
effector:target ratios (Figure 3.8 A and B). The production of cytotoxic 
molecules by CD4+granzyme B+granulysin+perforin+ as measured at day 3 
correlated well with the killing capacity of PPD-specific T cells at a 
effector:target ratio of 10:1 (Figure 3.8 C). No correlations could be detected 
between other CD4 subsets and effector:target ratios. 
We conclude that the cytotoxic molecules measured after 3 days culture 
with BCG, have the capacity to kill monocytes infected with mycobacterium. 
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Figure 3.8. Killing capacity of mycobacteria-specific T cells producing cytotoxic 
molecules measured on day 3. (A) PBMC stimulated for 6 days with PPD were co-
cultured with PPD-pulsed monocytes at different effector:target ratios for 18 hours. (B) 
PPD-specific T cell production of cytotoxic molecules measured at day 3 was assessed 
for killing capacity measured after 6 days of PPD-expansion. (C) Correlation between 

















The analysis described in this thesis forms part of a greater study to identify 
biomarkers which can predict risk of TB disease prospectively [142]. Our 
group has previously shown that BCG induces a broad immune response, 
including Th1, Th2 and cytotoxic responses, in infants 10 weeks after 
vaccination  [49] [90].  
Contradictary to our hypothesis, analysis of BCG-induced responses in our 
infant cohorts showed no differences in cytotoxic potential or proliferative 
capacity between newborn-vaccinated infants at risk and those not at risk of 
TB disease. Initial analysis of a primary infant cohort showed increased 
expression of cytotoxic molecules in infants who developed TB compared to 
those who did not. However, analysis of the test cohort, did not support this 
observation; with the exception of CD4 T cells expressing only granzyme B, 
protected and unprotected infants showed similar expression of cytotoxic 
molecules. We found that the community controls in the test cohort showed 
similar cytotoxic marker expression to the TB cases, however, this was 
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significantly higher than the controls in the training cohort. This discrepancy 
may be due to technical reasons. PBMC were cryopreserved for ±8 years 
before this analysis was done and, additionally, analysis of the cohort 
followed more than 6 months after the analysis of the training cohort. This 
means that these samples were cryopreserved for a longer period. Quality 
control data in our laboratory to assess the effect of cryopreservation, shows 
a decrease of about 10% in PBMC viability after 4 years of cryopreservation. 
Indeed, inclusion of a viability dye revealed high levels of cell death possibly 
as a result of cryopreservation which may affect immunological outcomes as 
observed by others [143]. We did not assess the effect of cryopreservation 
on proliferation or cytotoxic molecule expression and function. However, 
good responses in terms of proliferation and production of cytokine and 
cytotoxic molecules were observed in our study groups, in response to the 
positive control. In addition, due to the time-delay, a different set of reagents 
was used for the analysis of the test cohort which may also account for this 
disparity. These variables need to be controlled for in future studies of such 
nature. However, it remains unclear why the cytotoxic responses of only the 
controls in our second cohort increased compared to the other controls. 
Granulysin, together with perforin and IFN-γ, have been implicated as a 
potential biomarker of protection to evaluate bovine BCG-vaccination 
efficacy [144]. Clinical studies, however, have identified granulysin rather as 
a possible biomarker of TB disease activity. Mueller et al, showed increased 
CD4+ memory populations expressing granulysin by TB cases compared to 
controls [145]. This is in contradiction to Di Liberto who found decreased 
plasma granulysin in TB cases compared to controls [137]. Taking this into 
consideration, it may be possible that the increased cytotoxic activity 
observed in the unprotected infants may be an indication of M. bovis BCG 
persisting 10 weeks post-vaccination; exposure to enviromental 
mycobacteria at this age is unlikely and M.tb infection was controlled for by 
excluding infants with a cough or household TB contact.  However, further 
analysis is required to establish BCG persistence. Hesseling et al, have 
reported the persistance of BCG in a immunocompetent infant six months 
after vaccination [146]. 
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Cytotoxic molecules have also been implicated in autoimmune diseases. 
The protease activity of, primarily, extracellular granzyme B allow for its 
ability to cleave proteins involved in the extracellular matrix. This in turn, 
leads to an array of inflammatory responses which manifests in autoimmune 
diseases of the lung, amongst other, such as chronic obstructive pulmonary 
disease, asthma and acute respiratory distress syndrome [147]. Thus, it 
may be informative to explore inflammation further as it is possible that 
these infants may have an inherent capacity to induce excessive pro-
inflammatory response after subsequent infection.  
Additional analysis of these samples, not described in this thesis, supports 
the concept of excessive inflammation in response to mycobacterial 
infection. BCG-stimulated and unstimulated PBMC from our study 
participants were analysed at gene-expression level. TB cases showed 
increased expression of genes associated with inflammation. 
The immune response against M.tb infection is of a pro-inflammatory nature 
characterised by increased expression of chemokines for cell recruitment as 
well as pro-inflammatory cytokines such as IFN-γ and TNF-α for APC 
activation and granuloma formation. The ability to control this immune 
response in order to prevent tissue damage and further immunopathology, is 
thus crucial to resolve the infection. Recently, Horne et al described a 
genetic association between TB disease and inflammation; a single-
nucleotide polymorphism in a IL1-TLR inhibitor leading to increased 
inflammation was identified in TB diseased individuals [148]. Knock-out of 
this inhibitor lead to increased inflammation and subsequent death of mice 
after M.tb infection [149]. Such an analysis of our study participants at 
genetic level would  be insightful.     
Evaluation of proliferative responses and concomitant Th1 cytokine 
production, the most commonly used outcome of mycobacteria-specific 
immunity, showed no differences in TB protected and unprotected infants. 
Our initial analysis of the proliferative response of CD4 T cells of the training 
set detected significant differences between the groups. However, statistical 
significance was lost when correcting for multiple comparisons between the 
groups. No differences were detected in the test cohorts. Together, this  
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support previous data generated on these samples. Short-term stimulation of 
whole blood with BCG also showed no differences in the production of IFN-γ, 
IL-2 and TNF-α between TB protected and unprotected infants [50]. Our data 
is also consistant with findings by Kori et al who reported no difference in 
proliferative capacity and cytokine production in reponse to PPD between 
active TB cases and controls irrespective of BCG vaccination as determined 
by thymidine incorporation and ELISA, respectively [150].  
Furthermore, CD4 production of IL-4 did not associate with disease 
progression.  Literature suggests a strong association between IL-4 and TB-
disease progression. Based on this, we restricted our investigation of the 
role of the Th2 response to IL-4. We can not exclude that other Th2-
cytokines may be involved. However, our data is consistent with a two year 
follow-up study which showed no difference in IL-4 expression between TB 
cases and their household controls [151]. Hussain et al, however, describes 
IL-4 as a predictor of disease progression in household contacts six months 
after the diagnosis of the household TB index case in genetically susceptible 
families [64]. Our study design did not allow for assessment of additional 
time-points which may have showed a more complete view of the immune 
response to M.tb infection in BCG vaccinated infants.This motivates further 
genetic evaluation of our study participants.  
Our data shows that reduced proliferative potential as well as reduced Th1 
cytokine production by BCG-specifc T cells, post-vaccination, do not 
correlate with risk of developing TB disease. Rather, our data eludes to the 
possibility of an increased cytotoxic response as a risk factor to develop TB 
disease. Further analysisis, at both genetic and protein level, are underway 
to dissect the underlying mechanisms involved.  
 
3.6. Contributions 
Jane Hughes optimised and designed the assays. Alana Keyser conducted 
the experiments, analysed the data and wrote this chapter under 
supervision of Prof. W.A. Hanekom and Prof. T. Scriba. 
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Chapter 4: Optimisation of a flow cytometric bead array 
assay for quantification of soluble proteins 
4.1. Background 
Our study which compared immune responses of infants at risk of TB with 
those who are not at risk implicated frequencies of BCG-specific T cells that 
produced cytotoxic molecules as a possible risk of TB disease. Higher levels 
of T cell expressing intracellular cytotoxic molecules were detected in infants 
who ultimately developed TB, compared to those who remained healthy. 
Cytotoxic molecules are maintained inside cytotoxic granules within effector 
cells. Upon activation, the granules migrate to the cell surface distal to the 
immunological synapse, a highly organized interface, between the effector 
and target cell [27]. Killing of the target cell requires the release of the 
contents of the granules into the immunological synapse. Failure to release 
cytotoxic molecules may lead to increased levels of intracellular cytotoxic 
molecules and subsequent inability to kill target cells. Soluble levels of 
granzyme B, perforin and granulysin have been detected in serum or 
plasma samples and culture supernatants, and high levels have been 
associated with active TB disease [78] [137] [152].  
We sought to determine if soluble levels of granzyme B, perforin and 
granulysin are correlates of risk of TB in BCG-vaccinated infants. We 
collected 130μL of culture supernatant per condition from the cytotoxic 
marker assay, described in section 3.3.2 of chapter 3, to compare soluble 
levels of these molecules in the two groups of infants. Since measurement 
of analytes by ELISA requires 100μL of sample for each individual molecule, 
we aimed to develop a method that allows measurement of granzyme B, 
granulysin and perforin in a single sample volume of 100μL or less. 
Cytometric bead-based multiplex technology using the Luminex® platform 
allows detection of up to 42 analytes from 50μL of sample (Figure 4.1). 
Cytometric bead kits for the detection of granzyme B and perforin are 
commercially available and can be detected simultaneously using the 
LEGENDplexTM Luminex xMAP bead-based multiplex assay. Currently no 
kit is available for detection of granulysin.  
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Figure 4.1. The multiplexed microsphere-based flow cytometric immunoassay.  
Immunoassays using an antigen-antibody format can be performed on microplex beads 
(A). Microspheres consists of a fluorescent dye dilution excited by the red laser and 
analytes are measured as PE fluorescence excited by the green laser (B). Each beadset 
for a particular analyte can be detected at a specific fluorescence intensity (C). 
Quantification of different analytes of an 8-plex assay is shown (D). (From Kellar et al, 
















Luminex kits consist primarily of 5.6μm polystyrene beads containing a 
fluorescent dye which, upon excitation by a laser emitting red light, yields a 
specific spectral signature. These beads are also coated with carboxyl 
groups which can be covalently coupled to amine groups of proteins by 
using a two-step carbodiimide reaction. Activation of the carboxyl group 
yields a stable ester which can react with amines of proteins to form a 
covalent bond. Capture antibodies for a specific analyte can thus be 
conjugated onto the surface of a bead. A specific secondary biotinylated 
antibody is then used for detection, followed by binding of a PE-conjugated 
streptavidin for quantification by flow-cytometry.  Using this technology, 
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carboxylated beads can be custom-conjugated with specific antibodies for 
any analyte of interest.  
Based on these principles, we aimed to design a two-step optimisation 
protocol to custom-conjugate beads for measurement of granulysin. In the 
first step, as a proof of principle which is described in this chapter, we 
optimised conditions for detection of IFN-γ. IFN-γ levels detected by custom-
conjugated beads can easily be validated by direct comparison of observed 
results with those from commercial bead kits or ELISA kits. Once 
satisfactory performance of the detection system is achieved, the second 
step would be to apply the validated optimisation protocol for development 
of reagents to the detection of granulysin. The final custom-conjugate beads 
can then be incorporated into commercial kits for simultaneous detection of 
granulysin, granzyme B and perforin. The latter aspects of this process are 
not addressed in this thesis, because of insufficient time. 
 
4.2. Methods 
4.2.1. Conjugation of microplex beads 
Microplex beads (xMAP carboxylated microplex beads Region 55 
microsphere, Luminex) were conjugated with a mouse anti-human IFN-γ 
antibody (clone MD-1, Biolegend) by using the protocol for two-step 
carbodiimide coupling of protein to carboxylated beads, according to the 
manufacturer’s instructions. Briefly, 5 x 106 of resuspended stock 
microspheres were washed with 80µL 100mM monobasic sodium 
phosphate (Sigma-Aldrich) and vortexed for approximately 20 seconds. Ten 
µL of each 50mg/mL Sulfo-NHS (N-hydroxysulfosuccinimide, Thermo 
Scientific) and 50mg/mL EDC (1-ethyl-4-[4dimethylaminopropyl] 
carbodiimide hydrochloride)  were added to the beads and mixed gently by 
vortex. Beads were incubated for 20 minutes at room temperature with 
gentle mixing by vortex at 10-minute intervals. Activated beads were 
centrifuged at 14,000 x g for 2 minutes and washed twice with 250µL 50mM 
MES (2-[N-Morpholino] ethanesulfonic acid hydrate, Sigma-Aldrich) followed 
by centrifugation. Pelleted beads were resuspended in 500µL of 50mM MES 
and added at 100µL per antibody concentration ranging from 1-50µg/mL. 
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The bead-protein mix was brought up to 500µL with 50mM MES, mixed by 
vortexing and then incubated for 2 hours with mixing by rotation at room 
temperature. Following incubation, beads were centrifuged, resuspended in 
500µL PBS-TBN (1% PBS, 0.1% BSA, 0.02% Tween-20, 0.05% Azide, pH 
7.4) and again vortexed for 20 seconds. Beads were incubated for 40 
minutes with mixing by rotation at room temperature and washed twice with 
1mL PBS-TBN. Finally, beads were resuspended in 1mL PBS-TBN and 
counted under the microscope. Coupled beads were diluted to a final 
concentration of 100 beads/µL in PBS-TBN and stored in the dark at 4°C 
until use.  
4.2.2. Confirmation of conjugation of microplex beads 
Binding of anti-IFN-γ antibody to the beads was determined by following the 
protocol for confirmation of antibody coupling according to the 
manufacturer’s instructions. A two-fold serial dilution, ranging from 4 to 
0.0625µg/mL, of a PE-labeled anti-mouse IgG detection antibody (R & D 
Systems) was prepared in PBS-TBN. Fifty µL of the working microsphere 
stock was mixed with 50µL diluted detection antibody and incubated for 30 
minutes at room temperature. The microsphere-antibody mix was washed 
twice with 1mL PBS-TBN followed by centrifugation after each step. Beads 
were resuspended in 100µL of PBS-TBN and acquired on a LSR Fortessa 
flow-cytometer using FACS Diva 6.1 software, to confirm conjugation. Data 
was analyzed using FlowJo 8.8.4. 
4.2.3. Detection of IFN-γ  concentration with microplex beads 
Five-fold serial dilutions of a known recombinant human IFN-γ standard (BD 
Biosciences) was prepared with PBS-TBN.  Reaction mixes were prepared 
in FACS tubes by adding 50µL diluted protein to 50µL working bead stock. 
Samples were incubated for 1 hour at room temperature, followed by two 
wash steps: in 1mL PBS-TBN, followed by centrifugation at 14,000 x g for 5 
minutes and supernatants were decanted. Fifty µL biotinylated anti-IFN-γ 
detection antibody (clone 4S.B4, Biolegend) was added. Samples were 
incubated for 30 minutes at room temperature followed by two wash steps. 
Fifty µL Streptavidin PE (Sigma-Aldrich) was added followed by a 30-minute 
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incubation at room temperature. Beads were washed twice, resuspended in 
100µL PBS-TBN and acquired on a LSR Fortessa flow cytometer using 
FACS Diva 6.1 software. Data was analyzed using Flowjo 8.8.4. Similarly, 
the IFN-γ concentrations in unknown blood plasma samples were 
determined by using two-fold serial dilutions. 
4.2.4. IFN-γ  ELISA 
IFN-γ concentrations of unknown blood plasma samples were quantified in 
parallel using the Human IFN gamma ELISA Ready-SET-Go!® 
(eBioscience), following the manufacturer’s instructions. Briefly, 96-well 
plates were coated overnight at 4°C with 100µL/well IFN-γ capture antibody 
(clone NIB42) in coating buffer. Plates were washed and blocked with assay 
diluent. Hundred µL two-fold serial dilutions of the IFN-γ standard or blood 
plasma samples were added to the appropriate wells. Plates were incubated 
for 2 hours at room temperature. After washing, plates were incubated for 1 
hour at room temperature with 100µL/well IFN-γ detection antibody (clone 
4S.B4). Plates were washed and incubated with 100µL/well Avidin-HRP for 
30 minutes at room temperature. After washing, 100µL/well substrate 
solution was added. The reaction was developed at room temperature and 
stopped after 15 minutes by adding 50µL 2N H2SO4 to each well. Plates 
were read at 450nm on a Versamax ELISA plate reader using Softmax Pro 
software Version 4.7.1. IFN-γ standards ranged from 4-500pg/mL. 
 
4.3. Results 
4.3.1. Detection of microplex beads and specific analytes by flow 
cytometry. 
Luminex microplex bead-technology typically makes use of a luminometer 
for detection of bead fluorescence at a wavelength of approximately 650nm 
upon red laser excitation (at a wavelength of 635nm) and quantification of 
specific analytes by detection of fluorescence at approximately 575nm upon 
excitation by a green laser (560nm). We wanted to optimise this assay to 
allow acquisition on a BD LSR Fortessa, equipped with red, green, blue and 
violet lasers.   
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To determine if microplex beads and specific analytes could be detected on 
this flow-cytometer, we used three beadsets, with different luminescent dye 
dilutions, of the Milliplex® Map Human cytokine/chemokine kit (Millipore). 
Each beadset is conjugated to antibody specific for a particular analyte; in 
this case TNF-α, IFN-γ and IL-2.  
As shown in Figure 4.2.A, the fluorochromes on the three beads were 
excited by the red laser and could be detected at different fluorescence 
intensities using a 660/20 bandpass filter (typically used to detect APC or 
AlexaFluor 647). Titration of the kit standards allowed detection of all three 
beadsets at different fluorescence intensities upon green laser excitation 
using a 576/26 bandpass filter (typically used to detect PE, Figure 4.2.B).  
We concluded that fluorescence of Luminex microplex beads can 
successfully be detected by using a BD LSR Fortessa flow cytometer. 
4.3.2. Custom conjugation of a microplex beadset with a IFN-γ  capture 
antibody. 
Commercially available kits for the detection of granzyme B and perforin 
consist of carboxylated microplex beads manufactured by Luminex. We  
conjugated a carboxylated microplex beadset with a mouse anti-human IFN-
γ antibody following the manufacturers instructions. Four different 
concentrations of the antibody were used: 5µg/ml, 10µg/ml, 20µg/ml and 
50µg/ml. Conjugation of the antibody was confirmed by using a two-fold 
dilution of a PE-conjugated anti-mouse IgG antibody. The beads were then 
acquired on the LSR Fortessa flow cytometer. 
As shown in Figure 4.3.A, the microspheres were detected in the red laser 
650nm channel. The anti-mouse IgG was also detected as a dilution of the 
fluorescence intensity in the green 570nm channel. However, we observed 
overlap in fluorescence signal of the anti-mouse IgG concentrations, 
resulting in difficulty to resolve the different IFN-γ concentrations. Further, 
fluorescence of the highest concentrations fell above the linear range of 
detection in the green 570nm (PE) channel. This was possibly due to 
suboptimal photomultiplier tube (PMT) voltage settings, which were likely set  
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Figure 4.2.	   Detection of Milliplex beads using a flow-cytometer.  Three Milliplex 
beadsets were acquired on a LSR Fortessa flow cytometer. The beadsets were 
detectable in the APC channel, as shown in A. Histograms show the beadsets at different 
fluorescence intensities. Beads were incubated with a concentration range of the kit 
standards followed by a biotinylated detection antibody and a PE-conjugated streptavidin. 
Histograms show the dilution in fluorescence intensities in the PE channel for each 
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too high, or suboptimal ratio of biotin and streptavidin concentrations. 
Fluorescence intensities were plotted against the antibody concentration, 
Figure 4.3 B, which showed that each of the IFN-γ antibody concentrations 
used appeared to be efficiently conjugated to the microplex beads.  
We concluded that, using the manufacturer’s instructions, we could 
successfully custom-conjugate microplex beads with specific capture 
antibodies. Further optimisation for optimal detection of IFN-γ, such as 
















4.3.3. Optimal PMT voltage for acquisition in green 570 PE channel 
To determine the optimal PMT voltage at which analytes can be detected in 
the green 570 PE channel, custom conjugated beads (5000 beads per 
reaction) were incubated with recombinant IFN-γ at a low (3.2pg/ml) and 
high concentration (2000pg/ml). Beads were also incubated without IFN-γ 
Figure 4.3.	  Confirmation of custom conjugation.  Microplex beads were conjugated 
with 5, 10, 20 and 50µg/ml IFN-γ capture antibody, respectively. Beads were incubated 
with a range of anti-mouse lgG-PE concentrations.  Dot plots and histograms showing 
the fluorescence intensity of different antibody dilutions in the green 570nm PE channel. 
Detection of the beads conjugated with 5µg/ml IFN-γ detection antibody is shown in A.  
Fluorescence intensities for beads conjugated with capture antibody is plotted against 
anti-mouse IgG PE concentrations in B. 
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standard, to control for background bead fluorescence.  Following 
incubation with biotinylated IFN-γ detection antibody and streptavidin PE, 
beads were acquired at different PMT voltage settings ranging from 250V to 
350V, at 25V increments. 
Fluorescence intensities of the background signal as well as the low and 
high standard concentrations increased when PMT voltage was raised 
(Figure 4.4. A). Signal:noise ratios were calculated for each voltage setting, 
where signal was the PE fluorescence intensity of the beads incubated with 
low or high concentrations of IFN-γ and noise was the fluorescence intensity 
of the unstained background beads. Using this approach, we observed that 
the difference in MFI between the high and low IFN-γ concentrations did not 
change at different PMT voltage settings (Figure 4.4. B).  However, different 
voltage settings did influence the ratio of fluorescence intensities of the 
background control beads and the low IFN-γ concentration beads (Figure 
4.4. C). Acquisition at 250V showed little difference between the background 
MFI and the MFI of the low IFN-γ concentration. Acquisition at 400V and 
higher voltages led to increased background MFI and poorer resolution of 
background from IFN-γ beads. Acquisition at 275V showed the best 
distinction between the signals of the background beads and low standard 
concentration. Routine instrument setup and performance standardisation 
procedures and quality control measures of the LSR Fortessa flow 
cytometer had identified 280V as the optimal PMT voltage with the lowest 
background noise for acquisition in the green 570 PE channel.   
We concluded that 280V was optimal for detection of cytometric beads and 
quantification of specific analytes.  
 
4.3.4. Determining optimal concentrations of biotinylated IFN-γ  
detection antibody and streptavidin-PE. 
Luminex microplex technology detects and quantifies specific analytes using 
a biotinylated detection antibody followed by a PE-conjugated streptavidin.  
Biotin binds to streptavidin, which, in this case is conjugated to PE.  If 
concentrations of specific analytes are directly proportional to the PE MFI of 
a known standard, linear quantification can be achieved. However, the  
	   64	  
Figure 4.4. Optimal PMT voltage for acquisition in the PE channel.  Beads 
conjugated with 10µg/ml IFN-γ capture antibody were incubated with (3.2 and 2000pg/ml 
IFN-γ standard) or without (background) IFN-γ standard and acquired at different PMT 
voltages to determine optimal voltage settings for acquisition of the microplex beads. 
Histograms of the mean fluorescence intensities at each voltage (A) Mean fluorescence 
intensities were determined (A) and signal:noise ratios at each voltage calculated to 















accuracy of detection depends on optimal concentrations of biotin and 
streptavidin. 
Conjugated beads incubated with a five-fold dilution of known IFN-γ 
standard were used to determine effects of different concentrations of 
biotinylated detection antibody (biot-dAb) and streptavidin PE (SA-PE) at a 
constant 5:1 ratio, as described elsewhere [153]. The concentrations tested 
were as follows: 0.5µg/ml biot-dAb with 2.5µg/ml SA-PE, 1µg/ml biot-dAb 
with 5µg/ml SA-PE and 2µg/ml biot-dAb with 10µg/ml SA-PE. Signal:noise 
ratios were calculated as described above. 
We observed no difference in signal:noise ratio between the three 
concentrations used (Figure 4.5. A). PE fluorescence intensity was also not 
different between the different biotin:streptavidin concentrations. However, 
an increase in signal spread between the background signal and the lowest 
standard concentration was observed when biotin and streptavidin 
concentrations were increased (Figure 4.5. B).  
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Figure 4.5. Optimising biotin:streptavidin concentrations.  Beads conjugated with 
10µg/ml IFN-γ capture antibody were incubated with IFN-γ standard, and a range of 
Biotin:streptavidin-PE concentrations, and acquired at 280V. Mean fluorescence 
intensities were determined and signal:noise ratios were calculated (A). Histograms of 
the mean fluorescence intensities at each voltage were also assessed to determine an 

















We concluded that an optimal concentration of biot-dAb and SA-PE could 
not be determined from these experiments. However, using 0.5µg/ml  
detection antibody with 2.5µg/ml streptavidin was sufficient for detection of 
analyte concentrations covering a wide dynamic range, as there was no 
difference compared to other concentrations. 
 
4.3.5. Optimising concentrations of capture antibody.	  
Next, we determined the concentration of IFN-γ capture antibody required to 
optimally quantify concentations of soluble IFN-γ. Microplex beads were 
conjugated with different concentrations of anti-IFN-γ antibody. Beads were 
incubated with a five-fold titration of a known IFN-γ standard and acquired at 
280V to determine the MFI for each concentration.  
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Figure 4.6. Optimising concentrations of IFN-γ capture antibody. Beads were 
conjugated with 10, 20 and 50µg/ml of IFN-γ capture antibody and incubated with IFN-γ 
standards at a range of concentrations and acquired at 280V. Mean fluorescence 
intensities for each beadset were assessed to determine an optimal IFN-γ capture 
antibody concentration (A). Mean fluorescence intensities were determined and 















Signal:noise ratios were highest at a concentration of 50µg/ml capture 
antibody, compared with the lower concentrations (Figure 4.6 A). There was 
no difference in signal:noise ratios between 10 and 20µg/mL. However, 
fluorescence overlap between the background sample and the lowest 
standard increased when 50µg/ml capture antibody was used (Figure 4.6 
B). In essence, all three concentrations of capture antibody could detect the 
recombinant IFN-γ. We thus explored the use of 10 and 20µg/mL further and 
directly compared IFN-γ detection between the bead detection method 
developed here and a commercial IFN-γ ELISA. 
Beads were incubated with a two-fold serial dilution of a human plasma 
sample to allow quantification of IFN-γ. This sample was also quantified by  
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Figure 4.7. Validation of beadsets. Beads conjugated with 10 and 20µg/ml IFN-γ capture 
antibody were incubated with a two-fold dilution of a human plasma sample with unknown 
IFN-γ content and a known IFN-γ standard. Mean fluorescence intensities were determined 
and IFN-γ concentrations were calculated against the standard (A). IFN-γ concentrations of 
the plasma sample were determined by ELISA and the calculated concentrations were 
compared to concentrations determined by using the microplex beads (B). Correlation of 
IFN-γ concentrations of the plasma sample, as determined by ELISA and the custom 
conjugated bead sets was determined (C). Linear regression analysis of the expected and 
observed OD and mean fluorescence intensity of the standard was performed for the 



















using the Human IFN-gamma ELISA Ready-SET-Go! as described above. 
Concentrations were then compared between the two assay systems. The 
two beadsets detected soluble IFN-γ at similar levels (Figure 4.7. A and B). 
However, higher concentrations of IFN-γ were observed using the ELISA 
assay, compared with the beadsets. This possibly indicated a lower level of 
sensitivity of the beadsets which required further optimisation. IFN-γ  
concentrations determined by ELISA and the fluorescent bead sets, showed 
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good correlation (Figure 4.7. C). In addition, linear regression analysis of the 
expected and observed OD and mean fluorescence intensity of the standard 
was performed for the ELISA and the custom conjugated beads, 
respectively, indicated optimal performance of the two quantification 
platforms (Figure 4.7. D). 
 
4.4. Discussion 
Luminex bead arrays have become a very helpful tool for measuring levels 
of multiple proteins in low sample volumes owing to their highly multiplexed 
nature. This property makes bead arrays ideal for infant studies, where 
sample volumes are generally very small. Commercially available kits have 
been used to identify correlates of risk of TB disease in infants three months 
after BCG-vaccination [154]. Various groups have used this technology to 
determine diagnostic markers of infection and disease progression in TB 
and HIV [155] [156] [157].  
Cytolytic killing of infected target cells requires the release of cytotoxic 
molecules into the immunological synapse. Failure to release these 
molecules may associate with poor outcome in M.tb. infection. Differential 
levels of soluble cytotoxic molecules may associate with risk of TB disease. 
Ultimately, we wanted to assess soluble levels of granzyme B, perforin and 
granulysin by comparing concentrations of granzyme B, perforin and 
granulysin in culture supernatants of PBMC stimulated with BCG of infants 
at risk and infants not at of TB disease. Here we optimised a flow cytometric 
bead array assay to quantify soluble levels of cytotoxic molecules. 
Addressing this aim by applying the optimised bead array assay was not 
possible in the timeframe of my project. 
Our optimisation process involved a number of steps. The first step was to 
determine optimal conditions for a flow cytometric bead array assay to 
measure IFN-γ. The performance of this custom IFN-γ bead array assay was 
then validated against a IFN-γ ELISA as a second quantification platform. 
We showed that a standard flow cytometer can detect these fluoro-
chromatically labeled beads and identified an optimal acquisition PMT 
voltage. Using a step-wise approach, we also identified optimal 
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concentrations of capture and detection antibody for binding of soluble IFN-
γ. These optimal conditions were applied to quantify IFN-γ in a human 
plasma sample using the custom-conjugated beads. However, comparison 
of calculated values against that of an IFN-γ ELISA for the same sample, 
showed that IFN-γ levels were detected at higher levels with the ELISA 
compared to the beads. Regardless, the bead array method yielded highly 
linear quantification and a high regression co-efficient when compared to a 
commercial IFN-γ ELISA. Others have reported comparable results between 
the two platforms with an even higher sensitivity of the beads in some cases 
[153] [154] [158]. Together, this may indicate reduced sensitivity of our 
custom-conjugated beads compared to the ELISA. A plausible reason may 
be that different IFN-γ antibody clone sets were used in the two platforms. 
Switching to identical IFN-γ antibody clone sets may eliminate this 
discrepancy. 
The Luminex platform remains a robust, yet costly technology to assess 
multiple analytes in small volume samples. Continued optimisation of a 
custom-conjugated beadset and conditions was not warranted given limited 
availability of funds and timelines. However, we developed custom-
conjugated beadsets that can quantify soluble IFN-γ and, pending further 
optimisation optimisation and conjugation with an anti-human granulysin 
antibody, these beads could ultimately be used to quantify soluble cytotoxic 
molecules. Kits for custom-conjugation of fluorescent beads are also 
becoming commercially available and may be useful to explore analytes not 
included in the multiplex kits.  
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Chapter 5: General Discussion 
Identification of biomarkers of protection against TB disease requires a 
placebo-controlled trial of a successful vaccine, where the vaccine-induced 
protective immune responses are contrasted with immune responses in 
unvaccinated individuals [159]. All infants in our cohort had received BCG, 
at birth as is routine in South Africa due to the high TB prevalence. These 
infants were followed for two years to identify those who became TB 
diseased and those who remained healthy. In this context, we are able to 
explore prospective correlates of risk of TB disease, using blood collected at 
a time-point prior to M.tb infection and TB disease development.  
In this thesis we took a novel approach to identify biomarkers of risk of TB 
disease: we explored BCG-specific cytotoxic T cells as candidate correlates. 
In order to do this, we first optimised an assay to demonstrate BCG-specific 
cytotoxic T cell-mediated killing of mycobacteria-infected monocytes. 
Secondly, we compared BCG-specific cytotoxic T cell responses in infants 
who are at risk of TB disease to those who remained healthy. We also 
measured and compared the BCG-specific Th1 and Th2 immune response 
in these infants. Thirdly, we optimised a fluorescent bead array system to 
ultimately measure release of cytotoxic molecules in cell-culture 
supernatants upon mycobacterial stimulation. 
We successfully optimised a flow cytometry-based killing assay showing 
that BCG-expanded cytotoxic T cells can kill monocytes infected with BCG. 
This optimisation presented two challenges. Firstly, BCG itself has the ability 
to kill infected cells. Hence, we identified optimal assay conditions in terms 
of incubation time and dose to infect monocytes to measure BCG-specific T 
cell-mediated killing. Secondly, only limited volumes of blood are obtainable 
from infants. However, the killing assay requires more PBMC than the 
amount harvested from the maximum blood volume accessible at 10 weeks 
of age. Thus, we proceeded with optimisation using adult blood. We cannot 
exclude that infant and adult cytotoxic responses may differ. Kollmann et al 
reported similar responsiveness between adult and infant monocytes when 
stimulated with different TLR agonists [160]. However, differences became 
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prominent when DC responsiveness and cytokine production by monocytes 
and DC were assessed. These kinds of differences may also apply between 
cytotoxic CD4 and CD8 T cells of adults and infants.  
In this study, assessment of the CD4 and CD8 T cells revealed responses 
suggestive of increased cytotoxic potential in BCG-vaccinated infants who 
were at risk of TB, compared with those who were not at risk of TB disease. 
Our training cohort showed statistical differences in cytotoxic responses of 
infants who ultimately developed culture positive TB when compared with 
healthy infants. However these findings could not be validated in a second 
cohort of infants at risk, and not at risk, of TB disease. Our initial 
investigation of a correlate of risk of TB disease did not include validation of 
findings as described by Qin et al [159]. Validation studies usually require 
identical clinical case definition as discover studies. However, due to limited 
sample sizes, there was a slight difference in the case definition between 
our training and validation cohorts. The first ultimately developed culture 
confirmed TB, while the latter did not have culture confirmed disease, but 
strong clinical, radiological and epidemiological evidence of TB disease 
(described in chapter 3). We cannot exclude that this small difference in 
phenotype could have contributed to the failure of validation.  
Assessment of Th1 effector function showed no differences between infants 
at risk and those who were not at risk of TB disease. BCG-specific CD4 and 
CD8 T cell effector function of these infants were also assessed in a 
complementary study using direct ex vivo short-term stimulation of whole 
blood [101]. Interestingly, in the latter study, patterns of BCG-specific IFN-γ, 
IL-2 and/or TNF-α expression in polyfunctional CD4 and CD8 T cells were 
similar to those shown with our longer term stimulation; in the current study, 
no differences were detectable between the different groups. Although these 
effector T cell populations are important in control of M.tb growth and 
disease progression, it appears that BCG-specific effector function does not 
correlate with protection or risk of TB disease. We cannot exclude that use 
of a different mycobacterial antigen, or another time point of evaluation, 
could have revealed differences between the infants at risk and those not at 
risk of TB disease. However, results from the historical MVA85A vaccine 
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trial have been informative in these respects [161]. In this trial infants were 
vaccinated in a BCG prime-MVA85A boost strategy. Direct ex vivo, short-
term stimulation of whole blood with Ag85A showed increased antigen-
specific Th1 responses in MVA85A-vaccinated infants compared to the 
placebo group. However, these responses did not confer protection against 
M.tb infection or TB disease in the vaccinated group. During the three-year 
follow-up period, equal numbers of infants in both groups became M.tb 
infected and similar numbers of infants also develop TB disease. These 
results appear to confirm that effector T cell responses do not correlate with 
risk of TB disease. 
Recent advances in our understanding of the evolution of BCG-induced 
memory responses have also provided insight into our observations. In a 
one-year follow-up study of newborn BCG vaccinees, Soares et al showed 
peak CD4 T cell responses between 6 and 10 weeks of age [91]. 
Furthermore, the proportion of central memory BCG-specific CD4 T cell 
population was greater at 27 weeks compared with 6 weeks post-
vaccination. Also, BCG has been shown to persist for up to 6 months after 
vaccination in an immunocompetent infant [146]. Together, this information 
may suggest that our time-point of 10 weeks post-vaccination may have 
been too early for clearance of BCG and for establishment of memory 
populations. Evaluation of infant responses after 27 weeks post-vaccination 
could have provided complementary information in terms of the cytotoxic 
and Th1 potential of BCG-specific memory T cells.  
We also attempted to uncover differences in the release of cytotoxic 
molecules between infants at risk and those not at risk of TB disease, using 
cytometric bead array technology. This presented challenges in that 
cytotoxic molecules are not included in the commercially available Luminex 
kits, which measures cytokine related to CD4 helper T cell function, plus 
additional chemokines and growth factors. Data from the current study seem 
to confirm other published data that there are no differences in the 
frequency of Th-related cytokine producing CD4 T cell populations between 
infants at risk and those not at risk of TB disease. Expansion of 
commercially available kits to assess beyond the current 42 analytes may 
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be a helpful tool in determining biomarkers correlating to risk of or protection 
against TB disease. Our optimisation of a custom bead array lays the 
groundwork for assessment of novel analytes, if so required, for future 
studies. 
In summary, comparison of BCG-induced responses in infants who were at 
risk of TB disease and those not at risk of TB disease showed no 
differences in the conventionally protection-associated Th1 cytokines. We 
also showed that BCG can induce specific cytotoxic T cell-mediated killing 
of infected cells. We were unable to validate increased production of 
cytotoxic molecules by BCG-specific T cells in infants at risk of TB disease 
in a secondary cohort. Identifying a biomarker of risk of TB disease may 
require an unbiased systems biology approach to explore global gene 
expression in this cohort. 
74	  
References: 
[1] WHO,	  “Global	  Tuberculosis	  Report	  2013,”	  2013.	  [Online].	  Available:
http://www.who.int/tb/publications/global_report/en/.
[2] WHO,	  “Ten	  facts	  about	  TB,”	  2013.	  [Online].	  Available:
http://www.who.int/features/factfiles/tb_facts/en/index1.html.




[4] S.	  T.	  Reece	  and	  S.	  H.	  Kaufmann,	  “Floating	  between	  the	  poles	  of	  pathology
and	  protection:	  can	  we	  pin	  down	  the	  granuloma	  in	  tuberculosis?,”	  Curr
Opin	  Microbiol,	  vol.	  15,	  no.	  1,	  pp.	  63–70,	  2012.
[5] S.	  H.	  E.	  Kaufmann,	  G.	  Hussey,	  and	  P.-­‐H.	  Lambert,	  “New	  vaccines	  for
tuberculosis.,”	  Lancet,	  vol.	  375,	  no.	  9731,	  pp.	  2110–9,	  Jun.	  2010.
[6] S.	  H.	  E.	  Kaufmann	  and	  A.	  J.	  McMichael,	  “Annulling	  a	  dangerous	  liaison:
vaccination	  strategies	  against	  AIDS	  and	  tuberculosis.,”	  Nat.	  Med.,	  vol.	  11,
no.	  4	  Suppl,	  pp.	  S33–44,	  Apr.	  2005.
[7] A.	  L.	  Blasius	  and	  B.	  Beutler,	  “Intracellular	  toll-­‐like	  receptors.,”	  Immunity,
vol.	  32,	  no.	  3,	  pp.	  305–15,	  Mar.	  2010.
[8] T.	  K.	  Means,	  S.	  Wang,	  E.	  Lien,	  A.	  Yoshimura,	  D.	  T.	  Golenbock,	  and	  M.	  J.
Fenton,	  “Human	  toll-­‐like	  receptors	  mediate	  cellular	  activation	  by
Mycobacterium	  tuberculosis.,”	  J.	  Immunol.,	  vol.	  163,	  no.	  7,	  pp.	  3920–7,
Oct.	  1999.
[9] A.	  Ozinsky,	  D.	  M.	  Underhill,	  J.	  D.	  Fontenot,	  A.	  M.	  Hajjar,	  K.	  D.	  Smith,	  C.	  B.
Wilson,	  L.	  Schroeder,	  and	  A.	  Aderem,	  “The	  repertoire	  for	  pattern
recognition	  of	  pathogens	  by	  the	  innate	  immune	  system	  is	  defined	  by
cooperation	  between	  toll-­‐like	  receptors.,”	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A.,
vol.	  97,	  no.	  25,	  pp.	  13766–71,	  Dec.	  2000.
[10] K.	  Farhat,	  S.	  Riekenberg,	  H.	  Heine,	  J.	  Debarry,	  R.	  Lang,	  J.	  Mages,	  U.	  Buwitt-­‐
Beckmann,	  K.	  Röschmann,	  G.	  Jung,	  K.-­‐H.	  Wiesmüller,	  and	  A.	  J.	  Ulmer,
“Heterodimerization	  of	  TLR2	  with	  TLR1	  or	  TLR6	  expands	  the	  ligand
spectrum	  but	  does	  not	  lead	  to	  differential	  signaling.,”	  J.	  Leukoc.	  Biol.,	  vol.
83,	  no.	  3,	  pp.	  692–701,	  Mar.	  2008.
[11] R.	  I.	  Tapping	  and	  P.	  S.	  Tobias,	  “Mycobacterial	  lipoarabinomannan
mediates	  physical	  interactions	  between	  TLR1	  and	  TLR2	  to	  induce
signaling,”	  J	  Endotoxin	  Res,	  vol.	  9,	  no.	  4,	  pp.	  264–268,	  2003.
[12] Y.	  Bulut,	  E.	  Faure,	  L.	  Thomas,	  O.	  Equils,	  and	  M.	  Arditi,	  “Cooperation	  of
Toll-­‐like	  receptor	  2	  and	  6	  for	  cellular	  activation	  by	  soluble	  tuberculosis
factor	  and	  Borrelia	  burgdorferi	  outer	  surface	  protein	  A	  lipoprotein:	  role
of	  Toll-­‐interacting	  protein	  and	  IL-­‐1	  receptor	  signaling	  molecules	  in	  Toll-­‐
like	  receptor	  2	  s,”	  J	  Immunol,	  vol.	  167,	  no.	  2,	  pp.	  987–994,	  2001.
[13] T.	  B.	  Geijtenbeek,	  S.	  J.	  Van	  Vliet,	  E.	  A.	  Koppel,	  M.	  Sanchez-­‐Hernandez,	  C.	  M.
Vandenbroucke-­‐Grauls,	  B.	  Appelmelk,	  and	  Y.	  Van	  Kooyk,	  “Mycobacteria
target	  DC-­‐SIGN	  to	  suppress	  dendritic	  cell	  function,”	  J	  Exp	  Med,	  vol.	  197,
no.	  1,	  pp.	  7–17,	  2003.
[14] H.	  Hemmi,	  O.	  Takeuchi,	  T.	  Kawai,	  T.	  Kaisho,	  S.	  Sato,	  H.	  Sanjo,	  M.
Matsumoto,	  K.	  Hoshino,	  H.	  Wagner,	  K.	  Takeda,	  and	  S.	  Akira,	  “A	  Toll-­‐like
	   75	  
receptor	  recognizes	  bacterial	  DNA,”	  Nature,	  vol.	  408,	  no.	  6813,	  pp.	  740–
745,	  2000.	  
[15]	   L.	  S.	  Schlesinger,	  C.	  G.	  Bellinger-­‐Kawahara,	  N.	  R.	  Payne,	  and	  M.	  A.	  Horwitz,	  
“Phagocytosis	  of	  Mycobacterium	  tuberculosis	  is	  mediated	  by	  human	  
monocyte	  complement	  receptors	  and	  complement	  component	  C3,”	  J	  
Immunol,	  vol.	  144,	  no.	  7,	  pp.	  2771–2780,	  1990.	  
[16]	   L.	  S.	  Schlesinger,	  “Macrophage	  phagocytosis	  of	  virulent	  but	  not	  
attenuated	  strains	  of	  Mycobacterium	  tuberculosis	  is	  mediated	  by	  
mannose	  receptors	  in	  addition	  to	  complement	  receptors,”	  J	  Immunol,	  vol.	  
150,	  no.	  7,	  pp.	  2920–2930,	  1993.	  
[17]	   R.	  C.	  Ryan,	  M.	  P.	  O’Sullivan,	  and	  J.	  Keane,	  “Mycobacterium	  tuberculosis	  
infection	  induces	  non-­‐apoptotic	  cell	  death	  of	  human	  dendritic	  cells,”	  BMC	  
Microbiol,	  vol.	  11,	  p.	  237,	  2011.	  
[18]	   M.	  Chieppa,	  G.	  Bianchi,	  A.	  Doni,	  A.	  Del	  Prete,	  M.	  Sironi,	  G.	  Laskarin,	  P.	  
Monti,	  L.	  Piemonti,	  A.	  Biondi,	  A.	  Mantovani,	  M.	  Introna,	  and	  P.	  Allavena,	  
“Cross-­‐linking	  of	  the	  mannose	  receptor	  on	  monocyte-­‐derived	  dendritic	  
cells	  activates	  an	  anti-­‐inflammatory	  immunosuppressive	  program,”	  J	  
Immunol,	  vol.	  171,	  no.	  9,	  pp.	  4552–4560,	  2003.	  
[19]	   J.	  Nigou,	  C.	  Zelle-­‐Rieser,	  M.	  Gilleron,	  M.	  Thurnher,	  and	  G.	  Puzo,	  
“Mannosylated	  lipoarabinomannans	  inhibit	  IL-­‐12	  production	  by	  human	  
dendritic	  cells:	  evidence	  for	  a	  negative	  signal	  delivered	  through	  the	  
mannose	  receptor,”	  J	  Immunol,	  vol.	  166,	  no.	  12,	  pp.	  7477–7485,	  2001.	  
[20]	   P.	  B.	  Kang,	  A.	  K.	  Azad,	  J.	  B.	  Torrelles,	  T.	  M.	  Kaufman,	  A.	  Beharka,	  E.	  
Tibesar,	  L.	  E.	  DesJardin,	  and	  L.	  S.	  Schlesinger,	  “The	  human	  macrophage	  
mannose	  receptor	  directs	  Mycobacterium	  tuberculosis	  
lipoarabinomannan-­‐mediated	  phagosome	  biogenesis,”	  J	  Exp	  Med,	  vol.	  
202,	  no.	  7,	  pp.	  987–999,	  2005.	  
[21]	   J.	  Chan,	  Y.	  Xing,	  R.	  S.	  Magliozzo,	  and	  B.	  R.	  Bloom,	  “Killing	  of	  virulent	  
Mycobacterium	  tuberculosis	  by	  reactive	  nitrogen	  intermediates	  
produced	  by	  activated	  murine	  macrophages.,”	  J.	  Exp.	  Med.,	  vol.	  175,	  no.	  4,	  
pp.	  1111–22,	  Apr.	  1992.	  
[22]	   R.	  S.	  Flannagan,	  G.	  Cosio,	  and	  S.	  Grinstein,	  “Antimicrobial	  mechanisms	  of	  
phagocytes	  and	  bacterial	  evasion	  strategies,”	  Nat	  Rev	  Microbiol,	  vol.	  7,	  
no.	  5,	  pp.	  355–366,	  2009.	  
[23]	   M.	  G.	  Gutierrez,	  S.	  S.	  Master,	  S.	  B.	  Singh,	  G.	  A.	  Taylor,	  M.	  I.	  Colombo,	  and	  V.	  
Deretic,	  “Autophagy	  is	  a	  defense	  mechanism	  inhibiting	  BCG	  and	  
Mycobacterium	  tuberculosis	  survival	  in	  infected	  macrophages,”	  Cell,	  vol.	  
119,	  no.	  6,	  pp.	  753–766,	  2004.	  
[24]	   J.-­‐M.	  Yuk,	  D.-­‐M.	  Shin,	  H.-­‐M.	  Lee,	  C.-­‐S.	  Yang,	  H.	  S.	  Jin,	  K.-­‐K.	  Kim,	  Z.-­‐W.	  Lee,	  
S.-­‐H.	  Lee,	  J.-­‐M.	  Kim,	  and	  E.-­‐K.	  Jo,	  “Vitamin	  D3	  induces	  autophagy	  in	  
human	  monocytes/macrophages	  via	  cathelicidin.,”	  Cell	  Host	  Microbe,	  vol.	  
6,	  no.	  3,	  pp.	  231–43,	  Sep.	  2009.	  
[25]	   M.	  Zasloff,	  “Antimicrobial	  peptides	  of	  multicellular	  organisms.,”	  Nature,	  
vol.	  415,	  no.	  6870,	  pp.	  389–95,	  Jan.	  2002.	  
[26]	   A.	  Sonawane,	  J.	  C.	  Santos,	  B.	  B.	  Mishra,	  P.	  Jena,	  C.	  Progida,	  O.	  E.	  Sorensen,	  
R.	  Gallo,	  R.	  Appelberg,	  and	  G.	  Griffiths,	  “Cathelicidin	  is	  involved	  in	  the	  
intracellular	  killing	  of	  mycobacteria	  in	  macrophages.,”	  Cell.	  Microbiol.,	  
vol.	  13,	  no.	  10,	  pp.	  1601–17,	  Oct.	  2011.	  
[27]	   K.	  Murphy,	  Janeway’s	  Immunobiology	  8th	  Ed.	  2012.	  
	   76	  
[28]	   R.	  J.	  Mazzaccaro,	  M.	  Gedde,	  E.	  R.	  Jensen,	  H.	  M.	  van	  Santen,	  H.	  L.	  Ploegh,	  K.	  
L.	  Rock,	  and	  B.	  R.	  Bloom,	  “Major	  histocompatibility	  class	  I	  presentation	  of	  
soluble	  antigen	  facilitated	  by	  Mycobacterium	  tuberculosis	  infection.,”	  
Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A.,	  vol.	  93,	  no.	  21,	  pp.	  11786–91,	  Oct.	  1996.	  
[29]	   F.	  Winau,	  S.	  Weber,	  S.	  Sad,	  J.	  de	  Diego,	  S.	  L.	  Hoops,	  B.	  Breiden,	  K.	  Sandhoff,	  
V.	  Brinkmann,	  S.	  H.	  E.	  Kaufmann,	  and	  U.	  E.	  Schaible,	  “Apoptotic	  vesicles	  
crossprime	  CD8	  T	  cells	  and	  protect	  against	  tuberculosis.,”	  Immunity,	  vol.	  
24,	  no.	  1,	  pp.	  105–17,	  Jan.	  2006.	  
[30]	   L.	  M.	  Sly,	  S.	  M.	  Hingley-­‐Wilson,	  N.	  E.	  Reiner,	  and	  W.	  R.	  McMaster,	  
“Survival	  of	  Mycobacterium	  tuberculosis	  in	  host	  macrophages	  involves	  
resistance	  to	  apoptosis	  dependent	  upon	  induction	  of	  antiapoptotic	  Bcl-­‐2	  
family	  member	  Mcl-­‐1.,”	  J.	  Immunol.,	  vol.	  170,	  no.	  1,	  pp.	  430–7,	  Jan.	  2003.	  
[31]	   A.	  Baena	  and	  S.	  A.	  Porcelli,	  “Evasion	  and	  subversion	  of	  antigen	  
presentation	  by	  Mycobacterium	  tuberculosis.,”	  Tissue	  Antigens,	  vol.	  74,	  
no.	  3,	  pp.	  189–204,	  Sep.	  2009.	  
[32]	   J.	  J.	  O’Shea	  and	  W.	  E.	  Paul,	  “Mechanisms	  underlying	  lineage	  commitment	  
and	  plasticity	  of	  helper	  CD4+	  T	  cells.,”	  Science,	  vol.	  327,	  no.	  5969,	  pp.	  
1098–102,	  Feb.	  2010.	  
[33]	   H.	  Yamane	  and	  W.	  E.	  Paul,	  “Early	  signaling	  events	  that	  underlie	  fate	  
decisions	  of	  naive	  CD4(+)	  T	  cells	  toward	  distinct	  T-­‐helper	  cell	  subsets.,”	  
Immunol.	  Rev.,	  vol.	  252,	  no.	  1,	  pp.	  12–23,	  Mar.	  2013.	  
[34]	   K.	  R.	  Wick	  and	  M.	  T.	  Berton,	  “IL-­‐4	  induces	  serine	  phosphorylation	  of	  the	  
STAT6	  transactivation	  domain	  in	  B	  lymphocytes.,”	  Mol.	  Immunol.,	  vol.	  37,	  
no.	  11,	  pp.	  641–52,	  Aug.	  2000.	  
[35]	   H.-­‐C.	  Chen	  and	  N.	  C.	  Reich,	  “Live	  cell	  imaging	  reveals	  continuous	  STAT6	  
nuclear	  trafficking.,”	  J.	  Immunol.,	  vol.	  185,	  no.	  1,	  pp.	  64–70,	  Jul.	  2010.	  
[36]	   C.	  Bogdan,	  Y.	  Vodovotz,	  J.	  Paik,	  Q.	  W.	  Xie,	  and	  C.	  Nathan,	  “Mechanism	  of	  
suppression	  of	  nitric	  oxide	  synthase	  expression	  by	  interleukin-­‐4	  in	  
primary	  mouse	  macrophages.,”	  J.	  Leukoc.	  Biol.,	  vol.	  55,	  no.	  2,	  pp.	  227–33,	  
Feb.	  1994.	  
[37]	   V.	  P.	  Dwivedi,	  D.	  Bhattacharya,	  S.	  Chatterjee,	  D.	  V.	  R.	  Prasad,	  D.	  
Chattopadhyay,	  L.	  Van	  Kaer,	  W.	  R.	  Bishai,	  and	  G.	  Das,	  “Mycobacterium	  
tuberculosis	  directs	  T	  helper	  2	  cell	  differentiation	  by	  inducing	  
interleukin-­‐1β	  production	  in	  dendritic	  cells.,”	  J.	  Biol.	  Chem.,	  vol.	  287,	  no.	  
40,	  pp.	  33656–63,	  Sep.	  2012.	  
[38]	   G.	  A.	  W.	  Rook,	  R.	  Hernandez-­‐Pando,	  K.	  Dheda,	  and	  G.	  Teng	  Seah,	  “IL-­‐4	  in	  
tuberculosis:	  implications	  for	  vaccine	  design.,”	  Trends	  Immunol.,	  vol.	  25,	  
no.	  9,	  pp.	  483–8,	  Sep.	  2004.	  
[39]	   L.	  A.	  Zúñiga,	  R.	  Jain,	  C.	  Haines,	  and	  D.	  J.	  Cua,	  “Th17	  cell	  development:	  from	  
the	  cradle	  to	  the	  grave.,”	  Immunol.	  Rev.,	  vol.	  252,	  no.	  1,	  pp.	  78–88,	  Mar.	  
2013.	  
[40]	   S.	  A.	  Khader,	  G.	  K.	  Bell,	  J.	  E.	  Pearl,	  J.	  J.	  Fountain,	  J.	  Rangel-­‐Moreno,	  G.	  E.	  
Cilley,	  F.	  Shen,	  S.	  M.	  Eaton,	  S.	  L.	  Gaffen,	  S.	  L.	  Swain,	  R.	  M.	  Locksley,	  L.	  
Haynes,	  T.	  D.	  Randall,	  and	  A.	  M.	  Cooper,	  “IL-­‐23	  and	  IL-­‐17	  in	  the	  
establishment	  of	  protective	  pulmonary	  CD4+	  T	  cell	  responses	  after	  
vaccination	  and	  during	  Mycobacterium	  tuberculosis	  challenge.,”	  Nat.	  
Immunol.,	  vol.	  8,	  no.	  4,	  pp.	  369–77,	  Apr.	  2007.	  
[41]	   T.	  M.	  Wozniak,	  B.	  M.	  Saunders,	  A.	  A.	  Ryan,	  and	  W.	  J.	  Britton,	  
“Mycobacterium	  bovis	  BCG-­‐specific	  Th17	  cells	  confer	  partial	  protection	  
	   77	  
against	  Mycobacterium	  tuberculosis	  infection	  in	  the	  absence	  of	  gamma	  
interferon.,”	  Infect.	  Immun.,	  vol.	  78,	  no.	  10,	  pp.	  4187–94,	  Oct.	  2010.	  
[42]	   J.	  A.	  Bluestone	  and	  A.	  K.	  Abbas,	  “Natural	  versus	  adaptive	  regulatory	  T	  
cells.,”	  Nat.	  Rev.	  Immunol.,	  vol.	  3,	  no.	  3,	  pp.	  253–7,	  Mar.	  2003.	  
[43]	   H.-­‐W.	  Mittrücker	  and	  S.	  H.	  E.	  Kaufmann,	  “Mini-­‐review:	  regulatory	  T	  cells	  
and	  infection:	  suppression	  revisited.,”	  Eur.	  J.	  Immunol.,	  vol.	  34,	  no.	  2,	  pp.	  
306–12,	  Feb.	  2004.	  
[44]	   M.	  Kursar,	  M.	  Koch,	  H.-­‐W.	  Mittrücker,	  G.	  Nouailles,	  K.	  Bonhagen,	  T.	  
Kamradt,	  and	  S.	  H.	  E.	  Kaufmann,	  “Cutting	  Edge:	  Regulatory	  T	  cells	  
prevent	  efficient	  clearance	  of	  Mycobacterium	  tuberculosis.,”	  J.	  Immunol.,	  
vol.	  178,	  no.	  5,	  pp.	  2661–5,	  Mar.	  2007.	  
[45]	   S.	  Shafiani,	  G.	  Tucker-­‐Heard,	  A.	  Kariyone,	  K.	  Takatsu,	  and	  K.	  B.	  Urdahl,	  
“Pathogen-­‐specific	  regulatory	  T	  cells	  delay	  the	  arrival	  of	  effector	  T	  cells	  
in	  the	  lung	  during	  early	  tuberculosis.,”	  J.	  Exp.	  Med.,	  vol.	  207,	  no.	  7,	  pp.	  
1409–20,	  Jul.	  2010.	  
[46]	   C.	  King,	  “New	  insights	  into	  the	  differentiation	  and	  function	  of	  T	  follicular	  
helper	  cells.,”	  Nat.	  Rev.	  Immunol.,	  vol.	  9,	  no.	  11,	  pp.	  757–66,	  Nov.	  2009.	  
[47]	   S.	  R.	  Slight,	  J.	  Rangel-­‐Moreno,	  R.	  Gopal,	  Y.	  Lin,	  B.	  A.	  Fallert	  Junecko,	  S.	  
Mehra,	  M.	  Selman,	  E.	  Becerril-­‐Villanueva,	  J.	  Baquera-­‐Heredia,	  L.	  Pavon,	  D.	  
Kaushal,	  T.	  A.	  Reinhart,	  T.	  D.	  Randall,	  and	  S.	  A.	  Khader,	  “CXCR5+	  T	  helper	  
cells	  mediate	  protective	  immunity	  against	  tuberculosis.,”	  J.	  Clin.	  Invest.,	  
vol.	  123,	  no.	  2,	  pp.	  712–26,	  Feb.	  2013.	  
[48]	   C.	  Y.	  Chen,	  D.	  Huang,	  R.	  C.	  Wang,	  L.	  Shen,	  G.	  Zeng,	  S.	  Yao,	  Y.	  Shen,	  L.	  
Halliday,	  J.	  Fortman,	  M.	  McAllister,	  J.	  Estep,	  R.	  Hunt,	  D.	  Vasconcelos,	  G.	  
Du,	  S.	  A.	  Porcelli,	  M.	  H.	  Larsen,	  W.	  R.	  Jacobs	  	  Jr.,	  B.	  F.	  Haynes,	  N.	  L.	  Letvin,	  
and	  Z.	  W.	  Chen,	  “A	  critical	  role	  for	  CD8	  T	  cells	  in	  a	  nonhuman	  primate	  
model	  of	  tuberculosis,”	  PLoS	  Pathog,	  vol.	  5,	  no.	  4,	  p.	  e1000392,	  2009.	  
[49]	   R.	  A.	  Murray,	  N.	  Mansoor,	  R.	  Harbacheuski,	  J.	  Soler,	  V.	  Davids,	  A.	  Soares,	  
A.	  Hawkridge,	  G.	  D.	  Hussey,	  H.	  Maecker,	  G.	  Kaplan,	  and	  W.	  A.	  Hanekom,	  
“Bacillus	  Calmette	  Guerin	  vaccination	  of	  human	  newborns	  induces	  a	  
specific,	  functional	  CD8+	  T	  cell	  response,”	  J	  Immunol,	  vol.	  177,	  no.	  8,	  pp.	  
5647–5651,	  2006.	  
[50]	   B.	  M.	  Kagina,	  B.	  Abel,	  T.	  J.	  Scriba,	  E.	  J.	  Hughes,	  A.	  Keyser,	  A.	  Soares,	  H.	  
Gamieldien,	  M.	  Sidibana,	  M.	  Hatherill,	  S.	  Gelderbloem,	  H.	  Mahomed,	  A.	  
Hawkridge,	  G.	  Hussey,	  G.	  Kaplan,	  and	  W.	  A.	  Hanekom,	  “Specific	  T	  cell	  
frequency	  and	  cytokine	  expression	  profile	  do	  not	  correlate	  with	  
protection	  against	  tuberculosis	  after	  bacillus	  Calmette-­‐Guerin	  
vaccination	  of	  newborns,”	  Am	  J	  Respir	  Crit	  Care	  Med,	  vol.	  182,	  no.	  8,	  pp.	  
1073–1079,	  2010.	  
[51]	   N.	  G.	  Tena-­‐Coki,	  T.	  J.	  Scriba,	  N.	  Peteni,	  B.	  Eley,	  R.	  J.	  Wilkinson,	  P.	  Andersen,	  
W.	  A.	  Hanekom,	  and	  B.	  Kampmann,	  “CD4	  and	  CD8	  T-­‐cell	  responses	  to	  
mycobacterial	  antigens	  in	  African	  children.,”	  Am.	  J.	  Respir.	  Crit.	  Care	  Med.,	  
vol.	  182,	  no.	  1,	  pp.	  120–9,	  Jul.	  2010.	  
[52]	   B.	  Abel,	  M.	  Tameris,	  N.	  Mansoor,	  S.	  Gelderbloem,	  J.	  Hughes,	  D.	  Abrahams,	  
L.	  Makhethe,	  M.	  Erasmus,	  M.	  de	  Kock,	  L.	  van	  der	  Merwe,	  A.	  Hawkridge,	  A.	  
Veldsman,	  M.	  Hatherill,	  G.	  Schirru,	  M.	  G.	  Pau,	  J.	  Hendriks,	  G.	  J.	  Weverling,	  
J.	  Goudsmit,	  D.	  Sizemore,	  J.	  B.	  McClain,	  M.	  Goetz,	  J.	  Gearhart,	  H.	  Mahomed,	  
G.	  D.	  Hussey,	  J.	  C.	  Sadoff,	  and	  W.	  A.	  Hanekom,	  “The	  novel	  tuberculosis	  
vaccine,	  AERAS-­‐402,	  induces	  robust	  and	  polyfunctional	  CD4+	  and	  CD8+	  
78	  
T	  cells	  in	  adults.,”	  Am.	  J.	  Respir.	  Crit.	  Care	  Med.,	  vol.	  181,	  no.	  12,	  pp.	  1407–
17,	  Jun.	  2010.	  
[53] R.	  L.	  Modlin,	  C.	  Pirmez,	  F.	  M.	  Hofman,	  V.	  Torigian,	  K.	  Uyemura,	  T.	  H.	  Rea,
B.	  R.	  Bloom,	  and	  M.	  B.	  Brenner,	  “Lymphocytes	  bearing	  antigen-­‐specific
gamma	  delta	  T-­‐cell	  receptors	  accumulate	  in	  human	  infectious	  disease
lesions.,”	  Nature,	  vol.	  339,	  no.	  6225,	  pp.	  544–8,	  Jun.	  1989.
[54] S.	  M.	  Behar,	  C.	  C.	  Dascher,	  M.	  J.	  Grusby,	  C.	  R.	  Wang,	  and	  M.	  B.	  Brenner,
“Susceptibility	  of	  mice	  deficient	  in	  CD1D	  or	  TAP1	  to	  infection	  with
Mycobacterium	  tuberculosis.,”	  J.	  Exp.	  Med.,	  vol.	  189,	  no.	  12,	  pp.	  1973–80,
Jun.	  1999.
[55] J.	  Mattner,	  K.	  L.	  Debord,	  N.	  Ismail,	  R.	  D.	  Goff,	  C.	  Cantu,	  D.	  Zhou,	  P.	  Saint-­‐
Mezard,	  V.	  Wang,	  Y.	  Gao,	  N.	  Yin,	  K.	  Hoebe,	  O.	  Schneewind,	  D.	  Walker,	  B.
Beutler,	  L.	  Teyton,	  P.	  B.	  Savage,	  and	  A.	  Bendelac,	  “Exogenous	  and
endogenous	  glycolipid	  antigens	  activate	  NKT	  cells	  during	  microbial
infections.,”	  Nature,	  vol.	  434,	  no.	  7032,	  pp.	  525–9,	  Mar.	  2005.
[56] F.	  Dieli,	  M.	  Troye-­‐Blomberg,	  J.	  Ivanyi,	  J.	  J.	  Fournié,	  A.	  M.	  Krensky,	  M.
Bonneville,	  M.	  A.	  Peyrat,	  N.	  Caccamo,	  G.	  Sireci,	  and	  A.	  Salerno,
“Granulysin-­‐dependent	  killing	  of	  intracellular	  and	  extracellular
Mycobacterium	  tuberculosis	  by	  Vgamma9/Vdelta2	  T	  lymphocytes.,”	  J.
Infect.	  Dis.,	  vol.	  184,	  no.	  8,	  pp.	  1082–5,	  Oct.	  2001.
[57] J.	  L.	  Flynn,	  J.	  Chan,	  K.	  J.	  Triebold,	  D.	  K.	  Dalton,	  T.	  A.	  Stewart,	  and	  B.	  R.
Bloom,	  “An	  essential	  role	  for	  interferon	  gamma	  in	  resistance	  to
Mycobacterium	  tuberculosis	  infection,”	  J	  Exp	  Med,	  vol.	  178,	  no.	  6,	  pp.
2249–2254,	  1993.
[58] T.	  H.	  Ottenhoff,	  D.	  Kumararatne,	  and	  J.	  L.	  Casanova,	  “Novel	  human
immunodeficiencies	  reveal	  the	  essential	  role	  of	  type-­‐I	  cytokines	  in
immunity	  to	  intracellular	  bacteria.,”	  Immunol.	  Today,	  vol.	  19,	  no.	  11,	  pp.
491–4,	  Nov.	  1998.
[59] H.	  Dooms,	  E.	  Kahn,	  B.	  Knoechel,	  and	  A.	  K.	  Abbas,	  “IL-­‐2	  induces	  a
competitive	  survival	  advantage	  in	  T	  lymphocytes,”	  J	  Immunol,	  vol.	  172,
no.	  10,	  pp.	  5973–5979,	  2004.
[60] J.	  L.	  Flynn,	  M.	  M.	  Goldstein,	  J.	  Chan,	  K.	  J.	  Triebold,	  K.	  Pfeffer,	  C.	  J.
Lowenstein,	  R.	  Schreiber,	  T.	  W.	  Mak,	  and	  B.	  R.	  Bloom,	  “Tumor	  necrosis
factor-­‐alpha	  is	  required	  in	  the	  protective	  immune	  response	  against
Mycobacterium	  tuberculosis	  in	  mice,”	  Immunity,	  vol.	  2,	  no.	  6,	  pp.	  561–
572,	  1995.
[61] D.	  R.	  Roach,	  A.	  G.	  D.	  Bean,	  C.	  Demangel,	  M.	  P.	  France,	  H.	  Briscoe,	  and	  W.	  J.
Britton,	  “TNF	  regulates	  chemokine	  induction	  essential	  for	  cell
recruitment,	  granuloma	  formation,	  and	  clearance	  of	  mycobacterial
infection.,”	  J.	  Immunol.,	  vol.	  168,	  pp.	  4620–4627,	  2002.
[62] S.-­‐O.	  Lee,	  “Patients	  treated	  with	  a	  tumor	  necrosis	  factor-­‐α	  inhibitor	  are
more	  likely	  to	  develop	  extrapulmonary	  tuberculosis.,”	  Korean	  J.	  Intern.
Med.,	  vol.	  28,	  no.	  2,	  pp.	  159–61,	  Mar.	  2013.
[63] D.	  J.	  Ordway,	  L.	  Costa,	  M.	  Martins,	  H.	  Silveira,	  L.	  Amaral,	  M.	  J.	  Arroz,	  F.	  A.
Ventura,	  and	  H.	  M.	  Dockrell,	  “Increased	  Interleukin-­‐4	  production	  by	  CD8
and	  gammadelta	  T	  cells	  in	  health-­‐care	  workers	  is	  associated	  with	  the
subsequent	  development	  of	  active	  tuberculosis,”	  J	  Infect	  Dis,	  vol.	  190,	  no.
4,	  pp.	  756–766,	  2004.
	   79	  
[64]	   R.	  Hussain,	  N.	  Talat,	  A.	  Ansari,	  F.	  Shahid,	  Z.	  Hasan,	  and	  G.	  Dawood,	  
“Endogenously	  activated	  interleukin-­‐4	  differentiates	  disease	  progressors	  
and	  non-­‐progressors	  in	  tuberculosis	  susceptible	  families:	  a	  2-­‐year	  
biomarkers	  follow-­‐up	  study,”	  J	  Clin	  Immunol,	  vol.	  31,	  no.	  5,	  pp.	  913–923,	  
2011.	  
[65]	   E.	  Roy,	  J.	  Brennan,	  S.	  Jolles,	  and	  D.	  B.	  Lowrie,	  “Beneficial	  effect	  of	  anti-­‐
interleukin-­‐4	  antibody	  when	  administered	  in	  a	  murine	  model	  of	  
tuberculosis	  infection,”	  Tuberc.,	  vol.	  88,	  no.	  3,	  pp.	  197–202,	  2008.	  
[66]	   J.	  L.	  Flynn	  and	  J.	  Chan,	  “Immunology	  of	  tuberculosis.,”	  Annu.	  Rev.	  
Immunol.,	  vol.	  19,	  pp.	  93–129,	  Jan.	  2001.	  
[67]	   A.	  M.	  Green,	  R.	  Difazio,	  and	  J.	  L.	  Flynn,	  “IFN-­‐γ	  from	  CD4	  T	  cells	  is	  essential	  
for	  host	  survival	  and	  enhances	  CD8	  T	  cell	  function	  during	  
Mycobacterium	  tuberculosis	  infection.,”	  J.	  Immunol.,	  vol.	  190,	  no.	  1,	  pp.	  
270–7,	  Jan.	  2013.	  
[68]	   S.	  Srivastava	  and	  J.	  D.	  Ernst,	  “Cutting	  edge:	  Direct	  recognition	  of	  infected	  
cells	  by	  CD4	  T	  cells	  is	  required	  for	  control	  of	  intracellular	  
Mycobacterium	  tuberculosis	  in	  vivo.,”	  J.	  Immunol.,	  vol.	  191,	  no.	  3,	  pp.	  
1016–20,	  Aug.	  2013.	  
[69]	   T.	  Mogues,	  M.	  E.	  Goodrich,	  L.	  Ryan,	  R.	  LaCourse,	  and	  R.	  J.	  North,	  “The	  
relative	  importance	  of	  T	  cell	  subsets	  in	  immunity	  and	  immunopathology	  
of	  airborne	  Mycobacterium	  tuberculosis	  infection	  in	  mice.,”	  J.	  Exp.	  Med.,	  
vol.	  193,	  no.	  3,	  pp.	  271–80,	  Feb.	  2001.	  
[70]	   J.	  L.	  Flynn,	  M.	  M.	  Goldstein,	  K.	  J.	  Triebold,	  B.	  Koller,	  and	  B.	  R.	  Bloom,	  
“Major	  histocompatibility	  complex	  class	  I-­‐restricted	  T	  cells	  are	  required	  
for	  resistance	  to	  Mycobacterium	  tuberculosis	  infection.,”	  Proc.	  Natl.	  Acad.	  
Sci.	  U.	  S.	  A.,	  vol.	  89,	  no.	  24,	  pp.	  12013–7,	  Dec.	  1992.	  
[71]	   P.	  Wolint,	  M.	  R.	  Betts,	  R.	  A.	  Koup,	  and	  A.	  Oxenius,	  “Immediate	  cytotoxicity	  
but	  not	  degranulation	  distinguishes	  effector	  and	  memory	  subsets	  of	  
CD8+	  T	  cells.,”	  J.	  Exp.	  Med.,	  vol.	  199,	  no.	  7,	  pp.	  925–36,	  Apr.	  2004.	  
[72]	   D.	  Martorelli,	  E.	  Muraro,	  A.	  Merlo,	  R.	  Turrini,	  A.	  Rosato,	  and	  R.	  Dolcetti,	  
“Role	  of	  CD4+	  cytotoxic	  T	  lymphocytes	  in	  the	  control	  of	  viral	  diseases	  
and	  cancer.,”	  Int.	  Rev.	  Immunol.,	  vol.	  29,	  no.	  4,	  pp.	  371–402,	  Aug.	  2010.	  
[73]	   D.	  H.	  Canaday,	  R.	  J.	  Wilkinson,	  Q.	  Li,	  C.	  V	  Harding,	  R.	  F.	  Silver,	  and	  W.	  H.	  
Boom,	  “CD4(+)	  and	  CD8(+)	  T	  cells	  kill	  intracellular	  Mycobacterium	  
tuberculosis	  by	  a	  perforin	  and	  Fas/Fas	  ligand-­‐independent	  mechanism.,”	  
J.	  Immunol.,	  vol.	  167,	  pp.	  2734–2742,	  2001.	  
[74]	   V.	  Appay,	  J.	  J.	  Zaunders,	  L.	  Papagno,	  J.	  Sutton,	  A.	  Jaramillo,	  A.	  Waters,	  P.	  
Easterbrook,	  P.	  Grey,	  D.	  Smith,	  A.	  J.	  McMichael,	  D.	  A.	  Cooper,	  S.	  L.	  
Rowland-­‐Jones,	  and	  A.	  D.	  Kelleher,	  “Characterization	  of	  CD4(+)	  CTLs	  ex	  
vivo,”	  J	  Immunol,	  vol.	  168,	  no.	  11,	  pp.	  5954–5958,	  2002.	  
[75]	   S.	  Stenger,	  R.	  J.	  Mazzaccaro,	  K.	  Uyemura,	  S.	  Cho,	  P.	  F.	  Barnes,	  J.	  P.	  Rosat,	  A.	  
Sette,	  M.	  B.	  Brenner,	  S.	  A.	  Porcelli,	  B.	  R.	  Bloom,	  and	  R.	  L.	  Modlin,	  
“Differential	  effects	  of	  cytolytic	  T	  cell	  subsets	  on	  intracellular	  infection,”	  
Science	  (80-­‐.	  ).,	  vol.	  276,	  no.	  5319,	  pp.	  1684–1687,	  1997.	  
[76]	   S.	  Stenger,	  D.	  A.	  Hanson,	  R.	  Teitelbaum,	  P.	  Dewan,	  K.	  R.	  Niazi,	  C.	  J.	  
Froelich,	  T.	  Ganz,	  S.	  Thoma-­‐Uszynski,	  A.	  Melian,	  C.	  Bogdan,	  S.	  A.	  Porcelli,	  
B.	  R.	  Bloom,	  A.	  M.	  Krensky,	  and	  R.	  L.	  Modlin,	  “An	  antimicrobial	  activity	  of	  
cytolytic	  T	  cells	  mediated	  by	  granulysin,”	  Science	  (80-­‐.	  ).,	  vol.	  282,	  no.	  
5386,	  pp.	  121–125,	  1998.	  
	   80	  
[77]	   S.	  M.	  Smith,	  M.	  R.	  Klein,	  A.	  S.	  Malin,	  J.	  Sillah,	  K.	  Huygen,	  P.	  Andersen,	  K.	  P.	  
McAdam,	  and	  H.	  M.	  Dockrell,	  “Human	  CD8(+)	  T	  cells	  specific	  for	  
Mycobacterium	  tuberculosis	  secreted	  antigens	  in	  tuberculosis	  patients	  
and	  healthy	  BCG-­‐vaccinated	  controls	  in	  The	  Gambia,”	  Infect	  Immun,	  vol.	  
68,	  no.	  12,	  pp.	  7144–7148,	  2000.	  
[78]	   J.	  Andersson,	  A.	  Samarina,	  J.	  Fink,	  S.	  Rahman,	  and	  S.	  Grundstrom,	  
“Impaired	  expression	  of	  perforin	  and	  granulysin	  in	  CD8+	  T	  cells	  at	  the	  
site	  of	  infection	  in	  human	  chronic	  pulmonary	  tuberculosis,”	  Infect	  
Immun,	  vol.	  75,	  no.	  11,	  pp.	  5210–5222,	  2007.	  
[79]	   L.	  L.	  Bi,	  G.	  Pan,	  T.	  P.	  Atkinson,	  L.	  Zheng,	  J.	  K.	  Dale,	  C.	  Makris,	  V.	  Reddy,	  J.	  M.	  
McDonald,	  R.	  M.	  Siegel,	  J.	  M.	  Puck,	  M.	  J.	  Lenardo,	  and	  S.	  E.	  Straus,	  
“Dominant	  inhibition	  of	  Fas	  ligand-­‐mediated	  apoptosis	  due	  to	  a	  
heterozygous	  mutation	  associated	  with	  autoimmune	  
lymphoproliferative	  syndrome	  (ALPS)	  Type	  Ib.,”	  BMC	  Med.	  Genet.,	  vol.	  8,	  
p.	  41,	  Jan.	  2007.	  
[80]	   I.	  Voskoboinik,	  M.	  A.	  Dunstone,	  K.	  Baran,	  J.	  C.	  Whisstock,	  and	  J.	  A.	  Trapani,	  
“Perforin:	  structure,	  function,	  and	  role	  in	  human	  immunopathology.,”	  
Immunol.	  Rev.,	  vol.	  235,	  no.	  1,	  pp.	  35–54,	  May	  2010.	  
[81]	   J.	  A.	  Lopez,	  O.	  Susanto,	  M.	  R.	  Jenkins,	  N.	  Lukoyanova,	  V.	  R.	  Sutton,	  R.	  H.	  P.	  
Law,	  A.	  Johnston,	  C.	  H.	  Bird,	  P.	  I.	  Bird,	  J.	  C.	  Whisstock,	  J.	  A.	  Trapani,	  H.	  R.	  
Saibil,	  and	  I.	  Voskoboinik,	  “Perforin	  forms	  transient	  pores	  on	  the	  target	  
cell	  plasma	  membrane	  to	  facilitate	  rapid	  access	  of	  granzymes	  during	  
killer	  cell	  attack.,”	  Blood,	  vol.	  121,	  no.	  14,	  pp.	  2659–68,	  Apr.	  2013.	  
[82]	   O.	  Susanto,	  J.	  A.	  Trapani,	  and	  D.	  Brasacchio,	  “Controversies	  in	  granzyme	  
biology.,”	  Tissue	  Antigens,	  vol.	  80,	  no.	  6,	  pp.	  477–87,	  Dec.	  2012.	  
[83]	   V.	  R.	  Sutton,	  J.	  E.	  Davis,	  M.	  Cancilla,	  R.	  W.	  Johnstone,	  A.	  A.	  Ruefli,	  K.	  
Sedelies,	  K.	  A.	  Browne,	  and	  J.	  A.	  Trapani,	  “Initiation	  of	  apoptosis	  by	  
granzyme	  B	  requires	  direct	  cleavage	  of	  bid,	  but	  not	  direct	  granzyme	  B-­‐
mediated	  caspase	  activation.,”	  J.	  Exp.	  Med.,	  vol.	  192,	  no.	  10,	  pp.	  1403–14,	  
Nov.	  2000.	  
[84]	   S.	  Gamen,	  D.	  A.	  Hanson,	  A.	  Kaspar,	  J.	  Naval,	  A.	  M.	  Krensky,	  and	  A.	  Anel,	  
“Granulysin-­‐induced	  apoptosis.	  I.	  Involvement	  of	  at	  least	  two	  distinct	  
pathways.,”	  J.	  Immunol.,	  vol.	  161,	  no.	  4,	  pp.	  1758–64,	  Aug.	  1998.	  
[85]	   W.	  A.	  Ernst,	  S.	  Thoma-­‐Uszynski,	  R.	  Teitelbaum,	  C.	  Ko,	  D.	  A.	  Hanson,	  C.	  
Clayberger,	  A.	  M.	  Krensky,	  M.	  Leippe,	  B.	  R.	  Bloom,	  T.	  Ganz,	  and	  R.	  L.	  
Modlin,	  “Granulysin,	  a	  T	  cell	  product,	  kills	  bacteria	  by	  altering	  membrane	  
permeability.,”	  J.	  Immunol.,	  vol.	  165,	  no.	  12,	  pp.	  7102–8,	  Dec.	  2000.	  
[86]	   M.	  Thurnher,	  R.	  Ramoner,	  G.	  Gastl,	  C.	  Radmayr,	  G.	  Böck,	  M.	  Herold,	  H.	  
Klocker,	  and	  G.	  Bartsch,	  “Bacillus	  Calmette-­‐Guérin	  mycobacteria	  
stimulate	  human	  blood	  dendritic	  cells.,”	  Int.	  J.	  Cancer,	  vol.	  70,	  no.	  1,	  pp.	  
128–34,	  Jan.	  1997.	  
[87]	   E.	  J.	  Cheadle,	  P.	  J.	  Selby,	  and	  A.	  M.	  Jackson,	  “Mycobacterium	  bovis	  bacillus	  
Calmette-­‐Guérin-­‐infected	  dendritic	  cells	  potently	  activate	  autologous	  T	  
cells	  via	  a	  B7	  and	  interleukin-­‐12-­‐dependent	  mechanism.,”	  Immunology,	  
vol.	  108,	  no.	  1,	  pp.	  79–88,	  Jan.	  2003.	  
[88]	   T.	  Kawashima,	  Y.	  Norose,	  Y.	  Watanabe,	  Y.	  Enomoto,	  H.	  Narazaki,	  E.	  
Watari,	  S.	  Tanaka,	  H.	  Takahashi,	  I.	  Yano,	  M.	  B.	  Brenner,	  and	  M.	  Sugita,	  
“Cutting	  edge:	  major	  CD8	  T	  cell	  response	  to	  live	  bacillus	  Calmette-­‐Guérin	  
81	  
is	  mediated	  by	  CD1	  molecules.,”	  J.	  Immunol.,	  vol.	  170,	  no.	  11,	  pp.	  5345–8,	  
Jun.	  2003.	  
[89] S.	  Burl,	  U.	  J.	  Adetifa,	  M.	  Cox,	  E.	  Touray,	  M.	  O.	  Ota,	  A.	  Marchant,	  H.	  Whittle,
H. McShane,	  S.	  L.	  Rowland-­‐Jones,	  and	  K.	  L.	  Flanagan,	  “Delaying	  bacillus
Calmette-­‐Guérin	  vaccination	  from	  birth	  to	  4	  1/2	  months	  of	  age	  reduces
postvaccination	  Th1	  and	  IL-­‐17	  responses	  but	  leads	  to	  comparable
mycobacterial	  responses	  at	  9	  months	  of	  age.,”	  J.	  Immunol.,	  vol.	  185,	  no.	  4,
pp.	  2620–8,	  Aug.	  2010.
[90] A.	  P.	  Soares,	  T.	  J.	  Scriba,	  S.	  Joseph,	  R.	  Harbacheuski,	  R.	  A.	  Murray,	  S.	  J.
Gelderbloem,	  A.	  Hawkridge,	  G.	  D.	  Hussey,	  H.	  Maecker,	  G.	  Kaplan,	  and	  W.
A. Hanekom,	  “Bacillus	  Calmette-­‐Guerin	  vaccination	  of	  human	  newborns
induces	  T	  cells	  with	  complex	  cytokine	  and	  phenotypic	  profiles,”	  J
Immunol,	  vol.	  180,	  no.	  5,	  pp.	  3569–3577,	  2008.
[91] A.	  P.	  Soares,	  C.	  K.	  C.	  Kwong	  Chung,	  T.	  Choice,	  E.	  J.	  Hughes,	  G.	  Jacobs,	  E.	  J.
van	  Rensburg,	  G.	  Khomba,	  M.	  de	  Kock,	  L.	  Lerumo,	  L.	  Makhethe,	  M.	  H.
Maneli,	  B.	  Pienaar,	  E.	  Smit,	  N.	  G.	  Tena-­‐Coki,	  L.	  van	  Wyk,	  W.	  H.	  Boom,	  G.
Kaplan,	  T.	  J.	  Scriba,	  and	  W.	  A.	  Hanekom,	  “Longitudinal	  changes	  in	  CD4(+)
T-­‐cell	  memory	  responses	  induced	  by	  BCG	  vaccination	  of	  newborns.,”	  J.
Infect.	  Dis.,	  vol.	  207,	  no.	  7,	  pp.	  1084–94,	  Apr.	  2013.
[92] P.	  L.	  Semple,	  M.	  Watkins,	  V.	  Davids,	  A.	  M.	  Krensky,	  W.	  A.	  Hanekom,	  G.
Kaplan,	  and	  S.	  Ress,	  “Induction	  of	  granulysin	  and	  perforin	  cytolytic
mediator	  expression	  in	  10-­‐week-­‐old	  infants	  vaccinated	  with	  BCG	  at
birth.,”	  Clin.	  Dev.	  Immunol.,	  vol.	  2011,	  p.	  438463,	  Jan.	  2011.
[93] S.	  Crotty,	  P.	  Felgner,	  H.	  Davies,	  J.	  Glidewell,	  L.	  Villarreal,	  and	  R.	  Ahmed,
“Cutting	  edge:	  long-­‐term	  B	  cell	  memory	  in	  humans	  after	  smallpox
vaccination.,”	  J.	  Immunol.,	  vol.	  171,	  no.	  10,	  pp.	  4969–73,	  Nov.	  2003.
[94] J.	  D.	  Poland,	  C.	  H.	  Calisher,	  T.	  P.	  Monath,	  W.	  G.	  Downs,	  and	  K.	  Murphy,
“Persistence	  of	  neutralizing	  antibody	  30-­‐35	  years	  after	  immunization
with	  17D	  yellow	  fever	  vaccine.,”	  Bull.	  World	  Health	  Organ.,	  vol.	  59,	  no.	  6,
pp.	  895–900,	  Jan.	  1981.
[95] R.	  Ahmed	  and	  R.	  S.	  Akondy,	  “Insights	  into	  human	  CD8(+)	  T-­‐cell	  memory
using	  the	  yellow	  fever	  and	  smallpox	  vaccines.,”	  Immunol.	  Cell	  Biol.,	  vol.
89,	  no.	  3,	  pp.	  340–5,	  Mar.	  2011.
[96] A.	  Soysal,	  K.	  A.	  Millington,	  M.	  Bakir,	  D.	  Dosanjh,	  Y.	  Aslan,	  J.	  J.	  Deeks,	  S.	  Efe,
I. Staveley,	  K.	  Ewer,	  and	  A.	  Lalvani,	  “Effect	  of	  BCG	  vaccination	  on	  risk	  of
Mycobacterium	  tuberculosis	  infection	  in	  children	  with	  household
tuberculosis	  contact:	  a	  prospective	  community-­‐based	  study,”	  Lancet,	  vol.
366,	  no.	  9495,	  pp.	  1443–1451,	  2005.
[97] P.-­‐C.	  Chan,	  C.-­‐H.	  Yang,	  L.-­‐Y.	  Chang,	  K.-­‐F.	  Wang,	  Y.-­‐C.	  Kuo,	  C.-­‐J.	  Lin,	  S.-­‐W.
Lee,	  P.-­‐R.	  Hsueh,	  C.-­‐T.	  Fang,	  and	  L.-­‐M.	  Huang,	  “Lower	  prevalence	  of
tuberculosis	  infection	  in	  BCG	  vaccinees:	  a	  cross-­‐sectional	  study	  in	  adult
prison	  inmates.,”	  Thorax,	  vol.	  68,	  no.	  3,	  pp.	  263–8,	  Mar.	  2013.
[98] G.	  A.	  Colditz,	  T.	  F.	  Brewer,	  C.	  S.	  Berkey,	  M.	  E.	  Wilson,	  E.	  Burdick,	  H.	  V
Fineberg,	  and	  F.	  Mosteller,	  “Efficacy	  of	  BCG	  vaccine	  in	  the	  prevention	  of
tuberculosis.	  Meta-­‐analysis	  of	  the	  published	  literature.,”	  JAMA,	  vol.	  271,
no.	  9,	  pp.	  698–702,	  Mar.	  1994.
[99] P.	  E.	  Fine,	  “Variation	  in	  protection	  by	  BCG:	  implications	  of	  and	  for
heterologous	  immunity.,”	  Lancet,	  vol.	  346,	  no.	  8986,	  pp.	  1339–45,	  Nov.
1995.
82	  
[100] E.	  Bonifachich,	  M.	  Chort,	  A.	  Astigarraga,	  N.	  Diaz,	  B.	  Brunet,	  S.	  M.	  Pezzotto,
and	  O.	  Bottasso,	  “Protective	  effect	  of	  Bacillus	  Calmette-­‐Guerin	  (BCG)
vaccination	  in	  children	  with	  extra-­‐pulmonary	  tuberculosis,	  but	  not	  the
pulmonary	  disease.	  A	  case-­‐control	  study	  in	  Rosario,	  Argentina,”	  Vaccine,
vol.	  24,	  no.	  15,	  pp.	  2894–2899,	  2006.
[101] B.	  M.	  N.	  Kagina,	  B.	  Abel,	  T.	  J.	  Scriba,	  E.	  J.	  Hughes,	  A.	  Keyser,	  A.	  Soares,	  H.
Gamieldien,	  M.	  Sidibana,	  M.	  Hatherill,	  S.	  Gelderbloem,	  H.	  Mahomed,	  A.
Hawkridge,	  G.	  Hussey,	  G.	  Kaplan,	  and	  W.	  A.	  Hanekom,	  “Specific	  T	  cell
frequency	  and	  cytokine	  expression	  profile	  do	  not	  correlate	  with
protection	  against	  tuberculosis	  after	  bacillus	  Calmette-­‐Guérin
vaccination	  of	  newborns.,”	  Am.	  J.	  Respir.	  Crit.	  Care	  Med.,	  vol.	  182,	  pp.
1073–1079,	  2010.
[102] N.	  Ritz,	  B.	  Dutta,	  S.	  Donath,	  D.	  Casalaz,	  T.	  G.	  Connell,	  M.	  Tebruegge,	  R.
Robins-­‐Browne,	  W.	  A.	  Hanekom,	  W.	  J.	  Britton,	  and	  N.	  Curtis,	  “The
influence	  of	  bacille	  Calmette-­‐Guerin	  vaccine	  strain	  on	  the	  immune
response	  against	  tuberculosis:	  a	  randomized	  trial.,”	  Am.	  J.	  Respir.	  Crit.
Care	  Med.,	  vol.	  185,	  no.	  2,	  pp.	  213–22,	  Jan.	  2012.
[103] M.	  O.	  C.	  Ota,	  J.	  Vekemans,	  S.	  E.	  Schlegel-­‐Haueter,	  K.	  Fielding,	  M.	  Sanneh,
M. Kidd,	  M.	  J.	  Newport,	  P.	  Aaby,	  H.	  Whittle,	  P.-­‐H.	  Lambert,	  K.	  P.	  W.	  J.
McAdam,	  C.-­‐A.	  Siegrist,	  and	  A.	  Marchant,	  “Influence	  of	  Mycobacterium
bovis	  bacillus	  Calmette-­‐Guérin	  on	  antibody	  and	  cytokine	  responses	  to
human	  neonatal	  vaccination.,”	  J.	  Immunol.,	  vol.	  168,	  no.	  2,	  pp.	  919–25,
Jan.	  2002.
[104] R.	  F.	  Breiman,	  P.	  K.	  Streatfield,	  M.	  Phelan,	  N.	  Shifa,	  M.	  Rashid,	  and	  M.
Yunus,	  “Effect	  of	  infant	  immunisation	  on	  childhood	  mortality	  in	  rural
Bangladesh:	  analysis	  of	  health	  and	  demographic	  surveillance	  data.,”
Lancet,	  vol.	  364,	  no.	  9452,	  pp.	  2204–11.
[105] D.	  Lehmann,	  J.	  Vail,	  M.	  J.	  Firth,	  N.	  H.	  de	  Klerk,	  and	  M.	  P.	  Alpers,	  “Benefits
of	  routine	  immunizations	  on	  childhood	  survival	  in	  Tari,	  Southern
Highlands	  Province,	  Papua	  New	  Guinea.,”	  Int.	  J.	  Epidemiol.,	  vol.	  34,	  no.	  1,
pp.	  138–48,	  Feb.	  2005.
[106] A.	  Roth,	  P.	  Gustafson,	  A.	  Nhaga,	  Q.	  Djana,	  A.	  Poulsen,	  M.-­‐L.	  Garly,	  H.
Jensen,	  M.	  Sodemann,	  A.	  Rodriques,	  and	  P.	  Aaby,	  “BCG	  vaccination	  scar
associated	  with	  better	  childhood	  survival	  in	  Guinea-­‐Bissau.,”	  Int.	  J.
Epidemiol.,	  vol.	  34,	  no.	  3,	  pp.	  540–7,	  Jun.	  2005.
[107] L.	  H.	  Moulton,	  L.	  Rahmathullah,	  N.	  A.	  Halsey,	  R.	  D.	  Thulasiraj,	  J.	  Katz,	  and
J. M.	  Tielsch,	  “Evaluation	  of	  non-­‐specific	  effects	  of	  infant	  immunizations
on	  early	  infant	  mortality	  in	  a	  southern	  Indian	  population.,”	  Trop.	  Med.	  Int.
Health,	  vol.	  10,	  no.	  10,	  pp.	  947–55,	  Oct.	  2005.
[108] J.	  M.	  Tufariello,	  J.	  Chan,	  and	  J.	  L.	  Flynn,	  “Latent	  tuberculosis:	  mechanisms
of	  host	  and	  bacillus	  that	  contribute	  to	  persistent	  infection.,”	  Lancet	  Infect.
Dis.,	  vol.	  3,	  no.	  9,	  pp.	  578–90,	  Sep.	  2003.
[109] T.	  R.	  Sterling,	  T.	  Martire,	  A.	  S.	  de	  Almeida,	  L.	  Ding,	  D.	  E.	  Greenberg,	  L.	  A.
Moreira,	  H.	  Elloumi,	  A.	  P.	  V	  Torres,	  C.	  C.	  Sant’Anna,	  E.	  Calazans,	  G.
Paraguassu,	  T.	  Gebretsadik,	  A.	  Shintani,	  K.	  Miller,	  A.	  Kritski,	  J.	  R.	  Lapa	  e
Silva,	  and	  S.	  M.	  Holland,	  “Immune	  function	  in	  young	  children	  with
previous	  pulmonary	  or	  miliary/meningeal	  tuberculosis	  and	  impact	  of
BCG	  vaccination.,”	  Pediatrics,	  vol.	  120,	  pp.	  e912–e921,	  2007.
	   83	  
[110]	  W.	  A.	  Hanekom,	  J.	  Hughes,	  M.	  Mavinkurve,	  M.	  Mendillo,	  M.	  Watkins,	  H.	  
Gamieldien,	  S.	  J.	  Gelderbloem,	  M.	  Sidibana,	  N.	  Mansoor,	  V.	  Davids,	  R.	  A.	  
Murray,	  A.	  Hawkridge,	  P.	  A.	  J.	  Haslett,	  S.	  Ress,	  G.	  D.	  Hussey,	  and	  G.	  Kaplan,	  
“Novel	  application	  of	  a	  whole	  blood	  intracellular	  cytokine	  detection	  
assay	  to	  quantitate	  specific	  T-­‐cell	  frequency	  in	  field	  studies.,”	  J.	  Immunol.	  
Methods,	  vol.	  291,	  no.	  1–2,	  pp.	  185–95,	  Aug.	  2004.	  
[111]	  J.	  D.	  Altman,	  P.	  A.	  H.	  Moss,	  P.	  J.	  R.	  Goulder,	  D.	  H.	  Barouch,	  M.	  G.	  McHeyzer-­‐
Williams,	  J.	  I.	  Bell,	  A.	  J.	  McMichael,	  and	  M.	  M.	  Davis,	  “Phenotypic	  analysis	  
of	  antigen-­‐specific	  T	  lymphocytes.	  Science.	  1996.	  274:	  94-­‐96.,”	  J.	  
Immunol.,	  vol.	  187,	  no.	  1,	  pp.	  7–9,	  Jul.	  2011.	  
[112]	  O.	  B.	  Dintwe,	  C.	  L.	  Day,	  E.	  Smit,	  E.	  Nemes,	  C.	  Gray,	  M.	  Tameris,	  H.	  McShane,	  
H.	  Mahomed,	  W.	  A.	  Hanekom,	  and	  T.	  J.	  Scriba,	  “Heterologous	  vaccination	  
against	  human	  tuberculosis	  modulates	  antigen-­‐specific	  CD4+	  T-­‐cell	  
function.,”	  Eur.	  J.	  Immunol.,	  vol.	  43,	  no.	  9,	  pp.	  2409–20,	  Sep.	  2013.	  
[113]	  A.	  Soares,	  L.	  Govender,	  J.	  Hughes,	  W.	  Mavakla,	  M.	  de	  Kock,	  C.	  Barnard,	  B.	  
Pienaar,	  E.	  Janse	  van	  Rensburg,	  G.	  Jacobs,	  G.	  Khomba,	  L.	  Stone,	  B.	  Abel,	  T.	  
J.	  Scriba,	  and	  W.	  A.	  Hanekom,	  “Novel	  application	  of	  Ki67	  to	  quantify	  
antigen-­‐specific	  in	  vitro	  lymphoproliferation.,”	  J.	  Immunol.	  Methods,	  vol.	  
362,	  no.	  1–2,	  pp.	  43–50,	  Oct.	  2010.	  
[114]	  K.	  L.	  Kellar	  and	  M.	  A.	  Iannone,	  “Multiplexed	  microsphere-­‐based	  flow	  
cytometric	  assays.,”	  Exp.	  Hematol.,	  vol.	  30,	  no.	  11,	  pp.	  1227–37,	  Nov.	  
2002.	  
[115]	  M.	  K.	  Lalor,	  S.	  Floyd,	  P.	  Gorak-­‐Stolinska,	  A.	  Ben-­‐Smith,	  R.	  E.	  Weir,	  S.	  G.	  
Smith,	  M.	  J.	  Newport,	  R.	  Blitz,	  H.	  Mvula,	  K.	  Branson,	  N.	  McGrath,	  A.	  C.	  
Crampin,	  P.	  E.	  Fine,	  and	  H.	  M.	  Dockrell,	  “BCG	  vaccination	  induces	  
different	  cytokine	  profiles	  following	  infant	  BCG	  vaccination	  in	  the	  UK	  and	  
Malawi.,”	  J.	  Infect.	  Dis.,	  vol.	  204,	  no.	  7,	  pp.	  1075–85,	  Oct.	  2011.	  
[116]	  B.	  A.	  Reikie,	  R.	  C.	  M.	  Adams,	  C.	  E.	  Ruck,	  K.	  Ho,	  A.	  Leligdowicz,	  S.	  Pillay,	  S.	  
Naidoo,	  E.	  S.	  Fortuno,	  C.	  de	  Beer,	  W.	  Preiser,	  M.	  F.	  Cotton,	  D.	  P.	  Speert,	  M.	  
Esser,	  and	  T.	  R.	  Kollmann,	  “Ontogeny	  of	  Toll-­‐like	  receptor	  mediated	  
cytokine	  responses	  of	  South	  African	  infants	  throughout	  the	  first	  year	  of	  
life.,”	  PLoS	  One,	  vol.	  7,	  no.	  9,	  p.	  e44763,	  Jan.	  2012.	  
[117]	  K.	  T.	  Brunner,	  J.	  Mauel,	  J.	  C.	  Cerottini,	  and	  B.	  Chapuis,	  “Quantitative	  assay	  
of	  the	  lytic	  action	  of	  immune	  lymphoid	  cells	  on	  51-­‐Cr-­‐labelled	  allogeneic	  
target	  cells	  in	  vitro;	  inhibition	  by	  isoantibody	  and	  by	  drugs.,”	  
Immunology,	  vol.	  14,	  no.	  2,	  pp.	  181–96,	  Feb.	  1968.	  
[118]	  B.	  Fazekas	  de	  St	  Groth,	  A.	  L.	  Smith,	  W.	  P.	  Koh,	  L.	  Girgis,	  M.	  C.	  Cook,	  and	  P.	  
Bertolino,	  “Carboxyfluorescein	  diacetate	  succinimidyl	  ester	  and	  the	  
virgin	  lymphocyte:	  a	  marriage	  made	  in	  heaven.,”	  Immunol.	  Cell	  Biol.,	  vol.	  
77,	  no.	  6,	  pp.	  530–8,	  Dec.	  1999.	  
[119]	  G.	  G.	  Kim,	  V.	  S.	  Donnenberg,	  A.	  D.	  Donnenberg,	  W.	  Gooding,	  and	  T.	  L.	  
Whiteside,	  “A	  novel	  multiparametric	  flow	  cytometry-­‐based	  cytotoxicity	  
assay	  simultaneously	  immunophenotypes	  effector	  cells:	  comparisons	  to	  
a	  4	  h	  51Cr-­‐release	  assay.,”	  J.	  Immunol.	  Methods,	  vol.	  325,	  no.	  1–2,	  pp.	  51–
66,	  Aug.	  2007.	  
[120]	  S.	  A.	  Plotkin,	  “Correlates	  of	  protection	  induced	  by	  vaccination.,”	  Clin.	  
Vaccine	  Immunol.,	  vol.	  17,	  no.	  7,	  pp.	  1055–65,	  Jul.	  2010.	  
	   84	  
[121]	  F.	  Abebe	  and	  G.	  Bjune,	  “The	  protective	  role	  of	  antibody	  responses	  during	  
Mycobacterium	  tuberculosis	  infection.,”	  Clin.	  Exp.	  Immunol.,	  vol.	  157,	  no.	  
2,	  pp.	  235–43,	  Aug.	  2009.	  
[122]	  I.	  F.	  Hermans,	  J.	  D.	  Silk,	  J.	  Yang,	  M.	  J.	  Palmowski,	  U.	  Gileadi,	  C.	  McCarthy,	  
M.	  Salio,	  F.	  Ronchese,	  and	  V.	  Cerundolo,	  “The	  VITAL	  assay:	  A	  versatile	  
fluorometric	  technique	  for	  assessing	  CTL-­‐	  and	  NKT-­‐mediated	  
cytotoxicity	  against	  multiple	  targets	  in	  vitro	  and	  in	  vivo,”	  J.	  Immunol.	  
Methods,	  vol.	  285,	  pp.	  25–40,	  2004.	  
[123]	  M.	  F.	  Rodrigues,	  M.	  M.	  Barsante,	  C.	  C.	  S.	  Alves,	  M.	  A.	  Souza,	  A.	  P.	  Ferreira,	  
G.	  P.	  Amarante-­‐Mendes,	  and	  H.	  C.	  Teixeira,	  “Apoptosis	  of	  macrophages	  
during	  pulmonary	  Mycobacterium	  bovis	  infection:	  correlation	  with	  
intracellular	  bacillary	  load	  and	  cytokine	  levels.,”	  Immunology,	  vol.	  128,	  
no.	  1	  Suppl,	  pp.	  e691–9,	  Sep.	  2009.	  
[124]	  L.	  Kremer,	  J.	  Estaquier,	  E.	  Brandt,	  J.	  C.	  Ameisen,	  and	  C.	  Locht,	  
“Mycobacterium	  bovis	  Bacillus	  Calmette	  Guérin	  infection	  prevents	  
apoptosis	  of	  resting	  human	  monocytes.,”	  Eur.	  J.	  Immunol.,	  vol.	  27,	  no.	  9,	  
pp.	  2450–6,	  Sep.	  1997.	  
[125]	  T.	  Miyazaki,	  Z.	  J.	  Liu,	  A.	  Kawahara,	  Y.	  Minami,	  K.	  Yamada,	  Y.	  Tsujimoto,	  E.	  
L.	  Barsoumian,	  R.	  M.	  Permutter,	  and	  T.	  Taniguchi,	  “Three	  distinct	  IL-­‐2	  
signaling	  pathways	  mediated	  by	  bcl-­‐2,	  c-­‐myc,	  and	  lck	  cooperate	  in	  
hematopoietic	  cell	  proliferation.,”	  Cell,	  vol.	  81,	  no.	  2,	  pp.	  223–31,	  Apr.	  
1995.	  
[126]	  R.	  Rowland	  and	  H.	  McShane,	  “Tuberculosis	  vaccines	  in	  clinical	  trials.,”	  
Expert	  Rev.	  Vaccines,	  vol.	  10,	  pp.	  645–658,	  2011.	  
[127]	  H.	  Dooms,	  E.	  Kahn,	  B.	  Knoechel,	  and	  A.	  K.	  Abbas,	  “IL-­‐2	  induces	  a	  
competitive	  survival	  advantage	  in	  T	  lymphocytes.,”	  J.	  Immunol.,	  vol.	  172,	  
pp.	  5973–5979,	  2004.	  
[128]	  H.	  Dooms,	  K.	  Wolslegel,	  P.	  Lin,	  and	  A.	  K.	  Abbas,	  “Interleukin-­‐2	  enhances	  
CD4+	  T	  cell	  memory	  by	  promoting	  the	  generation	  of	  IL-­‐7R	  alpha-­‐
expressing	  cells.,”	  J.	  Exp.	  Med.,	  vol.	  204,	  pp.	  547–557,	  2007.	  
[129]	  R.	  E.	  Tascon,	  E.	  Stavropoulos,	  K.	  V	  Lukacs,	  and	  M.	  J.	  Colston,	  “Protection	  
against	  Mycobacterium	  tuberculosis	  infection	  by	  CD8+	  T	  cells	  requires	  
the	  production	  of	  gamma	  interferon.,”	  Infect.	  Immun.,	  vol.	  66,	  pp.	  830–
834,	  1998.	  
[130]	  A.	  A.	  Chackerian,	  T.	  V	  Perera,	  and	  S.	  M.	  Behar,	  “Gamma	  interferon-­‐
producing	  CD4+	  T	  lymphocytes	  in	  the	  lung	  correlate	  with	  resistance	  to	  
infection	  with	  Mycobacterium	  tuberculosis.,”	  Infect.	  Immun.,	  vol.	  69,	  pp.	  
2666–2674,	  2001.	  
[131]	  D.	  K.	  Dalton,	  S.	  Pitts-­‐Meek,	  S.	  Keshav,	  I.	  S.	  Figari,	  A.	  Bradley,	  and	  T.	  A.	  
Stewart,	  “Multiple	  defects	  of	  immune	  cell	  function	  in	  mice	  with	  disrupted	  
interferon-­‐gamma	  genes.,”	  Science,	  vol.	  259,	  pp.	  1739–1742,	  1993.	  
[132]	  D.	  R.	  Roach,	  A.	  G.	  Bean,	  C.	  Demangel,	  M.	  P.	  France,	  H.	  Briscoe,	  and	  W.	  J.	  
Britton,	  “TNF	  regulates	  chemokine	  induction	  essential	  for	  cell	  
recruitment,	  granuloma	  formation,	  and	  clearance	  of	  mycobacterial	  
infection,”	  J	  Immunol,	  vol.	  168,	  no.	  9,	  pp.	  4620–4627,	  2002.	  
[133]	  J.	  Keane,	  S.	  Gershon,	  R.	  P.	  Wise,	  E.	  Mirabile-­‐Levens,	  J.	  Kasznica,	  W.	  D.	  
Schwieterman,	  J.	  N.	  Siegel,	  and	  M.	  M.	  Braun,	  “Tuberculosis	  associated	  
with	  infliximab,	  a	  tumor	  necrosis	  factor	  alpha-­‐neutralizing	  agent.,”	  N.	  
Engl.	  J.	  Med.,	  vol.	  345,	  pp.	  1098–1104,	  2001.	  
	   85	  
[134]	  D.	  A.	  Kaveh,	  V.	  S.	  Bachy,	  R.	  G.	  Hewinson,	  and	  P.	  J.	  Hogarth,	  “Systemic	  BCG	  
immunization	  induces	  persistent	  lung	  mucosal	  multifunctional	  CD4	  TEM	  
cells	  which	  expand	  following	  virulent	  mycobacterial	  challenge,”	  PLoS	  
One,	  vol.	  6,	  2011.	  
[135]	  P.	  Oykhman	  and	  C.	  H.	  Mody,	  “Direct	  microbicidal	  activity	  of	  cytotoxic	  T-­‐
lymphocytes.,”	  J.	  Biomed.	  Biotechnol.,	  vol.	  2010,	  p.	  249482,	  2010.	  
[136]	  S.	  P.	  Cullen	  and	  S.	  J.	  Martin,	  “Mechanisms	  of	  granule-­‐dependent	  killing.,”	  
Cell	  Death	  Differ.,	  vol.	  15,	  pp.	  251–262,	  2008.	  
[137]	  D.	  Di	  Liberto,	  S.	  Buccheri,	  N.	  Caccamo,	  S.	  Meraviglia,	  A.	  Romano,	  P.	  Di	  
Carlo,	  L.	  Titone,	  F.	  Dieli,	  A.	  M.	  Krensky,	  and	  A.	  Salerno,	  “Decreased	  serum	  
granulysin	  levels	  in	  childhood	  tuberculosis	  which	  reverse	  after	  therapy.,”	  
Tuberculosis	  (Edinb).,	  vol.	  87,	  no.	  4,	  pp.	  322–8,	  Jul.	  2007.	  
[138]	  N.	  Pitabut,	  S.	  Mahasirimongkol,	  H.	  Yanai,	  C.	  Ridruechai,	  S.	  Sakurada,	  P.	  
Dhepakson,	  P.	  Kantipong,	  S.	  Piyaworawong,	  S.	  Moolphate,	  C.	  
Hansudewechakul,	  N.	  Yamada,	  N.	  Keicho,	  M.	  Okada,	  and	  S.	  Khusmith,	  
“Decreased	  plasma	  granulysin	  and	  increased	  interferon-­‐gamma	  
concentrations	  in	  patients	  with	  newly	  diagnosed	  and	  relapsed	  
tuberculosis.,”	  Microbiol.	  Immunol.,	  vol.	  55,	  pp.	  565–573,	  2011.	  
[139]	  E.	  B.	  Lindblad,	  M.	  J.	  Elhay,	  R.	  Silva,	  R.	  Appelberg,	  and	  P.	  Andersen,	  
“Adjuvant	  modulation	  of	  immune	  responses	  to	  tuberculosis	  subunit	  
vaccines.,”	  Infect.	  Immun.,	  vol.	  65,	  pp.	  623–629,	  1997.	  
[140]	  A.	  Demissie,	  L.	  Wassie,	  M.	  Abebe,	  A.	  Aseffa,	  G.	  Rook,	  A.	  Zumla,	  P.	  
Andersen,	  and	  T.	  M.	  Doherty,	  “The	  6-­‐kilodalton	  early	  secreted	  antigenic	  
target-­‐responsive,	  asymptomatic	  contacts	  of	  tuberculosis	  patients	  
express	  elevated	  levels	  of	  interleukin-­‐4	  and	  reduced	  levels	  of	  gamma	  
interferon.,”	  Infect.	  Immun.,	  vol.	  74,	  pp.	  2817–2822,	  2006.	  
[141]	  A.	  Hawkridge,	  M.	  Hatherill,	  F.	  Little,	  M.	  A.	  Goetz,	  L.	  Barker,	  H.	  Mahomed,	  J.	  
Sadoff,	  W.	  Hanekom,	  L.	  Geiter,	  and	  G.	  Hussey,	  “Efficacy	  of	  percutaneous	  
versus	  intradermal	  BCG	  in	  the	  prevention	  of	  tuberculosis	  in	  South	  
African	  infants:	  randomised	  trial.,”	  BMJ,	  vol.	  337,	  p.	  a2052,	  2008.	  
[142]	  W.	  A.	  Hanekom,	  “The	  immune	  response	  to	  BCG	  vaccination	  of	  
newborns.,”	  Ann.	  N.	  Y.	  Acad.	  Sci.,	  vol.	  1062,	  pp.	  69–78,	  2005.	  
[143]	  A.	  Weinberg,	  L.	  Zhang,	  D.	  Brown,	  A.	  Erice,	  B.	  Polsky,	  M.	  S.	  Hirsch,	  S.	  
Owens,	  and	  K.	  Lamb,	  “Viability	  and	  functional	  activity	  of	  cryopreserved	  
mononuclear	  cells.,”	  Clin.	  Diagn.	  Lab.	  Immunol.,	  vol.	  7,	  pp.	  714–716,	  2000.	  
[144]	  C.	  F.	  Capinos	  Scherer,	  J.	  J.	  Endsley,	  J.	  B.	  de	  Aguiar,	  W.	  R.	  Jacobs,	  M.	  H.	  
Larsen,	  M.	  V	  Palmer,	  B.	  J.	  Nonnecke,	  W.	  Ray	  Waters,	  and	  D.	  Mark	  Estes,	  
“Evaluation	  of	  granulysin	  and	  perforin	  as	  candidate	  biomarkers	  for	  
protection	  following	  vaccination	  with	  Mycobacterium	  bovis	  BCG	  or	  M.	  
bovisDeltaRD1.,”	  Transbound.	  Emerg.	  Dis.,	  vol.	  56,	  pp.	  228–239,	  2009.	  
[145]	  H.	  Mueller,	  K.	  C.	  Faé,	  K.	  Magdorf,	  C.	  A.	  Ganoza,	  U.	  Wahn,	  U.	  Guhlich,	  C.	  
Feiterna-­‐Sperling,	  and	  S.	  H.	  E.	  Kaufmann,	  “Granulysin-­‐Expressing	  CD4	  +	  
T	  cells	  as	  candidate	  immune	  marker	  for	  tuberculosis	  during	  childhood	  
and	  adolescence,”	  PLoS	  One,	  vol.	  6,	  2011.	  
[146]	  A.	  C.	  Hesseling,	  H.	  Rabie,	  B.	  J.	  Marais,	  M.	  Manders,	  M.	  Lips,	  H.	  S.	  Schaaf,	  R.	  
P.	  Gie,	  M.	  F.	  Cotton,	  P.	  D.	  van	  Helden,	  R.	  M.	  Warren,	  and	  N.	  Beyers,	  “Bacille	  
Calmette-­‐Guerin	  vaccine-­‐induced	  disease	  in	  HIV-­‐infected	  and	  HIV-­‐
uninfected	  children,”	  Clin	  Infect	  Dis,	  vol.	  42,	  no.	  4,	  pp.	  548–558,	  2006.	  
	   86	  
[147]	  W.	  A.	  Boivin,	  D.	  M.	  Cooper,	  P.	  R.	  Hiebert,	  and	  D.	  J.	  Granville,	  “Intracellular	  
versus	  extracellular	  granzyme	  B	  in	  immunity	  and	  disease:	  challenging	  
the	  dogma.,”	  Lab.	  Invest.,	  vol.	  89,	  pp.	  1195–1220,	  2009.	  
[148]	  D.	  J.	  Horne,	  A.	  K.	  Randhawa,	  T.	  T.	  H.	  Chau,	  N.	  D.	  Bang,	  N.	  T.	  B.	  Yen,	  J.	  J.	  
Farrar,	  S.	  J.	  Dunstan,	  and	  T.	  R.	  Hawn,	  “Common	  polymorphisms	  in	  the	  
PKP3-­‐SIGIRR-­‐TMEM16J	  gene	  region	  are	  associated	  with	  susceptibility	  to	  
tuberculosis.,”	  J.	  Infect.	  Dis.,	  vol.	  205,	  pp.	  586–94,	  2012.	  
[149]	  C.	  Garlanda,	  D.	  Di	  Liberto,	  A.	  Vecchi,	  M.	  P.	  La	  Manna,	  C.	  Buracchi,	  N.	  
Caccamo,	  A.	  Salerno,	  F.	  Dieli,	  and	  A.	  Mantovani,	  “Damping	  excessive	  
inflammation	  and	  tissue	  damage	  in	  Mycobacterium	  tuberculosis	  
infection	  by	  Toll	  IL-­‐1	  receptor	  8/single	  Ig	  IL-­‐1-­‐related	  receptor,	  a	  
negative	  regulator	  of	  IL-­‐1/TLR	  signaling.,”	  J.	  Immunol.,	  vol.	  179,	  pp.	  
3119–3125,	  2007.	  
[150]	  M.	  Kori,	  V.	  Barak,	  E.	  Leibovitz,	  Y.	  Altman,	  A.	  Eliraz,	  and	  Z.	  T.	  Handzel,	  
“Specific	  in	  vitro	  proliferative	  immune	  responses	  and	  lymphokine	  
production	  in	  Ethiopian	  children	  with	  and	  without	  tuberculosis.,”	  
Infection,	  vol.	  28,	  no.	  1,	  pp.	  42–5.	  
[151]	  A.	  Mendez,	  R.	  Hernandez-­‐Pando,	  S.	  Contreras,	  D.	  Aguilar,	  and	  G.	  A.	  W.	  
Rook,	  “CCL2,	  CCL18	  and	  sIL-­‐4R	  in	  renal,	  meningeal	  and	  pulmonary	  TB;	  A	  
2	  year	  study	  of	  patients	  and	  contacts,”	  Tuberculosis,	  vol.	  91,	  pp.	  140–145,	  
2011.	  
[152]	  D.	  Nisha	  Rajeswari,	  P.	  Selvaraj,	  M.	  S.	  Jawahar,	  A.	  R.	  Adhilakshmi,	  M.	  
Vidyarani,	  and	  P.	  R.	  Narayanan,	  “Elevated	  percentage	  of	  perforin	  positive	  
cells	  in	  active	  pulmonary	  tuberculosis.,”	  Indian	  J.	  Med.	  Res.,	  vol.	  123,	  no.	  5,	  
pp.	  687–90,	  May	  2006.	  
[153]	  K.	  L.	  Kellar	  and	  J.	  P.	  Douglass,	  “Multiplexed	  microsphere-­‐based	  flow	  
cytometric	  immunoassays	  for	  human	  cytokines.,”	  J.	  Immunol.	  Methods,	  
vol.	  279,	  no.	  1–2,	  pp.	  277–85,	  Aug.	  2003.	  
[154]	  M.	  K.	  Lalor,	  S.	  G.	  Smith,	  S.	  Floyd,	  P.	  Gorak-­‐Stolinska,	  R.	  E.	  Weir,	  R.	  Blitz,	  K.	  
Branson,	  P.	  E.	  Fine,	  and	  H.	  M.	  Dockrell,	  “Complex	  cytokine	  profiles	  
induced	  by	  BCG	  vaccination	  in	  UK	  infants,”	  Vaccine,	  vol.	  28,	  no.	  6,	  pp.	  
1635–1641,	  2010.	  
[155]	  K.	  L.	  Kellar,	  J.	  Gehrke,	  S.	  E.	  Weis,	  A.	  Mahmutovic-­‐Mayhew,	  B.	  Davila,	  M.	  J.	  
Zajdowicz,	  R.	  Scarborough,	  P.	  A.	  LoBue,	  A.	  A.	  Lardizabal,	  C.	  L.	  Daley,	  R.	  R.	  
Reves,	  J.	  Bernardo,	  B.	  H.	  Campbell,	  W.	  C.	  Whitworth,	  and	  G.	  H.	  Mazurek,	  
“Multiple	  cytokines	  are	  released	  when	  blood	  from	  patients	  with	  
tuberculosis	  is	  stimulated	  with	  Mycobacterium	  tuberculosis	  antigens.,”	  
PLoS	  One,	  vol.	  6,	  no.	  11,	  p.	  e26545,	  Jan.	  2011.	  
[156]	  N.	  N.	  Chegou,	  G.	  F.	  Black,	  M.	  Kidd,	  P.	  D.	  van	  Helden,	  and	  G.	  Walzl,	  “Host	  
markers	  in	  QuantiFERON	  supernatants	  differentiate	  active	  TB	  from	  
latent	  TB	  infection:	  preliminary	  report.,”	  BMC	  Pulm.	  Med.,	  vol.	  9,	  p.	  21,	  
Jan.	  2009.	  
[157]	  L.	  Roberts,	  J.-­‐A.	  S.	  Passmore,	  C.	  Williamson,	  F.	  Little,	  L.	  M.	  Bebell,	  K.	  
Mlisana,	  W.	  A.	  Burgers,	  F.	  van	  Loggerenberg,	  G.	  Walzl,	  J.	  F.	  Djoba	  Siawaya,	  
Q.	  A.	  Karim,	  and	  S.	  S.	  A.	  Karim,	  “Plasma	  cytokine	  levels	  during	  acute	  HIV-­‐
1	  infection	  predict	  HIV	  disease	  progression.,”	  AIDS,	  vol.	  24,	  no.	  6,	  pp.	  
819–31,	  Mar.	  2010.	  
[158]	  R.	  L.	  R.	  Powell,	  I.	  Ouellette,	  R.	  W.	  Lindsay,	  C.	  L.	  Parks,	  C.	  R.	  King,	  A.	  B.	  
McDermott,	  and	  G.	  Morrow,	  “A	  Multiplex	  Microsphere-­‐Based	  
87	  
Immunoassay	  Increases	  the	  Sensitivity	  of	  SIV-­‐Specific	  Antibody	  
Detection	  in	  Serum	  Samples	  and	  Mucosal	  Specimens	  Collected	  from	  
Rhesus	  Macaques	  Infected	  with	  SIVmac239.,”	  Biores.	  Open	  Access,	  vol.	  2,	  
no.	  3,	  pp.	  171–8,	  Jun.	  2013.	  
[159] L.	  Qin,	  P.	  B.	  Gilbert,	  L.	  Corey,	  M.	  J.	  McElrath,	  and	  S.	  G.	  Self,	  “A	  framework
for	  assessing	  immunological	  correlates	  of	  protection	  in	  vaccine	  trials.,”	  J.
Infect.	  Dis.,	  vol.	  196,	  no.	  9,	  pp.	  1304–12,	  Nov.	  2007.
[160] T.	  R.	  Kollmann,	  J.	  Crabtree,	  A.	  Rein-­‐Weston,	  D.	  Blimkie,	  F.	  Thommai,	  X.	  Y.
Wang,	  P.	  M.	  Lavoie,	  J.	  Furlong,	  E.	  S.	  Fortuno,	  A.	  M.	  Hajjar,	  N.	  R.	  Hawkins,	  S.
G. Self,	  and	  C.	  B.	  Wilson,	  “Neonatal	  innate	  TLR-­‐mediated	  responses	  are
distinct	  from	  those	  of	  adults.,”	  J.	  Immunol.,	  vol.	  183,	  no.	  11,	  pp.	  7150–60,
Dec.	  2009.
[161] M.	  D.	  Tameris,	  M.	  Hatherill,	  B.	  S.	  Landry,	  T.	  J.	  Scriba,	  M.	  A.	  Snowden,	  S.
Lockhart,	  J.	  E.	  Shea,	  J.	  B.	  McClain,	  G.	  D.	  Hussey,	  W.	  A.	  Hanekom,	  H.
Mahomed,	  and	  H.	  McShane,	  “Safety	  and	  efficacy	  of	  MVA85A,	  a	  new
tuberculosis	  vaccine,	  in	  infants	  previously	  vaccinated	  with	  BCG:	  a
randomised,	  placebo-­‐controlled	  phase	  2b	  trial.,”	  Lancet,	  vol.	  381,	  no.
9871,	  pp.	  1021–8,	  Mar.	  2013.
